 EXHIBIT 10.1    \t \t 

Ex. 10.1













AGREEMENT AND PLAN OF MERGER

BY AND AMONG

ALEXION PHARMACEUTICALS, INC.,

SYRACUSE MERGER SUB, INC.,

SYNTIMMUNE, INC.

AND

SHAREHOLDER REPRESENTATIVE SERVICES LLC, 
AS THE STOCKHOLDERS' REPRESENTATIVE









Dated as of September 25, 2018 




* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission. 





TABLE OF CONTENTS

Page 

--- 
| | | 

Article I

|

Defined Terms; Interpretation

|

3

|


 

Section 1.1

|

Defined Terms

|

3

|


 

Section 1.2

|

Interpretation

|

21

|


 

Article II The Merger

|

22

|


 

Section 2.1

|

The Merger

|

22

|


 

Section 2.2

|

Effective Time; Closing Date

|

22

|


 

Section 2.3

|

Effect of the Merger

|

22

|


 

Section 2.4

|

Certificate of Incorporation; Bylaws

|

23

|


 

Section 2.5

|

Board of Directors and Officers

|

23

|


 

Section 2.6

|

Further Assurances

|

23

|


 

Section 2.7

|

Closing Deliverables.

|

23

|


 

Article III Effects of the Merger; Consideration

|

24

|


 

Section 3.1

|

Conversion of Company Securities

|

24

|


 

Section 3.2

|

Closing Estimates

|

27

|


 

Section 3.3

|

Adjustment Amount

|

27

|


 

Section 3.4

|

Disbursements by Paying Agent and the Surviving Company

|

30

|


 

Section 3.5

|

Exchange Procedures

|

30

|


 

Section 3.6

|

Payments at Closing

|

31

|


 

Section 3.7

|

Escrow Amount

|

32

|


 

Section 3.8

|

Earn-Out Payments

|

34

|


 

Section 3.9

|

Stockholders' Representative Expense Amount

|

37

|


 

Section 3.10

|

Tax Documentation

|

37

|


 

Section 3.11

|

Withholding

|

38

|


 

Section 3.12

|

Dissenting Shares

|

38

|


 

Article IV Representations and Warranties of the Company

|

39

|


 

Section 4.1

|

Organization, Standing and Power

|

39

|


 

Section 4.2

|

Authority; Approvals

|

39

|


 

Section 4.3

|

Capitalization; Equity Interests

|

40

|


 

Section 4.4

|

Conflicts; Consents

|

42

|


 

Section 4.5

|

Financial Information; Undisclosed Liabilities

|

42

|


 

Section 4.6

|

Books and Records; Internal Controls; Off-Balance Sheet Arrangements

|

43

|


 

Section 4.7

|

Absence of Changes

|

43

|


 

Section 4.8

|

Real Property and Assets

|

46

|


 

Section 4.9

|

Material Contracts

|

47

|


 

Section 4.10

|

Environmental Matters

|

49

|

 

--- 
| | | 

Section 4.11

|

Litigation

|

49

|


 

Section 4.12

|

Compliance with Laws; Licenses and Permits

|

50

|


 

Section 4.13

|

Regulatory

|

50

|


 

Section 4.14

|

Intellectual Property

|

52

|


 

Section 4.15

|

Tax Matters

|

54

|


 

Section 4.16

|

Labor Relations; Employees

|

58

|


 

Section 4.17

|

Interested Party Transactions

|

61

|


 

Section 4.18

|

Brokers

|

61

|


 

Section 4.19

|

Insurance

|

61

|


 

Section 4.20

|

Powers of Attorney

|

62

|


 

Section 4.21

|

Government Restrictions on Business Activities

|

62

|


 

Section 4.22

|

Privacy and Security

|

62

|


 

Section 4.23

|

Disclaimer of Other Representations and Warranties

|

63

|


 

Article V Representations and Warranties of Buyer and Merger Sub

|

64

|


 

Section 5.1

|

Organization; Power and Authority

|

64

|


 

Section 5.2

|

Authority; Approvals

|

64

|


 

Section 5.3

|

Conflicts; Consents

|

64

|


 

Section 5.4

|

Brokers

|

65

|


 

Section 5.5

|

Litigation

|

65

|


 

Section 5.6

|

Financing

|

65

|


 

Section 5.7

|

Disclaimer of Other Representations and Warranties

|

65

|


 

Article VI Certain Covenants

|

65

|


 

Section 6.1

|

Conduct of Business

|

65

|


 

Section 6.2

|

Access and Information; Confidentiality

|

66

|


 

Section 6.3

|

Required Stockholder Approval; Disclosure Statement

|

67

|


 

Section 6.4

|

Best Efforts; Further Assurances

|

67

|


 

Section 6.5

|

Public Announcements

|

70

|


 

Section 6.6

|

Section 280G

|

70

|


 

Section 6.7

|

Expenses

|

71

|


 

Section 6.8

|

Tax Matters

|

71

|


 

Section 6.9

|

No Solicitations

|

75

|


 

Section 6.10

|

Payoff Letters

|

75

|


 

Section 6.11

|

Confidential Information

|

76

|


 

Section 6.12

|

Capital Structure Certificate

|

77

|


 

Section 6.13

|

Termination of Benefit Plans

|

78

|


 

Section 6.14

|

Employee Matters.

|

78

|


 

Section 6.15

|

Indemnification of Directors and Officers of the Company.

|

79

|


 

Section 6.16

|

Financing

|

80

|


 

Article VII Conditions Precedent

|

80

|


 

Section 7.1

|

Conditions Precedent to Obligations of Each Party

|

81

|


 

Section 7.2

|

Conditions Precedent to Obligations of Buyer and Merger Sub

|

81

|


 

Section 7.3

|

Conditions Precedent to Obligations of the Company

|

82

|


 

Article VIII Indemnification

|

83

|


 

Section 8.1

|

Indemnification of Buyer Indemnified Parties

|

83

|


 

Section 8.2

|

Indemnification of Securityholder Indemnified Parties

|

84

|


 

Section 8.3

|

Indemnification Procedures

|

85

|


 

 

-i-

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

B4870734.16

* * *




 

--- 
| | | 

Section 8.4

|

Limitations on Indemnification

|

88

|


 

Section 8.5

|

Survival of Representations, Warranties and Covenants

|

89

|


 

Section 8.6

|

Tax Treatment of Indemnification Payments

|

89

|


 

Section 8.7

|

Effect of Investigation

|

89

|


 

Section 8.8

|

Materiality

|

90

|


 

Section 8.9

|

Additions to Escrow Account

|

90

|


 

Article IX Stockholders' Representative

|

91

|


 

Section 9.1

|

Stockholders' Representative

|

91

|


 

Article X Termination

|

95

|


 

Section 10.1

|

Termination by Mutual Consent

|

95

|


 

Section 10.2

|

Termination by Either Buyer or the Company

|

95

|


 

Section 10.3

|

Termination by the Company

|

96

|


 

Section 10.4

|

Termination by Buyer

|

96

|


 

Section 10.5

|

Effect of Termination and Abandonment

|

96

|


 

Article XI Miscellaneous

|

96

|


 

Section 11.1

|

Entire Agreement

|

96

|


 

Section 11.2

|

Assignment and Binding Effect; No Third Party Beneficiaries

|

96

|


 

Section 11.3

|

Notices

|

97

|


 

Section 11.4

|

Amendment and Modification

|

98

|


 

Section 11.5

|

Governing Law; Jurisdiction; Enforcement

|

98

|


 

Section 11.6

|

Waiver of Jury Trial

|

99

|


 

Section 11.7

|

Severability

|

100

|


 

Section 11.8

|

Counterparts

|

100

|


 

Section 11.9

|

Specific Performance

|

100

|


 

Section 11.10

|

Mutual Drafting

|

100

|


 

Section 11.11

|

Continuing Counsel

|

100

|


 

 

EXHIBITS

Exhibit A Form of Voting Agreement

Exhibit B Form of Joinder Agreement

Exhibit C Form of Non-Competition Agreement

Exhibit D Form of Letter of Transmittal

Exhibit E Form of Paying Agent Agreement

Exhibit F Form of Certificate of Merger

Exhibit G Form of Escrow Agreement

Exhibit H Product Criteria

Exhibit I SC Formulation Criteria

Exhibit J Excluded Indication



-ii-

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

B4870734.16

* * *





AGREEMENT AND PLAN OF MERGER

This AGREEMENT AND PLAN OF MERGER (this "Agreement"), dated as of September
25, 2018, by and among ALEXION PHARMACEUTICALS, INC., a Delaware corporation
("Buyer"), SYRACUSE MERGER SUB, INC., a Delaware corporation and a wholly-
owned subsidiary of Buyer ("Merger Sub"), SYNTIMMUNE, INC., a Delaware
corporation (the "Company"), and SHAREHOLDER REPRESENTATIVE SERVICES LLC, a
Colorado limited liability company, solely in its capacity as representative
of the Securityholders (the "Stockholders' Representative").

RECITALS

A. The respective Boards of Directors of each of Buyer, Merger Sub and the
Company have unanimously (i) approved, and declared advisable and in the best
interests of Buyer, Merger Sub and the Company and their respective
stockholders the merger of Merger Sub with and into the Company, with the
Company continuing as the surviving entity (the "Merger") in accordance with
the provisions of the General Corporation Law of the State of Delaware, as
amended (the "DGCL"), upon the terms and subject to the conditions of this
Agreement, and (ii) approved this Agreement.

B. Concurrently with the execution and delivery of this Agreement by the
parties hereto, (i) each of the Principal Stockholders is entering into a
Voting Agreement, dated as of the date hereof, with Buyer, substantially in
the form attached hereto as Exhibit A (the "Voting Agreement"), pursuant to
which, among other things, such Principal Stockholders shall deliver to the
Company a written consent in lieu of a meeting of stockholders to adopt this
Agreement and approve the Merger in accordance with the DGCL and the Company
Charter (the "Written Consent"), which Written Consent shall constitute the
Required Stockholder Approval; (ii) each of the Principal Stockholders is
entering into a Joinder Agreement, dated as of the date hereof, with Buyer,
substantially in the form attached hereto as Exhibit B (the "Joinder
Agreement"), pursuant to which, among other things, such Principal
Stockholders are agreeing to certain agreements, undertakings,
representations, warranties, releases and waivers set forth therein; and
(iii); each of the Restricted Sellers is entering into a non-competition
agreement with Buyer, to be effective as of the Closing, substantially in the
form attached hereto as Exhibit C (collectively, the "Non-Competition
Agreements").

C. The right of Stockholders and Option Holders to receive any merger
consideration under this Agreement shall be subject to the indemnification
obligations of such parties set forth in this Agreement, and a portion of the
applicable merger consideration will be held by the Escrow Agent as security
for the indemnification obligations of such parties under this Agreement.

D. Certain capitalized terms used herein have the meanings set forth in
Section 1.1.



* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission. 

In consideration of the mutual representations, warranties, covenants and
other agreements set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged,
the parties hereto agree as follows:



2

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Article I 

DEFINED TERMS; INTERPRETATION

Section 1.1 Defined Terms. As used in this Agreement, the terms set forth
below shall have the following meanings:

"2016 BWH Agreement" has the meaning set forth in the definition of
Transaction Expenses in Section 1.1.

"401(k) Plan(s)" has the meaning specified in Section 6.13(a).

"Acquisition Transaction" has the meaning specified in Section 6.9.

"Actual Fraud" means (a) common law fraud with a specific intent to deceive or
(b) other intentional misrepresentation of a material fact, in each case of
(a) or (b), in connection with or relating to this Agreement, the Other
Transaction Documents and the transactions contemplated hereby.

"Adjustment Amount" has the meaning specified in Section 3.3(f).

"Adjustment Deficit Amount" has the meaning specified in Section 3.3(f).

"Adjustment Surplus Amount" has the meaning specified in Section 3.3(f).

"Affiliate" of a Person means any other Person who directly or indirectly
through one or more intermediaries Controls, is Controlled by or is under
common Control with such Person.

"Aggregate Liquidation Preference Amount" means the amount equal to the sum of
(a) the Series A Per Share Liquidation Preference Amount multiplied by the
number of shares of Series A Preferred Stock outstanding immediately prior to
the Effective Time and (b) the Series B Per Share Liquidation Preference
Amount multiplied by the number of shares of Series B Preferred Stock
outstanding immediately prior to the Effective Time.

"Agreement" has the meaning specified in the Preamble.

"BLA" has the meaning set forth in the definition of NDA in Section 1.1.

"Business Day" means a day other than Saturday or Sunday or a day on which
banks are required or authorized to close in the Commonwealth of
Massachusetts.

"Buyer" has the meaning specified in the Preamble.

"Buyer Indemnified Party" or "Buyer Indemnified Parties" has the meaning
specified in Section 8.1.



3

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Buyer Material Adverse Effect" means a material adverse effect on (i) the
ability of Buyer and Merger Sub to consummate the Merger and the other
transactions contemplated by this Agreement or (ii) the enforceability of this
Agreement against Buyer or Merger Sub.

"BWH" has the meaning set forth in the definition of Transaction Expenses in
Section 1.1.

"Cancelled Option" has the meaning specified in Section 3.1(b)(i).

"Capital Structure Certificate" means a certificate executed by an officer of
the Company setting forth the ownership of the number of Shares and Options
that are outstanding immediately prior to the Effective Time, and the other
information described in Section 6.12.

"Carve-Out Transaction" means any transaction (including a sale of assets,
merger, consolidation, share exchange, scheme of arrangement, sale of stock or
other equity interests, spin-off, split-off or licensing transaction), other
than a Change of Control, pursuant to which the rights to the Product are
sold, licensed, assigned or transferred, directly or indirectly, or a
substantial portion of the Intellectual Property (including without limitation
any data, marketing authorizations and applications for marketing
authorization) and/or Contracts relating to the Product are sold, licensed,
assigned or transferred, directly or indirectly, including through sale of or
license by Buyer or the Surviving Company.

"Cash" shall mean the consolidated cash, cash equivalents, marketable
securities and short term investments held by the Company and its
Subsidiaries, computed as of the applicable date and in accordance with GAAP.
Cash shall (i) be calculated net of issued but uncleared checks and drafts,
(ii) include checks and drafts deposited for the account of the Company and
its Subsidiaries, including deposits in transit, and (iii) be calculated net
of overdrawn accounts.

"Certificate of Merger" has the meaning specified in Section 2.2.

"Certificates" has the meaning specified in Section 3.5(a).

"Change of Control" means an event or series of events by which any "person"
or "group" (as such terms are used in Sections 13(d) and 14(d) of the
Securities Exchange Act of 1934, but excluding any employee benefit plan of
such person or its subsidiaries, and any person or entity acting in its
capacity as trustee, agent or other fiduciary or administrator of any such
plan) becomes the "beneficial owner" (as defined in Rules 13d-3 and 13d-5
under the Securities Exchange Act of 1934, except that a person or group shall
be deemed to have "beneficial ownership" of all securities that such person or
group has the immediate right to acquire, directly or indirectly, of 50% or
more of the equity securities of Buyer or the Surviving Company entitled to
vote for members of the board of directors or equivalent governing body of
Buyer or the Surviving Company (as applicable) on a fully-diluted basis (and
taking into account all such securities that such person or group has the
right to acquire pursuant to any derivative securities).



4

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Clinical Trial" means a clinical study of a pharmaceutical product conducted
on human subjects.

"Closing" has the meaning specified in Section 2.2.

"Closing Balance Sheet" has the meaning specified in Section 3.3(a).

"Closing Cash" shall mean the amount of the Cash as of the Closing.

"Closing Date" has the meaning specified in Section 2.2.

"Closing Indebtedness" means the sum, without duplication and with respect to
the Company and its Subsidiaries, of all (i) outstanding principal and accrued
and unpaid interest as of the Closing owing by the Company or its Subsidiaries
with respect to all indebtedness for borrowed money of the Company and its
Subsidiaries, plus any premium, fee or penalty paid or payable in connection
with the prepayment, repurchase or defeasance of such indebtedness to the
extent that such premiums, fees or penalties are incurred and unpaid at or
before the Closing, and relate to that portion, if any, of such indebtedness
that is repaid at the Closing, (ii) obligations evidenced by notes, bonds,
debentures or other similar instruments, (iii) amounts owing as deferred
purchase price for property or services, (iv) obligations under any interest
rate, currency swap or other hedging agreement or arrangement, (v) capital
lease obligations, (vi) amounts outstanding and owed in respect of commitments
or obligations by which the Company or any Subsidiary assures a creditor
against Loss (including contingent reimbursement obligations with respect to
letters of credit, bank guarantees or bankers' acceptances), (vii) obligations
or commitments to repay deposits or other amounts advanced by and owing to
third parties, or (viii) amounts outstanding and owed in respect of guarantees
or other contingent liabilities with respect to any indebtedness, obligation,
claim or liability of any other Person of a type described in clauses (i)
through (vii) above.

"COBRA" has the meaning specified in Section 4.16(l).

"Code" means the United States Internal Revenue Code of 1986, as amended.

"Commercially Reasonable Efforts" means, with respect to the Product, using
such efforts and resources [*] for the development and commercialization of
similar products at similar development stages taking into account, as
applicable, the Product's advantages and disadvantages, efficacy, safety,
regulatory authority-approved labeling and pricing, the competitiveness in the
marketplace, the status as an orphan product, the patent coverage and
proprietary position of the Product, the likelihood of development success or
Regulatory Approval, the regulatory structure involved, the anticipated
profitability of the Product, and other relevant scientific, technical and
commercial factors typically considered [*] in connection with such similar
products. The obligation to use such efforts and resources, however, does not
require that Buyer or its Affiliates act in a manner which would otherwise be
contrary to prudent business judgment and, furthermore, the fact that the
objective is not actually accomplished is not dispositive evidence that Buyer
or any of its Affiliates did not in fact utilize its Commercially Reasonable
Efforts in attempting to accomplish the objective.



5

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Common Stock" means the common stock, par value $0.001 per share, of the
Company.

"Company" has the meaning specified in the Preamble.

"Company Charter" means the Second Amended and Restated Certificate of
Incorporation of the Company.

"Company Financial Statements" has the meaning specified in Section 4.5(a).

"Company Indemnification Provisions" has the meaning specified in Section
6.15(a).

"Company Indemnified Parties" has the meaning specified in Section 6.15(a).

"Company Intellectual Property" shall mean all (i) Company Owned Intellectual
Property, (ii) Intellectual Property exclusively licensed to the Company or
any of its Subsidiaries, or (iii) Intellectual Property non-exclusively
licensed to the Company or any of its Subsidiaries, in each case ((i)-(iii))
that is held for use or used in the conduct of their respective business.

"Company Material Adverse Effect" means any change, event, development or
effect that has been, is, or would reasonably be expected to be, individually
or in the aggregate with all other changes, events, developments and effects,
materially adverse to (i) the business, assets (including the Product),
financial condition or results of operations of the Company and its
Subsidiaries, taken as a whole or (ii) the ability of the Company or any of
its Subsidiaries to consummate the transactions contemplated hereby, other
than, in the case of clauses (i) and (ii), any change, event, development or
effect to the extent resulting from any of the following: (A) changes in the
general economic, regulatory or political conditions or the securities, credit
or financial markets in the United States or any foreign jurisdiction, (B)
general changes or developments in the industries in which the Company and its
Subsidiaries operate, (C) changes in Law or GAAP or other applicable
accounting standards or the interpretation thereof, (D) changes resulting from
compliance with the terms of, or the taking of any actions required by, this
Agreement, any of the other agreements contemplated hereunder or the
transactions contemplated hereby or thereby, (E) any matters disclosed in the
Disclosure Schedule (excluding any material changes in the facts or
circumstances relating to such matters arising after the date of this
Agreement), (F) the failure of the Company to meet any financial forecast,
projection, estimate, prediction or models (but not the underlying cause of
such failure), (G) the execution and delivery of this Agreement or the Other
Transaction Documents, the performance by any Party of its obligations
hereunder or thereunder or the public announcement (including the identity of,
or any facts or circumstances relating to, Buyer, Merger Sub or their
respective Affiliates) or the pendency of any of the transactions contemplated
hereby or thereby, including the impact thereof on the relationships,
contractual or otherwise, of the Company or any Subsidiary with its employees
or with any other third party, or (H) any earthquakes, hurricanes, tsunamis,
tornadoes, floods, mudslides, wild fires or other natural disasters, weather
conditions and other force majeure events in the United States or any other
country or region in the world, terrorism, military action or war (whether or
not declared) or other geopolitical conditions,



6

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





except, in the case of the foregoing clauses (A) through (C) and (H), to the
extent such changes or developments referred to therein would reasonably be
expected to have a materially disproportionate impact on the Company and its
Subsidiaries, taken as a whole, relative to other Persons operating in the
industry sector or sectors in which the Company and/or its Subsidiaries
operate in the ordinary course of business.

"Company Owned Intellectual Property" shall mean all Intellectual Property
owned by the Company or any of its Subsidiaries.

"Company Privacy Policies" has the meaning specified in Section 4.22(a).

"Company Registered IP" has the meaning specified in Section 4.14(b).

"Company Systems" has the meaning specified in Section 4.14(g).

"Confidential Information" has the meaning specified in Section 6.11(b).

"Confidentiality Agreement" means the Confidentiality Agreement, dated as of
May 22, 2018 between the Company and Buyer.

"Continuation Period" has the meaning specified in Section 6.14(a).

"Continuing Employee" has the meaning specified in Section 6.14(a).

"Contract" means any written or oral contract, agreement, binding arrangement,
lease, license, mortgage, indenture, security agreement, franchise or other
binding instrument of any kind, including amendments thereto.

"Control" means the direct or indirect possession of the power to elect at
least a majority of the Board of Directors or other governing body of a Person
through the ownership of voting securities, ownership or partnership
interests, by contract or otherwise or, if no such governing body exists, the
direct or indirect ownership of 50% or more of the equity interests of a
Person.

"Copyrights" has the meaning set forth in the definition of Intellectual
Property in Section 1.1.

"Deemed Exercise Price" has the meaning specified in Section 4.3(e).

"Determination Date" has the meaning specified in Section 3.3(e).

"DGCL" has the meaning specified in the Recitals.

"Direct Claim" has the meaning specified in Section 8.3(d).

"Disclosure Schedule" has the meaning specified in the first paragraph of
Article IV.



7

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Disclosure Statement" has the meaning specified in Section 6.3(b).

"Disputed Amounts" has the meaning specified in Section 3.3(c).

"Dissenting Shares" has the meaning specified in Section 3.12(a).

"Earn-Out Payment" has the meaning specified in Section 3.8(a).

"Effective Time" has the meaning specified in Section 2.2.

"EMA" means the European Medicines Agency or any successor agency thereto.

"End Date" has the meaning specified in Section 6.9.

"Environment" means soil, surface waters, natural resources, groundwater,
land, stream sediments, surface or subsurface strata and ambient air.

"Environmental Laws" means all applicable Laws relating to protection and
clean-up of the Environment and activities or conditions related thereto,
including those relating to the generation, handling, disposal, transportation
or Release of Hazardous Substances into the Environment, the exposure of any
Person to Hazardous Substances and the protection of human health or
endangered or threatened species.

"Equity Plan" means the Syntimmune, Inc. 2013 Stock Incentive Plan.

"ERISA" means the Employee Retirement Income Security Act of 1974, as amended,
and all Laws promulgated pursuant thereto or in connection therewith.

"ERISA Affiliate" means, with respect to any Person, (i) a member of any
"controlled group" (as defined in Section 414(b) of the Code) of which that
Person is also a member, (ii) a trade or business, whether or not
incorporated, under common control (within the meaning of Section 414(c) of
the Code) with that Person or (iii) a member of any affiliated service group
(within the meaning of Section 414(m) of the Code) of which that Person is
also a member.

"Escrow Account" means the account established pursuant to the Escrow
Agreement to hold the Escrow Amount.

"Escrow Account Addition" has the meaning specified in Section 8.9(d).

"Escrow Agent" has the meaning specified in Section 3.7(a).

"Escrow Agreement" has the meaning specified in Section 3.7(a).

"Escrow Amount" means an amount equal to [*].

"Escrow Consideration" has the meaning specified in Section 3.7(a).



8

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Escrow Fund" has the meaning specified in Section 3.7(a).

"Escrow Fund Release Amount" has the meaning specified in Section 3.7(c).

"Estimated Aggregate Closing Merger Consideration" means the Upfront Purchase
Price, minus (i) the Estimated Closing Indebtedness, plus (ii) the Estimated
Closing Cash, minus (iii) the Estimated Transaction Expenses, plus (iv) the
Estimated Net Closing Working Capital Adjustment, minus (v) the Escrow Amount,
minus (vi) the Stockholders' Representative Expense Amount, plus (vii) the
aggregate exercise prices (including the Deemed Exercise Prices) of all
Cancelled Options plus (viii) the Promissory Note Balance, using the estimated
amounts for each of components (i), (ii), (iii) and (iv) pursuant to Section
3.2.

"Estimated Closing Cash" has the meaning specified in Section 3.2.

"Estimated Closing Indebtedness" has the meaning specified in Section 3.2.

"Estimated Net Closing Working Capital Adjustment" has the meaning specified
in Section 3.2.

"Estimated Per Common Share Closing Merger Consideration" means the quotient
obtained by dividing the (i) difference of the Estimated Aggregate Closing
Merger Consideration minus the Aggregate Liquidation Preference Amount, by
(ii) the Fully Diluted Common Share Count.

"Estimated Transaction Expenses" has the meaning specified in Section 3.2.

"Excluded Indication" has the meaning specified in Section 3.8(f).

"FDA" means the United States Food and Drug Administration, or any successor
agency thereto.

"FDCA" means the Federal Food, Drug, and Cosmetic Act, as amended.

"Final Aggregate Closing Merger Consideration" means the Upfront Purchase
Price, minus (i) the Closing Indebtedness, plus (ii) the Closing Cash, minus
(iii) the Transaction Expenses, plus (iv) Net Closing Working Capital minus
(v) the Target Net Working Capital, minus (vi) the Escrow Amount, minus (vii)
the Stockholders' Representative Expense Amount, plus (viii) the aggregate
exercise prices (including the Deemed Exercise Prices) of all Cancelled
Options, using the finally determined amounts for each of components (i),
(ii), (iii) and (iv) above pursuant to Section 3.3.

"First Escrow Fund Release Amount" has the meaning specified in Section
3.7(c).

"First Escrow Release Date" shall mean the [*] anniversary of the Closing
Date.

"First Indication" has the meaning specified in Section 3.8(f).



9

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Fully Diluted Common Share Count" means the sum of (i) the total number of
shares of Common Stock outstanding as of immediately prior to the Effective
Time (including, for the avoidance of doubt, shares of Restricted Stock, and
excluding any shares held by the Company as treasury stock), (ii) the total
number of shares of Common Stock into which shares of Preferred Stock
outstanding as of immediately prior to the Effective Time are convertible as
of the Effective Time, (iii) the total number of shares of Common Stock
issuable upon exercise of the Options outstanding immediately prior to the
Effective Time that become Cancelled Options pursuant to Section 3.1(b)(i),
and (iv) the total number of shares of Common Stock issuable upon exercise of
the Ungranted Options that become Cancelled Options pursuant to Section
3.1(b)(i).

"Fundamental Representations" shall mean the representations or warranties
contained in Section 4.1 (Organization, Standing and Power), Section 4.2
(Authorization), Section 4.3 (Capitalization), Section 4.13 (Regulatory),
Section 4.14 (Intellectual Property) and Section 4.18 (Brokers).

"GAAP" means United States generally accepted accounting principles in effect
from time to time.

"Goodwin" has the meaning specified in Section 11.11.

"Governmental Entity" means any United States or other national, state,
provincial, prefect, municipal or local government, domestic or foreign, any
subdivision, agency, entity, court, official, commission or authority thereof,
or any quasi-governmental or private body exercising any regulatory, taxing,
importing or other governmental or quasi-governmental authority.

"Governmental Permits" shall have the meaning specified in Section 4.12.

"Grossed-Up Expense Amount Contribution" means, with respect to each
Stockholder and each Option Holder, the sum of (i) such holder's Pro Rata
Share of the Stockholders' Representative Expense Amount, plus (ii) an
additional amount equal to any withholding Taxes applicable to the total
amount transferred to fund the Stockholders' Representative Expense Amount on
behalf of such holder such that, after taking into account any such
withholding Taxes applicable to the amounts described in (i) and this (ii),
such holder has contributed an amount equal to its Pro Rata Share of the
Stockholders' Representative Expense Amount.

"Hazardous Substance" means any pollutant, toxic substance, hazardous waste,
hazardous material, hazardous substance, biological material, petroleum or
petroleum-containing product as listed or regulated under any applicable
Environmental Law.

"HSR Act" has the meaning specified in Section 4.4.

"IND" means an Investigational New Drug Application filed with the FDA with
respect to the Product pursuant to 21 C.F.R. ยง 312 (or any equivalent filing
with any regulatory



10

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





authority outside the United States) before the commencement of clinical
trials involving the Product, including all amendments and supplements to such
application.

"Indemnified Party" has the meaning specified in Section 8.3(a).

"Indemnifying Party" has the meaning specified in Section 8.3(a).

"Independent Accountant" has the meaning specified in Section 3.3(d).

"Indication" means an individual, separate and distinct disease or medical
condition for which clinical results for such disease or condition and an NDA,
or supplement (or other addition) to an existing NDA, would be required for
Regulatory Approval in the United States.

"Intellectual Property" shall mean all intellectual property rights anywhere
in the world, including all rights in and to the following:

(a) all issued patents, reissued or reexamined patents, continuations,
continuations-in-part, requests for continued examinations, divisions,
revivals of patents, utility models, certificates of invention, industrial
design registrations, registrations of patents and extensions thereof,
regardless of country or formal name (collectively, "Issued Patents");

(b) all published or unpublished nonprovisional and provisional patent
applications, reissue applications, reexamination proceedings, invention
disclosures and records of invention, continuations, continuations-in-part,
applications for industrial design registrations and requests for continued
examination and divisionals (collectively, "Patent Applications," and, with
Issued Patents, "Patents");

(c) all copyrights, copyrightable works, database rights, semiconductor
topography and mask work rights, whether the applicable works are published or
unpublished, including all rights of authorship, use, publication,
reproduction, distribution, performance, transformation, moral rights and
rights of ownership of copyrightable works, mask works, and all rights to
register and obtain renewals and extensions of registrations, together with
all other interests accruing by reason of international copyright,
semiconductor topography and mask work conventions, including all such rights
in software, user and training manuals, marketing and promotional materials,
websites, internal reports, business plans and any other expressions, mask
works, firmware and videos, whether registered or unregistered, and all
registrations or applications for registration thereof (collectively,
"Copyrights");

(d) all trademarks, registered trademarks, applications for registration of
trademarks, service marks, registered service marks, applications for
registration of service marks, trade dress, registered trade dress and
applications for registrations of trade dress, trade names, registered trade
names and applications for registrations of trade names (collectively,
"Trademarks") and domain name registrations; and



11

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(e) all technologies, ideas, inventions, designs, proprietary information,
confidential information, manufacturing and operating specifications, lab
notes, notebooks and other records, know-how, formulae, Trade Secrets,
technical data, computer programs, hardware, software, plans, drawings,
blueprints and processes, whether tangible or intangible and whether stored,
compiled, or memorialized physically, electronically, photographically, or
otherwise.

"Interested Party" means any officer or director of the Company or any of its
Subsidiaries, any holder of more than 5% of the Shares (on an as-converted to
Common Stock basis) or, in the case of any such holder of Shares that is an
individual, any parent, sibling, descendant or spouse of any such holder of
Shares.

"Issued Patents" has the meaning set forth in the definition of Intellectual
Property in Section 1.1.

"Joinder Agreement" has the meaning specified in the Recitals.

"Joint Release" has the meaning specified in Section 6.5.

"knowledge of the Company" or "to the Company's knowledge" or similar words
means the actual knowledge of any of the individuals listed in Section 1.1 of
the Disclosure Schedule, after reasonable inquiry; provided that, solely for
purposes of Section 4.14, "knowledge of the Company" or "to the Company's
knowledge" means the actual knowledge of any of the individuals listed in
Section 1.1 of the Disclosure Schedule and [*].

"Laws" means all foreign, federal, state and local statutes, laws, ordinances,
regulations, rules, resolutions, orders, determinations, writs, injunctions,
awards (including, without limitation, awards of any arbitrator), judgments
and decrees applicable to the specified Persons.

"Leased Real Property" has the meaning specified in Section 4.8(a).

"Leases" has the meaning specified in Section 4.8(a).

"Legal Proceedings" has the meaning specified in Section 4.11.

"Letter of Transmittal" means (i) the letter of transmittal with respect to
Shares (which shall specify that delivery shall be effected, and risk of loss
and title to Certificates shall pass, only upon proper delivery by a
Stockholder, as the case may be, of his, her or its Certificates (or affidavit
of loss with respect thereto) in accordance with the instructions thereto),
together with (ii) the instructions thereto for use in effecting the surrender
of the Certificates (or affidavit of loss with respect thereto) in exchange
for the consideration contemplated to be paid pursuant to this Agreement, each
in substantially the form attached hereto as Exhibit D.

"Lien" means, with respect to any property or other assets of any Person, any
mortgage, pledge, lien, security interest, conditional or installment sale
agreement or other charge or encumbrance of any kind thereupon or in respect
thereof.



12

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Loss" or "Losses" has the meaning specified in Section 8.1.

"Material Contracts" has the meaning specified in Section 4.9(a).

"Merger" has the meaning specified in the Recitals.

"Merger Sub" has the meaning specified in the Preamble.

"Milestone Event" has the meaning specified in Section 3.8(a).

"Most Recent Balance Sheet" has the meaning specified in Section 4.5(a).

"Most Recent Balance Sheet Date" has the meaning specified in Section 4.5(a).

"NDA" means a new drug application or a biologics license application (a
"BLA"), including all supplements and amendments thereto and all necessary
documents, data, and other information concerning a product, required for
Regulatory Approval of the product as a pharmaceutical product by the FDA or
an equivalent application to the equivalent agency in any other country or
group of countries (e.g. the marketing authorization application (MAA) in the
European Union).

"Net Closing Working Capital" means (a) the consolidated current assets of the
Company and its Subsidiaries as of 5:00 PM (Eastern time) on the Business Day
immediately preceding the Closing Date, minus (b) the consolidated current
liabilities of the Company and its Subsidiaries as of 5:00 PM (Eastern time)
on the Business Day immediately preceding the Closing Date, in each case as
determined in accordance with GAAP and using the same accounting principles,
practices, policies and methodologies used in the preparation of the Company
Financial Statements; provided, that Net Closing Working Capital shall
exclude, without duplication, (i) any asset or liability related to or
included in the determination of Closing Indebtedness, the Option Cancellation
Payments or Transaction Expenses, (ii) any and all assets or liabilities for
federal, state, local and foreign income Taxes, and (iii) any deferred Tax
assets or deferred Tax liabilities, each to the extent they reflect temporary
differences between GAAP and Tax accounting. For the avoidance of doubt, Net
Closing Working Capital shall include accrued liabilities, if any, for the
prorated portion of annual employee bonuses for 2018.

"Net Closing Working Capital Adjustment" shall mean (i) if the Net Closing
Working Capital is greater than the Net Closing Working Capital Upper Target,
an amount equal to the Net Closing Working Capital minus the Net Closing
Working Capital Upper Target and (ii) if the Net Closing Working Capital is
less than the Net Closing Working Capital Lower Target, an amount equal to the
Net Closing Working Capital minus the Net Closing Working Capital Lower
Target. For the avoidance of doubt, the "Net Closing Working Capital
Adjustment" may be a positive or negative number. For the further avoidance of
doubt, if the Net Closing Working Capital is greater than the Net Working
Capital Lower Target but less than the Net Closing Working Capital Upper
Target, the "Net Working Capital Adjustment" shall be deemed to equal zero.



13

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Net Sales" shall mean, in a particular period of time, the sum of (i) and
(ii) below:

(i) net sales amounts reported by Buyer (or its Affiliates) for sales of the
Product to third parties, calculated in a manner consistent with Buyer's
calculations of net product sales across its product portfolio generally and
as such net product sales are reported in externally published audited
financial statements for the Product for that period (excluding sales to any
sublicensee or Affiliate) (provided that if for any reason Buyer does not have
externally published audited financial statements for the Product, then net
sales amounts for any period that would not be covered by an externally
published audited financial statement shall be calculated in accordance with
GAAP, provided that such amount reflects the gross invoice price at which the
Product was sold or otherwise disposed of by Buyer and its Affiliates
(excluding sales by any sublicensee) to third parties in that period reduced
by gross-to-net deductions, the fair-market-value amounts reasonably
attributable to other components (other than the Product) of any combination
product or bundled product but only if such other components are
therapeutically active compounds that are sold separately, and amounts from a
prior period which are not collected and are written off by Buyer or its
Affiliates (including bad debts), if not previously deducted from such
invoiced amount, taken in accordance with GAAP; and

(ii) net sales amounts reported by each sublicensee (excluding amounts
received by distributors for sales of Products sold to such distributor, if
the sale amounts for such sales to such distributor are otherwise included by
this definition of Net Sales) for sales of the Products to third parties as
determined in accordance with GAAP.

The calculations described in clauses (i) and (ii) above shall exclude hedging
gains or losses. In the case of sales of the Products for consideration other
than cash, such as barter or counter trade, Net Sales shall be calculated on
the fair market value of the consideration received. For the avoidance of
doubt, the supply of Product for compassionate use, commercial samples, or for
administration to patients enrolled in Clinical Trials or to Third Parties as
samples for evaluation purposes, in each case free of charge, shall not be
included in Net Sales.

"Net Working Capital Lower Target" shall mean an amount equal to the Target
Net Working Capital minus [*].

"Net Working Capital Upper Target" shall mean an amount equal to the Target
Net Working Capital plus [*].

"Non-Competition Agreement" has the meaning specified in the Recitals.

"Notice of Objection" has the meaning specified in Section 3.3(c).

"Option" means any outstanding option issued by the Company to purchase Common
Stock from the Company, whether or not issued under the Equity Plan.

"Option Cancellation Payment" means, with respect to each Cancelled Option, an
amount equal to the product of (i) the number of shares of Common Stock
subject to such Cancelled Option, multiplied by (ii) the excess of the
Estimated Per Common Share Closing



14

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Merger Consideration over the per share exercise price of such Option (or the
per share Deemed Exercise Price in the case of an Ungranted Option).

"Option Holder" means a Person holding any Options and a Specified Person
holding any Ungranted Options.

"Other Transaction Documents" means any document, certificate or agreement to
be executed and delivered by any of the Parties in connection with the
transactions contemplated hereby.

"Paid Purchase Price" means (a) the Upfront Purchase Price, plus (b) the Earn-
Out Payments (if any), in each case prior to any reductions, set-offs or
adjustments. For the avoidance of doubt, the total Paid Purchase Price shall
increase upon the achievement of each Milestone Event, up to the maximum
amount of $1,200,000,000.

"Parties" has the meaning set forth in Section 1.2.

"Patent Applications" has the meaning set forth in the definition of
Intellectual Property in Section 1.1.

"Patents" has the meaning set forth in the definition of Intellectual Property
in Section 1.1.

"Paying Agent" means Wilmington Trust Corporation or such other financial
institution that is reasonably acceptable to Buyer and the Stockholders'
Representative and which has been appointed to act as agent for the
Stockholders and Option Holders in connection with the Merger and to receive
the funds to which such Persons shall become entitled pursuant to Article III.

"Paying Agent Agreement" means the Paying Agent Agreement in substantially the
form attached hereto as Exhibit E and entered into at the Closing among Buyer,
the Stockholders' Representative and the Paying Agent.

"Payoff Letters" has the meaning specified in Section 6.10.

"Per Common Share Merger Consideration" means, with respect to each share of
Common Stock, the amount that the holder of such Share has the right to
receive from time to time as a result of the Merger pursuant to Section 3.1.

"Per Share Adjustment Surplus Amount" means the quotient obtained by dividing
(i) the Adjustment Surplus Amount, if positive, by (ii) the Fully Diluted
Common Share Count.

"Per Share Earn-Out Amount," with respect to each Earn-Out Payment, if any,
means the quotient obtained by dividing (i) the amount of such Earn-Out
Payment by (ii) the Fully Diluted Common Share Count.



15

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Per Share Escrow Fund Release Amount" means the quotient obtained by dividing
(i) the applicable Escrow Fund Release Amount, if any, by (ii) the Fully
Diluted Common Share Count.

"Per Share Representative Expense Fund Release Amount" means the quotient
obtained by dividing (i) the Representative Expense Fund Release Amount, if
any, by (ii) the Fully Diluted Common Share Count.

"Permitted Liens" means, with respect to the property or other assets of any
Person (or any revenues, income or profits of that Person therefrom): (i)
statutory Liens for Taxes if the same are not at the time due and delinquent
or are being diligently contested in good faith through appropriate
proceedings and for which an adequate reserve has been established on the
books of the Company or any applicable Subsidiary; (ii) Liens of carriers,
warehousemen, mechanics, laborers and materialmen for sums not yet due or that
are being contested in good faith; (iii) Liens incurred in the ordinary course
of that Person's business in connection with worker's compensation,
unemployment insurance and other social security legislation (other than
pursuant to ERISA or Section 412(n) of the Code); (iv) Liens incurred in the
ordinary course of that Person's business in connection with deposit accounts
or to secure the performance of bids, tenders, trade contracts, statutory
obligations, surety and appeal bonds, performance and return of money bonds
and other obligations of like nature; (v) easements, rights of way,
reservations, restrictions and other similar encumbrances incurred in the
ordinary course of that Person's business or existing on property and not
materially interfering with the ordinary conduct of that Person's business or
the use of that property; (vi) defects or irregularities in that Person's
title to its real properties which do not materially (A) diminish the value of
the surface estate, or (B) interfere with the ordinary conduct of that
Person's business or the use of any such properties; and (vii) any interest or
title of a lessor of assets that Person is leasing pursuant to any capital
lease or synthetic lease or any lease (other than a synthetic lease) that is
accounted for as an operating lease.

"Person" means any individual, corporation, partnership, joint venture,
limited partnership, limited liability company, trust, association, entity or
Governmental Entity.

"Personal Property Leases" has the meaning specified in Section 4.8(b).

"Personally Identifiable Information" means the following information: (i) a
person's first name or first initial, and last name, in combination with any
one or more of the following data elements that relate to that person:
address; phone number; fax number; email address; IP address; driver's license
number or state-issued identification card number; financial account number,
or credit or debit card number; or Social Security number; or (ii)
Individually Identifiable Health Information, as that term is defined in the
Health Information Portability and Accountability Act of 1996. "Personally
Identifiable Information" shall not include information that is lawfully
obtained from publicly available information, or from federal, state or local
government records lawfully made available to the general public.



16

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Phase I Clinical Trial" shall mean a Clinical Trial that is intended to
satisfy the requirements of 21 C.F.R. ยง 312.21(a), as amended from time to
time, or the equivalent regulation in a foreign jurisdiction.

"Pivotal Clinical Trial" means a Clinical Trial that is intended to satisfy or
otherwise acknowledged by the FDA or its foreign counterpart (a) to satisfy
the requirements of 21 C.F.R. ยง312.21(c), as amended, or the equivalent
regulation or definition in a foreign jurisdiction, or (b) to establish
sufficient data for submission of an application for Regulatory Approval of a
product in the U.S. or another country.

"Plan" has the meaning specified in Section 4.16(b).

"Pre-Closing Tax Period" means any Tax period ending on or prior to the
Closing Date.

"Preferred Stock" means (i) the Series A Preferred Stock and (ii) the Series B
Preferred Stock.

"Principal Stockholders" means each of (i) Apple Tree Partners IV, L.P., (ii)
Partners Innovation Fund LLC, (iii) AFB-2 Fund, LLC, (iv) Laurence Blumberg,
(v) Richard Blumberg, and (vi) Franklin Berger.

"Privacy Commitments" has the meaning specified in Section 4.22(b).

"Privacy Matters" means all matters relating to the collection, use, and
security of Personally Identifiable Information gathered or maintained in the
course of the operations of the Company or any of its Subsidiaries.

"Privileged Information" has the meaning specified in Section 11.11.

"Pro Rata Distribution" means, with respect to any amount to be distributed to
the Stockholders and Option Holders after the Merger, a distribution to such
Stockholders and Option Holders in accordance with their respective Pro Rata
Share of such amount, as set forth in the Capital Structure Certificate, which
distribution is to be paid in accordance with the procedures set forth in
Sections 3.4 and 3.5.

"Pro Rata Share" means, with respect to each Stockholder and Option Holder,
(a) the sum of (i) the total number of shares of Common Stock owned by such
Person as of immediately prior to the Effective Time, (ii) the total number of
shares of Common Stock into which shares of Preferred Stock owned by such
Person as of immediately prior to the Effective Time are convertible as of the
Effective Time, (iii) the total number of shares of Common Stock issuable upon
exercise of the Options held by such Person immediately prior to the Effective
Time that become Cancelled Options pursuant to Section 3.1(b)(i), and (iv) the
total number of shares of Common Stock issuable upon exercise of the Ungranted
Options held by such Specified Person that become Cancelled Options pursuant
to Section 3.1(b)(i) divided by (b) the Fully Diluted Common Share Count.



17

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Product" means any product, in any dosage form, formulation, presentation or
package configuration, which comprises or contains the monoclonal antibody
described in Exhibit H, including its peptide and nucleic acid sequence[*].

"Product Candidates" has the meaning specified in Section 4.13(a).

"Promissory Note Balance" means the aggregate principal and interest accrued
as of the Closing Date with respect to the De Graaf Note, the L. Blumberg Note
and the R. Blumberg Note (as such terms are defined in the Company Disclosure
Schedule).

"Property Taxes" has the meaning specified in Section 6.8(c).

"Regulatory Approval" means any and all licenses, registrations,
authorizations and approvals (including approvals of NDA or BLA, as
applicable, in the United States and including pricing and third party
reimbursement approvals in the EMA, but only to the extent such pricing and
third party reimbursement approvals are required to market or sell or obtain
reimbursement for a product as described in Section 3.8(c)) of any
Governmental Entity, necessary for the commercialization of a pharmaceutical
or medicinal product in a regulatory jurisdiction.

"Regulatory Submission" has the meaning specified in Section 4.13(b).

"Release" means any releasing, disposing, discharging, injecting, spilling,
leaking, pumping, dumping, emitting, escaping or emptying of any Hazardous
Substance into the Environment.

"Representative Expense Fund Release Amount" means the amount of the
Stockholders' Representative Expense Amount to be released on any given date
as determined by the Stockholders' Representative.

"Representative Losses" has the meaning specified in Section 9.1(b).

"Representatives" means, with respect to any Person, such Person's directors,
managers, partners, officers, employees, agents and representatives (including
legal counsel and independent accountants).

"Required Stockholder Approval" has the meaning specified in Section 4.2(c).

"Reserve Escrow Account" has the meaning specified in Section 8.9(a).

"Reserve Escrow Account Agreement" has the meaning specified in Section
8.9(a).

"Restricted Sellers" means each of [*].

"Restricted Stock" means any outstanding award of restricted Common Stock with
respect to which any restriction on transfer or requirement of forfeiture has
not previously expired or terminated, whether issued under the Equity Plan or
otherwise.



18

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Sales Earn-Out Goal" has the meaning specified in Section 3.8(a)(viii).

"Sales Earn-Out Payment" has the meaning specified in Section 3.8(a)(viii).

"SC Formulation" means a subcutaneous formulation of the Product that meets
the criteria set forth on Exhibit I.

"Second Escrow Fund Release Amount" has the meaning specified in Section
3.7(c).

"Second Escrow Release Date" shall mean the [*] anniversary of the Closing
Date.

"Second Indication" has the meaning specified in Section 3.8(f).

"Securities Act" means the Securities Act of 1933, as amended, and all Laws
promulgated pursuant thereto or in connection therewith.

"Securityholder" has the meaning specified in Section 6.12(a).

"Securityholder Indemnified Party" or "Securityholder Indemnified Parties" has
the meaning specified in Section 8.2.

"Series A Per Share Liquidation Preference Amount" means, with respect to each
share of Series A Preferred Stock (except as otherwise provided in Section
3.1(a)(ii) and except with respect to Dissenting Shares), $0.98774.

"Series A Preferred Stock" means preferred stock, par value $0.001 per share,
of the Company designated as Series A Preferred Stock.

"Series B Per Share Liquidation Preference Amount" means, with respect to each
share of Series B Preferred Stock (except as otherwise provided in Section
3.1(a)(ii) and except with respect to Dissenting Shares), $1.72855.

"Series B Preferred Stock" means preferred stock, par value $0.001 per share,
of the Company designated as Series B Preferred Stock.

"Shares" means shares of Common Stock and Preferred Stock.

"Specified Person" has the meaning specified in Section 4.3(e).

"Stockholder" means any holder of record of Shares immediately prior to the
Effective Time.

"Stockholders' Representative" has the meaning specified in the Preamble.

"Stockholders' Representative Expense Amount" means $400,000.



19

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





"Stockholders' Representative Group" has the meaning specified in Section
9.1(b).

"Straddle Period" has the meaning specified in Section 6.8(c).

"Subsidiary" of any Person means another Person under the Control of such
Person.

"Surviving Company" has the meaning specified in Section 2.1.

"Target Net Working Capital" means an amount equal to $[*].

"Tax" (and, with correlative meaning, "Taxes" and "Taxable") means any
federal, state, local or foreign income, gross receipts, franchise, estimated,
alternative minimum, add-on minimum, sales, use, license, transfer,
registration, value added, ad valorem, excise, natural resources,
environmental, severance, stamp, occupation, premium, windfall profit,
environmental, customs, duties, special assessment, real property, personal
property, escheat or unclaimed property, withholding, production, capital
stock, social security, employment, unemployment, disability, national
insurance, payroll, government pension plan premiums or any other tax, custom,
duty, governmental fee or other like assessment or charge of any kind
whatsoever, in each case, in the nature of a tax, together with any interest,
penalty or addition thereto, imposed by any Governmental Entity.

"Tax Claim" has the meaning specified in Section 8.3(c).

"Tax Proceedings" has the meaning specified in Section 4.15(a).

"Tax Return" means any return, declaration, report, estimate, information
return or other document (including any documents, statements or schedules
attached thereto), and any amendment thereof, filed or required to be filed
with any federal, state, local or foreign Governmental Entity with respect to
Taxes.

"Termination Date" has the meaning specified in Section 10.2(b).

"Third Party Claim" has the meaning specified in Section 8.3(a).

"Threshold" has the meaning specified in Section 8.4(a).

"Trade Secrets" has the meaning specified in Section 4.14(f).

"Trademarks" has the meaning set forth in the definition of Intellectual
Property in Section 1.1.

"Transaction Expenses" means, without duplication, and to the extent unpaid as
of the open of business on the Closing Date, the aggregate amount of
liabilities payable by the Company or any of its Subsidiaries for which the
Company or Buyer (or any of its Affiliates) could become liable on or after
the Closing, in connection with the negotiation and consummation of the
transactions contemplated by this Agreement or the Merger, including (i)



20

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





fees and expenses of any brokers, finders, consultants, agents and other
advisors incurred by the Company or any of its Subsidiaries in connection with
the negotiation and consummation of the transactions contemplated by this
Agreement, (ii) any change of control or similar compensatory payments, which,
for the avoidance of doubt, shall include severance payments, in each case
that become payable to directors, officers or employees, including Continuing
Employees, of the Company or any of its Subsidiaries solely as a result of the
consummation of the transactions contemplated by this Agreement (including any
termination of employment on or prior to the conclusion of the Continuation
Period) pursuant to any contract or arrangement entered into by the Company or
any of its Subsidiaries with such Person prior to the Closing (excluding any
payments made in respect of Cancelled Options pursuant to Section 3.1(b)(i)),
(iii) the amount of the employer's share of any employment or payroll
(including, for avoidance of doubt, Medicare and social security) Taxes with
respect to the amounts set forth in clause (ii) of this definition, any
payments from the Escrow Fund or the Reserve Escrow Account, and any payments
made in respect of Cancelled Options pursuant to Section 3.1(b)(i), (iv)
amounts owed as a result of the Closing (and, for the sake of clarity, not as
a result of Earn-Out Payments (if any)) to The Brigham and Women's Hospital,
Inc. ("BWH") pursuant to that certain Exclusive Patent License Agreement,
dated as of September 21, 2016, by and between BWH and the Company (the "2016
BWH Agreement") and/or that certain Exclusive Patent License Agreement, dated
as of December 14, 2017, by and between BWH and the Company, in each case
including any "Change of Control Fee" as defined therein, and (v) [*]% of all
fees and all other payments required to be paid to any Governmental Entity
pursuant to Section 6.4(b).

"Transaction Tax Deductions" has the meaning specified in Section 6.8(i)(v).

"Transfer Taxes" has the meaning specified in Section 6.8(a).

"Ungranted Option" has the meaning specified in Section 4.3(e).

"Unresolved Claim" has the meaning specified in Section 8.9(a).

"Unresolved Claim Amount" has the meaning specified in Section 8.9(a).

"Upfront Purchase Price" means an amount equal to $400,000,000.

"Voting Agreement" has the meaning specified in the Recitals.

"Written Consent" has the meaning specified in the Recitals.

Section 1.2 Interpretation. For purposes of this Agreement: (i) the table of
contents and headings contained in this Agreement are for reference purposes
only and shall in no way modify or restrict any of the terms or provisions
hereof, (ii) except as expressly provided herein, the terms "include,"
"includes" or "including" are deemed to be followed by the words "without
limitation", and "or" and "either" are not exclusive, (iii) the words "hereof"
and "herein" and words of similar import shall, unless otherwise stated, be
construed to refer to this Agreement as a whole and not to any particular
provision of this Agreement, (iv) article, section, paragraph, Preamble,
Recital, exhibit and schedule references are to the articles, sections,
paragraphs,



21

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Preamble, Recitals, exhibits and schedules of this Agreement unless otherwise
specified, (v) the meaning assigned to each term defined herein shall be
equally applicable to both the singular and the plural forms of such term, and
words denoting any gender shall include all genders, and the definitions
contained in this Agreement are applicable to the other grammatical forms of
such terms, (vi) a reference to any party to this Agreement or any other
agreement or document shall include such party's successors and permitted
assigns, (vii) a reference to any Laws or other legislation or to any
provision of any Law or legislation shall include any amendment to, and any
modification or re-enactment thereof, any provision substituted therefor and
all regulations and statutory instruments issued thereunder or pursuant
thereto, (viii) all references to "$" or "dollars" shall be deemed references
to United States dollars, (ix) capitalized terms used and not defined in the
exhibits and schedules attached to this Agreement shall have the respective
meanings set forth in this Agreement, (x) the word "or" is not exclusive,
unless the context clearly dictates otherwise, (xi) if any action is to be
taken by any Party pursuant to this Agreement on a day that is not a Business
Day, such action will be taken on the next Business Day following such day and
(x) Buyer, Merger Sub, the Stockholders' Representative, the Surviving Company
(following the Closing) and the Company (prior to the Closing) shall be
collectively referred to herein as the "Parties" and each, individually, as a
"Party".

ARTICLE II 

THE MERGER

Section 2.1 The Merger. At the Effective Time, upon the terms and subject to
the conditions of this Agreement and in accordance with the DGCL, (i) Merger
Sub shall be merged with and into the Company, (ii) the separate corporate
existence of Merger Sub shall cease, and (iii) the Company shall be the
surviving entity (the "Surviving Company") and shall continue its legal
existence under the DGCL as a wholly-owned subsidiary of Buyer.

Section 2.2 Effective Time; Closing Date. Upon the terms and subject to the
conditions of this Agreement, the Company and Merger Sub shall cause the
Merger to be consummated by filing a certificate of merger with the Secretary
of State of the State of Delaware in substantially the form attached hereto as
Exhibit F (the "Certificate of Merger") and all other filings or recordings
required by the DGCL in connection with the Merger. The Merger shall become
effective at such time as the Certificate of Merger is duly filed in
accordance with the provisions of Section 251 of the DGCL, or at such later
time as may be stated in the Certificate of Merger (the "Effective Time"). The
closing of the Merger (the "Closing") shall take place at the offices of Foley
Hoag LLP, Seaport West, 155 Seaport Boulevard, Boston, Massachusetts 02210, at
10:00 a.m., local time, on the date that is no later than two Business Days
after the date on which the last of the conditions set forth in Article VII
shall have been satisfied or waived (other than any such conditions that by
their nature cannot be satisfied until the Closing, which shall be satisfied
or (to the extent permitted by applicable Law) waived at the Closing), or on
such other date, time and place as the Company and Buyer may mutually agree
(the "Closing Date").

Section 2.3 Effect of the Merger. At the Effective Time, the effect of the
Merger shall be as provided in this Agreement, the Certificate of Merger and
the applicable provisions of the



22

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





DGCL. Without limiting the generality of the foregoing, and subject thereto,
at the Effective Time, all the property, rights, privileges, powers,
franchises and assets of the Company and Merger Sub shall vest in the
Surviving Company, and all debts, liabilities, obligations and duties of the
Company and Merger Sub shall become the debts, liabilities, obligations and
duties of the Surviving Company.

Section 2.4 Certificate of Incorporation; Bylaws. At the Effective Time, (i)
the certificate of incorporation of the Surviving Company shall be amended and
restated to be in the form of the certificate of incorporation of Merger Sub
as in effect immediately prior to the Effective Time, except that the name of
the Surviving Company shall be "Syntimmune, Inc.", until thereafter amended as
provided by the DGCL, and (ii) the bylaws of the Surviving Company shall be
amended and restated to be in the form of the bylaws of Merger Sub as in
effect immediately prior to the Effective Time, until thereafter amended as
provided by the DGCL and the certificate of incorporation of the Surviving
Company.

Section 2.5 Board of Directors and Officers. The Board of Directors and
officers of Merger Sub immediately prior to the Effective Time shall, from and
after the Effective Time, be the Board of Directors and officers,
respectively, of the Surviving Company, each to hold office until his or her
respective successors are duly elected or appointed and qualified or until
their earlier death, resignation or removal in accordance with applicable Law
and the certificate of incorporation and bylaws of the Surviving Company.

Section 2.6 Further Assurances. If at any time after the Effective Time the
Surviving Company shall consider or be advised that any deeds, bills of sale,
assignments or assurances or any other acts or things are necessary, desirable
or proper (a) to vest, perfect or confirm, of record or otherwise, in the
Surviving Company, its right, title or interest in, to or under any of the
properties, rights, privileges, powers, franchises or assets of either the
Company or Merger Sub, or (b) otherwise to carry out the purposes of this
Agreement, the Surviving Company and its proper officers, managers and members
or their designees shall be authorized to execute and deliver, in the name and
on behalf of the Company or Merger Sub, all such deeds, bills of sale,
assignments and assurances and do, in the name and on behalf of the Company or
Merger Sub, all such other acts and things necessary, desirable or proper to
vest, perfect or confirm its right, title or interest in, to or under any of
the properties, rights, privileges, powers, franchises or assets of the
Company or Merger Sub, as applicable, and otherwise to carry out the purposes
of this Agreement.

Section 2.7 Closing Deliverables.

(a) FIRPTA. Unless waived by Buyer in writing, at or prior to the Closing, the
Company shall deliver to Buyer a certificate(s), duly executed and
acknowledged, in form and substance reasonably satisfactory to Buyer,
certifying that the Merger is exempt from withholding under section 1445 of
the Code in accordance with Treasury Regulations under Sections 897 and 1445
of the Code, together with an executed notice to the Internal Revenue Service
in accordance with the provisions of Treasury Regulations Section
1.897-2(h)(2) to be filed by Buyer after the Closing. If Buyer does not
receive the certification and executed notice at or prior to the Closing,
Buyer, the Surviving Company, and the Paying Agent shall be



23

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





permitted to withhold from the payments to be made pursuant to this Agreement
any required withholding Tax under Section 1445 of the Code.

(b) Director and Officer Resignations. The Company shall deliver to Buyer
prior to the Closing a resignation (which may be conditioned upon the
occurrence of the Closing) from each then-current member of the Board of
Directors and all then-current officers of the Company and from each then-
current member of the Board of Directors or comparable governing body and all
then-current officers for each of the Company's Subsidiaries, unless Buyer
requests that any such resignations not be delivered no later than three
Business Days prior to Closing.

(c) Good Standing. Unless waived by Buyer in writing, the Company shall
deliver to Buyer prior to the Closing good standing certificates for the
Company issued by the State of Delaware and the Commonwealth of Massachusetts
and a good standing certificate (or equivalent certificate) for its Subsidiary
issued by the relevant Governmental Entity in the Subsidiary's jurisdiction of
organization (if such jurisdiction will provide such a certificate), in each
case dated no more than five (5) Business Days prior to the Closing Date.

ARTICLE III 

EFFECTS OF THE MERGER; CONSIDERATION

Section 3.1 Conversion of Company Securities.

(a) At the Effective Time, by virtue of the Merger and without any action on
the part of the Company, Merger Sub, Buyer or any of their respective
stockholders:

(i) each issued and outstanding share of common stock, par value $0.01 per
share, of Merger Sub shall be converted automatically into and become one
fully paid and nonassessable share of common stock, par value $0.01 per share,
of the Surviving Company;

(ii) each issued and outstanding share of Common Stock or Preferred Stock that
is owned by (i) the Company as treasury stock, (ii) Buyer, (iii) Merger Sub,
(iv) any other wholly-owned Subsidiary of Buyer or (v) any wholly-owned
Subsidiary of the Company, shall be canceled and extinguished without any
conversion thereof and no payment or distribution (including any Pro Rata
Distributions) shall be made with respect thereto;

(iii) except as otherwise provided in Section 3.1(a)(ii) and except with
respect to Dissenting Shares, each share of Common Stock outstanding
immediately prior to the Effective Time shall be cancelled and extinguished
and converted automatically into the right to receive, upon surrender of the
corresponding Certificate or submission of an affidavit of loss in accordance
with Section 3.5, (A) an amount in cash equal to the Estimated Per Common
Share Closing Merger Consideration, and (B) when, as and if any of the
following



24

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





become payable pursuant to the terms of this Agreement: (1) an amount in cash
equal to the Per Share Adjustment Surplus Amount, which amount will be paid in
accordance with Section 3.4; (2) if an Earn-Out Payment is made pursuant to
Section 3.8, an amount in cash equal to the Per Share Earn-Out Amount
associated with such Earn-Out Payment, which amount will be paid in accordance
with Section 3.4; and (3) an amount in cash equal to the Per Share Escrow Fund
Release Amount and/or the Per Share Representative Expense Fund Release
Amount, as applicable, which each such amount will be paid in accordance with
Section 3.4 and/or Section 3.9, as applicable, and each such payment made
under this Section 3.1(a)(iii) without interest and subject to any applicable
withholding Tax;

(iv) except as otherwise provided in Section 3.1(a)(ii) and except with
respect to Dissenting Shares, each share of Preferred Stock outstanding
immediately prior to the Effective Time shall be cancelled and extinguished
and converted automatically into the right to receive, with respect to each
share of Common Stock into which such share of Preferred Stock was convertible
immediately prior to the Effective Time, upon surrender of the corresponding
Certificate or submission of an affidavit of loss in accordance with Section
3.5, (A) the Series A Per Share Liquidation Preference Amount or the Series B
Per Share Liquidation Preference Amount, as applicable with respect to such
share, (B) an amount in cash equal to the Estimated Per Common Share Closing
Merger Consideration, and (C) when, as and if any of the following become
payable pursuant to the terms of this Agreement: (1) an amount in cash equal
to the Per Share Adjustment Surplus Amount, which amount will be paid in
accordance with Section 3.4; (2) if an Earn-Out Payment is made pursuant to
Section 3.8, an amount in cash equal to the Per Share Earn-Out Amount
associated with such Earn-Out Payment, which amount will be paid in accordance
with Section 3.4; and (3) an amount in cash equal to the Per Share Escrow Fund
Release Amount and/or the Per Share Representative Expense Fund Release
Amount, as applicable, which each such amount will be paid in accordance with
Section 3.4 and/or Section 3.9, as applicable, and each such payment made
under this Section 3.1(a)(iv) without interest and subject to any applicable
withholding Tax.

(b) Treatment of Options.

(i) At the Effective Time, each vested Option outstanding as of immediately
prior to the Effective Time and each Ungranted Option shall, automatically and
without any required action on the part of the holder thereof, be cancelled
(each a "Cancelled Option") and, subject to the applicable Option Holder
signing a Joinder Agreement, such Option Holder shall receive, in full
satisfaction of any rights such holder may have under such Option:

(A) an amount in cash equal to the Option Cancellation Payment applicable to
such Cancelled Option; and



25

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(B) when, as and if any of the following become payable pursuant to the terms
of this Agreement: (1) an amount in cash equal to the Per Share Adjustment
Surplus Amount multiplied by the number of shares of Common Stock subject to
such Cancelled Option, which amount will be paid in accordance with Section
3.4; (2) at such time and only to the extent that an Earn-Out Payment is made
pursuant to Section 3.8, an amount in cash equal to the Per Share Earn-Out
Amount associated with such Earn-Out Payment, which amount will be paid in
accordance with Section 3.4; and (3) an amount in cash equal to the Per Share
Escrow Fund Release Amount and/or the Per Share Representative Expense Fund
Release Amount, as applicable, multiplied by the number of shares of Common
Stock subject to such Cancelled Option, which each such amount will be paid in
accordance with Section 3.4 and/or Section 3.9, without interest and subject
to any applicable withholding Taxes; provided, that each payment under this
Section 3.1(b)(i)(B) shall be made in accordance with Treasury Regulation
1.409A-3(i)(5)(iv)(A), and to the extent that any payment under this Section
3.1(b)(i)(B) would be made later than five years following the Effective Time
such payment shall not be made unless Buyer determines reasonably in good
faith that payment complies with the requirements of such regulation.
Notwithstanding anything in this Agreement to the contrary, in the event that
a payment under this Section 3.1(b)(i)(B) shall fail to comply with the
requirements of Treasury Regulation 1.409A-3(i)(5)(iv)(A), such payment shall
be deemed forfeited by such Option Holder and reallocated to the Stockholders
in accordance with his, her or its Pro Rata Share (which, for the avoidance of
doubt, shall be recalculated to exclude in both the numerator and denominator
the Cancelled Options to which such forfeited payment relates).

(ii) At the Effective Time, each Option outstanding as of immediately prior to
the Effective Time that is not vested shall be canceled without payment of any
consideration whatsoever being made in respect thereof.

(iii) Any payments made pursuant to this Section 3.1(b) shall be treated as
compensation income to the holder of Cancelled Options receiving such payments
and shall be made without interest and subject to any applicable withholding
Tax.

(iv) As of the Effective Time, (A) each agreement evidencing Options or
Ungranted Options entered into by the Company (including the Equity Plan)
shall terminate and all rights under any provision of any other plan, program
or arrangement of the Company or any of its Subsidiaries providing for the
issuance or grant of any other interest in respect of the capital stock of the
Company or any of its Subsidiaries shall be cancelled, (B) each Cancelled
Option shall terminate and (C) all rights under any provision of any other
plan, program or arrangement of the Company or any of its Subsidiaries
providing for the issuance or grant of any other interest in respect of the
capital stock of the Company or any of its Subsidiaries shall be cancelled.



26

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(v) Prior to the Effective Time, the Company shall take any actions necessary
to effect the transactions contemplated by this Section 3.1(b) under the
Equity Plan and all agreements evidencing Options or Ungranted Options.

(c) Treatment of Restricted Stock. The Board of Directors of the Company (or
the appropriate committee thereof) shall adopt such resolutions or take such
other actions as shall be required to cause all restrictions on the then
outstanding shares of Restricted Stock to lapse as of immediately prior to the
Effective Time. Each holder of Restricted Stock shall be treated as a holder
of Common Stock issued and outstanding as of immediately prior to the
Effective Time; provided, however, that the Promissory Note Balance applicable
to each holder of Restricted Stock shall be deducted from the amounts payable
at the Closing with respect to each such holder of Restricted Stock, which
amount shall be deemed to have been received by the applicable holder of
Restricted Stock for all Tax purposes and then to have been paid by the holder
of Restricted Stock to the Company in satisfaction of the applicable
Promissory Note Balance.

(d) Cancellation of Company Securities. From and after the Effective Time, all
capital stock of the Company, and all options and warrants relating thereto,
shall no longer be outstanding and shall automatically be canceled and
retired, or converted in accordance with this Section 3.1, as the case may be,
and each holder of a certificate or other instrument representing any such
shares, options or warrants shall cease to have any rights with respect
thereto, other than the right to receive the consideration provided herein,
without interest thereon. In calculating the consideration payable under this
Section 3.1(d), Buyer shall be entitled to rely on the representations and
warranties contained in Section 4.3 and the Capital Structure Certificate.

Section 3.2 Closing Estimates. At least two (2) Business Days prior to the
Closing Date, the Company shall deliver to Buyer a statement setting forth (a)
its estimate of the Net Closing Working Capital Adjustment (such estimate, the
"Estimated Net Closing Working Capital Adjustment"), (b) its estimate of the
Transaction Expenses (such estimate, the "Estimated Transaction Expenses"),
(c) its estimate of the Closing Indebtedness (such estimate, the "Estimated
Closing Indebtedness"), and (d) its estimate of the Closing Cash (such
estimate, the "Estimated Closing Cash"), in the case of clauses (a) through
(d), as set forth on a statement in a form reasonably acceptable to Buyer and
along with reasonable supporting detail to evidence the calculations of such
amounts.

Section 3.3 Adjustment Amount.

(a) As soon as reasonably practicable following the Closing Date, and in any
event within one hundred twenty (120) days thereafter, Buyer shall cause to be
prepared and delivered to the Stockholders' Representative (i) an unaudited
consolidated balance sheet of the Company and its Subsidiaries as of 5:00 PM
(Eastern time) on the Business Day immediately preceding the Closing Date (the
"Closing Balance Sheet"), together with a statement setting forth Buyer's
calculation of the Net Closing Working Capital Adjustment as derived from the
Closing Balance Sheet, (ii) a statement setting forth Buyer's calculation of
the Transaction Expenses, (iii) a statement setting forth Buyer's calculation
of the Closing Indebtedness and (iv) a statement



27

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





setting forth Buyer's calculation of the Closing Cash, in each case, as set
forth on a statement in a form reasonably acceptable to the Stockholders'
Representative, along with reasonable supporting detail to evidence the
calculations of such amounts. The Closing Balance Sheet and Buyer's
calculations of the Net Closing Working Capital Adjustment, the Transaction
Expenses, the Closing Indebtedness and the Closing Cash shall be prepared in
accordance with GAAP and using the same accounting principles, practices,
policies and methodologies used in the preparation of the Company Financial
Statements.

(b) After the delivery of the Closing Balance Sheet, the Net Closing Working
Capital Adjustment, the Transaction Expenses, the Closing Indebtedness and the
Closing Cash in accordance with Section 3.3(a), at the Stockholders'
Representative's request, Buyer shall cause the Surviving Company and its
Subsidiaries, including their respective Representatives, to reasonably
cooperate with the Stockholders' Representative and its Representatives in
their review of the Closing Balance Sheet and Buyer's calculations of the Net
Closing Working Capital Adjustment, the Transaction Expenses, the Closing
Indebtedness and the Closing Cash and shall provide to the Stockholders'
Representative and its Representatives information that they may reasonably
request and access during normal business hours to the personnel, properties,
working papers, books and records of the Surviving Company and its
Subsidiaries for such purpose.

(c) Unless the Stockholders' Representative notifies Buyer in writing within
sixty (60) days after Buyer's delivery of the Closing Balance Sheet, the Net
Closing Working Capital Adjustment, the Transaction Expenses, the Closing
Indebtedness and the Closing Cash in accordance with Section 3.3(a), and the
supporting detail with respect thereto, of any objection to the computations
set forth in the Closing Balance Sheet or Buyer's calculations of the Net
Closing Working Capital Adjustment, the Transaction Expenses, the Closing
Indebtedness or the Closing Cash (the "Notice of Objection"), the Closing
Balance Sheet and Buyer's calculations of the Net Closing Working Capital
Adjustment, the Transaction Expenses, the Closing Indebtedness and the Closing
Cash shall be final and binding for all purposes hereunder. Any Notice of
Objection shall specify in reasonable detail the basis for the objections set
forth therein and shall include the Stockholders' Representative's calculation
of any amounts that are disputed by such Notice of Objection (the "Disputed
Amounts") to the extent that such amounts may be determined (it being
understood that an objection to one or more of the foregoing amounts shall not
prevent any other amount from becoming final and binding for all purposes
hereunder).

(d) If the Stockholders' Representative provides such Notice of Objection to
Buyer within such 60-day period, Buyer and the Stockholders' Representative
shall, during the 60-day period following the Stockholders' Representative's
delivery of such Notice of Objection to Buyer, attempt in good faith to
resolve any Disputed Amounts. If Buyer and the Stockholders' Representative
are unable to resolve all such Disputed Amounts within such period, the
matters remaining in dispute shall be submitted to a nationally recognized
public accounting firm mutually agreed upon by Buyer and the Stockholders'
Representative (such accounting firm being referred to herein as the
"Independent Accountant"). The parties shall instruct the Independent
Accountant to render its decision as promptly as possible, but no later than
sixty (60) days after its selection. The Independent Accountant will consider
only those items and



28

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





amounts in the Stockholders' Representative's and Buyer's respective
calculations of the Net Closing Working Capital Adjustment, the Transaction
Expenses, the Closing Indebtedness and the Closing Cash that are identified as
being items and amounts to which the Stockholders' Representative and Buyer
have been unable to agree. In resolving any disputed item, the Independent
Accountant may not assign a value to any item greater than the greatest value
for such item claimed by the Stockholders' Representative or Buyer or less
than the smallest value for such item claimed by either of them. The Surviving
Company and the Stockholders' Representative shall each furnish to the
Independent Accountant such work papers and other documents and information
relating to the Disputed Amounts as the Independent Accountant may reasonably
request. The resolution of the Disputed Amounts by the Independent Accountant
shall be final and binding, and the determination of the Independent
Accountant shall constitute an arbitral award that is final, binding and
unappealable and upon which a judgment may be entered by a court having
jurisdiction thereover. After final determination of the Net Closing Working
Capital Adjustment, the Transaction Expenses, the Closing Indebtedness and the
Closing Cash, the Stockholders' Representative shall have no further right to
make any claims in respect of any element of the foregoing amounts that the
Stockholders' Representative raised in the Notice of Objection.

(e) The date on which the Net Closing Working Capital Adjustment, the
Transaction Expenses, the Closing Indebtedness and the Closing Cash are
finally determined in accordance with this Section 3.3 is hereinafter referred
as to the "Determination Date." Buyer and the Stockholders' Representative (on
behalf of the Securityholders) shall each pay their own costs and expenses
incurred in connection with the resolution of the Disputed Amounts; provided,
that the fees and expenses of the Independent Accountant shall be allocated
between Buyer and the Stockholders' Representative in the same proportion that
the total amount of the Disputed Amounts submitted to the Independent
Accountant that is unsuccessfully disputed by each such party (as finally
determined by the Independent Accountant) bears to the total amount of the
Disputed Amounts so submitted by each such party (e.g., should the items in
dispute total in amount to $1,000 and the Independent Accountant awards $600
in favor of Buyer's position, 60% of the costs of its review would be borne by
the Stockholders' Representative and 40% of the costs would be borne by
Buyer).

(f) "Adjustment Amount" (positive or negative) means the Final Aggregate
Closing Merger Consideration minus the Estimated Aggregate Closing Merger
Consideration. If the Adjustment Amount is a positive number (an "Adjustment
Surplus Amount"), within ten (10) Business Days following the Determination
Date, Buyer shall deliver by wire transfer of immediately available funds (i)
to the Paying Agent, an amount equal to the applicable portion of the
Adjustment Surplus Amount payable to the Stockholders, and (ii) to the
Surviving Company, the applicable portion of the Adjustment Surplus Amount
payable to the holders of Cancelled Options. Upon receipt by the Paying Agent
of the applicable portion of the Adjustment Surplus Amount payable to the
Stockholders, Buyer shall direct the Paying Agent to promptly disburse the
amounts so received by it, subject to the procedures set forth in Section 3.4
and Section 3.5(a). Upon receipt by the Surviving Company of the applicable
portion of the Adjustment Surplus Amount payable to the holders of Cancelled
Options, the Surviving Company shall promptly disburse the amounts so received
by it, subject to the procedures set forth in Section 3.4



29

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





and Section 3.5(b). If the Adjustment Amount is a negative number (an
"Adjustment Deficit Amount"), within three (3) Business Days following the
Determination Date, the absolute value of such Adjustment Deficit Amount shall
be distributed, by wire transfer of immediately available funds, by the Escrow
Agent from the Escrow Fund to an account designated in writing by Buyer. In
the event that there is an Adjustment Deficit Amount in excess of [*] Buyer
shall be entitled to deposit a portion of the EarnโOut Payments (if any) equal
to such Adjustment Deficit Amount in the Escrow Account, which Escrow Account
shall be subject to release in accordance with Section 3.7.

Section 3.4 Disbursements by Paying Agent and the Surviving Company. In the
event that an Adjustment Surplus Amount exists, an Earn-Out Payment is to be
made or an Escrow Fund Release Amount exists, Buyer shall pay such amounts to
the Paying Agent (with respect to amounts to be paid to the Stockholders and
recipients of Transaction Expenses) and the Surviving Company (with respect to
amounts to be paid to the holders of Cancelled Options) for distribution to
the Stockholders and holders of Cancelled Options in accordance with the
procedures set forth in Section 3.5(a) and Section 3.5(b), respectively.

Section 3.5 Exchange Procedures.

(a) As soon as practicable following the date hereof, the Company shall mail
or cause to be mailed, or otherwise make available, to each holder of
certificates (the "Certificates") formerly evidencing Shares a form of the
Letter of Transmittal. After the Effective Time, each holder of Certificates,
promptly (but in any event within two (2) Business Days) following the
surrender of such Certificates (or affidavit of lost certificate(s)) to the
Paying Agent, together with the duly completed and validly executed Letter of
Transmittal, shall be entitled to receive from the Paying Agent, in exchange
therefor and subject to any additional terms and conditions of the Paying
Agent, by wire transfer of immediately available funds to the account
designated by such holder in the Letter of Transmittal, and otherwise by
check, the applicable portion of the consideration that such former holder of
Shares has the right to receive from time to time pursuant to this Article
III, and any Certificates so surrendered shall be cancelled. Notwithstanding
the foregoing, if requested by the Company, Buyer shall reasonably cooperate
in distributing the Letters of Transmittal prior to the Closing so that they
can be collected and delivered to the Paying Agent on or prior to the Closing
as coordinated by the Company's counsel.

(b) The Company shall use commercially reasonable efforts to obtain from each
holder of any Cancelled Options an executed Joinder Agreement with respect to
such Cancelled Options prior to the Closing; provided, however, that the
Company shall be under no obligation to offer any payment to the holders of
any Cancelled Options that do not provide an executed Joinder Agreement with
respect to such Cancelled Options. As soon as reasonably practicable after the
date hereof, but in any event not later than seven (7) Business Days after the
date hereof, the Company shall send a written notice in a form reasonably
acceptable to Buyer to each Option Holder that shall inform such Option Holder
of the treatment of the Options and Ungranted Options provided in Section
3.1(b) and providing instructions for the delivery of a Joinder Agreement in
exchange for the consideration as specified and allocated in Section 3.1(b).



30

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





After the Effective Time, each holder of Cancelled Options, subject to signing
a Joinder Agreement, shall be entitled to receive in exchange therefor, the
applicable portion of the consideration that the holder of such Cancelled
Options has the right to receive from time to time pursuant to this Article
III. In each case, the consideration payable to such former holder of
Cancelled Options shall be made by the Surviving Company in accordance with
its payroll practices on the Surviving Company's next regularly scheduled pay
day following the tenth (10th) Business Day after such holder becomes entitled
to receive such consideration under this Section 3.5(b).

(c) In the event of a transfer of ownership of any Shares that is not
registered in the transfer books of the Company, subject to any applicable
withholding Taxes, payment may be made to a Person other than the Person in
whose name the Certificate so surrendered is registered, if such Certificate
shall be properly endorsed or otherwise be in proper form for transfer.
Notwithstanding the foregoing, if any Certificate shall be lost, stolen or
destroyed, upon the making of an affidavit of that fact and an undertaking of
indemnity by the Person claiming such Certificate to be lost, stolen or
destroyed, the Surviving Company will issue in exchange for such lost, stolen
or destroyed Certificate the consideration deliverable in respect thereof
pursuant to this Agreement.

(d) At any time following the expiration of [*] after the Effective Time, the
Buyer shall, in its reasonable discretion, be entitled to require the Paying
Agent to deliver to it any funds (including any interest received with respect
thereto) which had been made available to the Paying Agent and which have not
been disbursed to holders of Certificates, and such funds shall thereafter
become the property of the Buyer. Such funds may be commingled with the
general funds of the Buyer and shall be free and clear of any claims or
interests of any Person. Thereafter, such holders of Certificates shall be
entitled to look to the Buyer (subject to any applicable abandoned property,
escheat or similar Law) only as general creditors thereof with respect to the
applicable consideration payable as contemplated by this Agreement (without
interest and subject to any applicable withholding Taxes) upon due surrender
of their Certificates. Any portion of such remaining cash unclaimed by
Stockholders as of a date that is immediately prior to such time as such
amounts would otherwise escheat to or become property of any Governmental
Entity shall, to the extent permitted by applicable Law, become the property
of the Buyer free and clear of any claims or interest of any Person previously
entitled thereto.

(e) At the Closing, the transfer books of the Company shall be closed, and
there shall be no further registration of transfer in the transfer books of
the Surviving Company of the Shares that were outstanding immediately prior to
the Effective Time. If, after the Effective Time, Certificates are presented
to the Surviving Company or the Paying Agent for any reason, they shall be
canceled and exchanged as provided in this Section 3.5.

Section 3.6 Payments at Closing. At the Closing, Buyer will make (or cause to
be made) the following payments:

(a) to the Paying Agent, an amount equal to the Aggregate Liquidation
Preference Amount payable to the holders of Preferred Stock;



31

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(b) to the Paying Agent, an amount equal to the applicable portion of the
Estimated Aggregate Closing Merger Consideration payable to the Stockholders;

(c) to the Surviving Company, the applicable portion of the Estimated
Aggregate Closing Merger Consideration payable to the holders of Cancelled
Options;

(d) to the Escrow Agent, an amount equal to the Escrow Amount;

(e) to the Stockholders' Representative, by wire transfer of immediately
available funds to the account or accounts designated by the Stockholders'
Representative in writing no later than two (2) Business Days prior to the
Closing Date, an amount equal to the Stockholders' Representative Expense
Amount; provided, that the Stockholders' Representative Expense Amount shall
be deemed for Tax purposes to have been paid to the Stockholders and Option
Holders at the Closing in proportion to their respective Pro Rata Shares; and,
provided further, to the extent that any withholding is required in connection
with such deemed payment, then to ensure that the Stockholder or Option Holder
to which the withholding applies has contributed its Pro Rata Share to the
Stockholders' Representative Expense Amount (after taking into account any
such withholding), such Stockholder or Option Holder shall be deemed to have
received an amount equal to its Grossed-Up Expense Amount Contribution to fund
the Stockholders' Representative Expense Amount and, notwithstanding anything
to the contrary in this Agreement, any other amount unrelated to the
Stockholders' Representative Expense Amount that otherwise would have been
payable to the applicable Stockholder or Option Holder at Closing shall be
reduced by the amount of any such payment deemed received by the Stockholder
or Option Holder in excess of its Pro Rata Share of the Stockholders'
Representative Expense Amount;

(f) on behalf of the Company, by wire transfer of immediately available funds
to the account or accounts designated by the Company in the statement of
Transaction Expenses delivered pursuant to Section 3.2, an amount in the
aggregate equal to the Transaction Expenses, which amounts shall be
distributed in accordance with the statement of Transaction Expenses delivered
pursuant to Section 3.2; and

(g) on behalf of the Company, by wire transfer of immediately available funds
to the account or accounts designated by the Payoff Letters obtained pursuant
to Section 6.10 in respect of the Closing Indebtedness or as otherwise
designated by the Company in writing no later than two (2) Business Days prior
to the Closing Date, an amount in the aggregate equal to the Closing
Indebtedness, as set forth in the statement of Closing Indebtedness delivered
pursuant to Section 3.2.

Section 3.7 Escrow Amount.

(a) At the Closing, Buyer shall deposit with Wilmington Trust Corporation (the
"Escrow Agent"), by wire transfer of immediately available funds, an amount
equal to the Escrow Amount, such amount plus all accumulated earnings thereon
(such amounts, if any, "Escrow Consideration") to constitute an escrow fund
(the "Escrow Fund") to be governed in accordance with the terms of this
Agreement and the escrow agreement in substantially the form



32

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





attached hereto as Exhibit G (the "Escrow Agreement"), among Buyer, the Escrow
Agent and the Stockholders' Representative.

(b) The Escrow Fund shall be used to satisfy any amounts owed to Buyer
pursuant to this Agreement, including the payment of the Adjustment Amount, if
any, pursuant to Section 3.3(f) and any indemnification amounts owed
hereunder. Buyer and the Stockholders' Representative shall timely provide any
joint written instructions contemplated by Section 3.3 or Article VIII so that
distributions can be made by the Escrow Agent within the time period required
by Section 3.3(f) or Article VIII.

(c) The First Escrow Fund Release Amount shall be released pursuant to joint
written instructions to be provided to the Escrow Agent by Buyer and the
Stockholders' Representative on the date that is one (1) Business Day after
the First Escrow Release Date. The "First Escrow Fund Release Amount" shall be
equal to [*]. Any remaining portion of the Escrow Fund that is not used to
satisfy any other amounts owing to Buyer pursuant to this Agreement, including
indemnification amounts, or not subject to any claims hereunder, shall be
released pursuant to joint written instructions to be provided to the Escrow
Agent by Buyer and the Stockholders' Representative on the date that is one
(1) Business Day after the Second Escrow Release Date (the "Second Escrow Fund
Release Amount") as provided in this Section 3.7(c); provided, that if there
are any indemnification claims hereunder that are properly pending on the
Second Escrow Release Date, such portion of the Escrow Fund corresponding to
the amounts subject to such claims shall not be released until the applicable
claims are finally resolved and satisfied. The First Escrow Fund Release
Amount and the Second Escrow Fund Release Amount are each referred to herein
from time to time as an "Escrow Fund Release Amount." Upon any release of the
Escrow Fund, the Escrow Agent shall release (i) to the Paying Agent, an amount
equal to the applicable portion of the Escrow Fund Release Amount payable to
the Stockholders and (ii) to the Surviving Company, the applicable portion of
the Escrow Fund Release Amount payable to the Option Holders. Upon the final
release of all of the Escrow Fund, the Escrow Agreement shall terminate. All
funds so released from the Escrow Fund shall include any Escrow Consideration
and shall be distributed by the Escrow Agent to the Paying Agent (with respect
to the applicable portion of the Escrow Fund Release Amount payable to the
Stockholders) or the Surviving Company (with respect to the applicable portion
of the Escrow Fund Release Amount payable to the holders of Cancelled
Options).

(d) The Escrow Fund shall be held as a trust fund and shall not be subject to
any Lien, and shall be held and disbursed solely for the purposes and in
accordance with the terms of this Agreement and the Escrow Agreement.

(e) The Parties agree that for Tax purposes: (i) it is intended that, if and
to the extent any portion of the Escrow Fund is actually distributed to Option
Holders in respect of their Cancelled Options or any Earn-Out Payment is
actually paid to Option Holders in respect of their Cancelled Options, such
portion shall be treated as compensation paid at the time the portion of the
Escrow Fund is actually released to the Option Holders or the amount of such
Earn-Out Payment is actually paid to the Option Holders and, in each case,
shall be subject to applicable withholding Tax at such time; (ii) it is
intended that the right of the holders of Common Stock



33

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





and Preferred Stock to the Escrow Fund and Earn-Out Payments be treated as
deferred contingent purchase price eligible for installment sale treatment
under Section 453 of the Code and any corresponding provision of foreign,
state or local law, as appropriate (provided, however, Buyer is making no
representation or covenant as to whether such Tax treatment shall be respected
by any Governmental Entity); (iii) it is intended that Buyer shall be treated
as the owner of the Escrow Fund, and all interest and earnings earned from the
investment and reinvestment of the Escrow Fund, or any portion thereof, shall
be allocable to Buyer and Buyer shall receive quarterly distributions from the
Escrow Fund equal to 25% of the amount of the income earned by the Escrow Fund
for such quarter in order for Buyer to pay its taxes on such income; and (iv)
if and to the extent any amount of the Escrow Fund is actually distributed to
the holders of Common Stock or Preferred Stock, interest may be imputed on
such amount as required by applicable Law. All Parties shall file all Tax
Returns consistently with the foregoing intended Tax treatment, unless
otherwise required by a change in applicable Law following the Closing Date.

Section 3.8 Earn-Out Payments; Diligence.

(a) From and after the Closing, upon the first achievement by Buyer or any of
its Affiliates (including Buyer), licensees or sublicensees of the following
events (each a "Milestone Event") with respect to the Product, as further
consideration for the Merger, Buyer shall make (or cause to be made) to the
Securityholders in accordance with Section 3.4, the following payments (each,
an "Earn-Out Payment"), in each case in accordance with Section 3.8(c) below
after the achievement of each Milestone Event described below as conditions
precedent for each such payment:

(i) a one-time payment of [*] upon the earlier of (A) [*] or (B) [*];

(ii) a one-time payment of [*] upon t[*] for any first Indication;

(iii) a one-time payment of [*] upon [*] for a second Indication.

(iv) a one-time payment of [*] upon receipt of Regulatory Approval from the
FDA for any first Indication;

(v) a one-time payment of [*] upon receipt of Regulatory Approval from the FDA
for a second Indication;

(vi) a one-time payment of [*] upon receipt of Regulatory Approval from the
EMA for any first Indication;

(vii) a one-time payment of [*] upon receipt of Regulatory Approval from the
EMA for a second Indication; and

(viii) a one-time payment of [*] (the "Sales Earn-Out Payment") upon the
determination at the end of Buyer's fiscal year that the Net Sales for such



34

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





fiscal year across all Indications equals or exceeds [*] (the "Sales Earn-Out
Goal").

(b) For clarity, the maximum aggregate amount of Earn-Out Payments payable
under this Agreement is Eight Hundred Million Dollars ($800,000,000). The
portion of each of the Earn-Out Payments in subclauses (i) through (viii) of
Section 3.8(a) that may become payable to Option Holders shall be deemed a
separate payment for purposes of Section 409A of the Code.

(c) The Milestone Events for Regulatory Approval in the EMA set forth in
Section 3.8(a)(vi) and Section 3.8(a)(vii) shall be achieved upon receipt of
the applicable reimbursement and/or pricing approval from the applicable
Governmental Entity in three (3) out of the following five (5) countries:
United Kingdom, France, Italy, Germany or Spain.

(d) If any given Earn-Out Payment is due and one or more previous Earn-Out
Payments would reasonably have been anticipated to precede such Earn-Out
Payment for the achievement of Milestone Events have not been paid for any
reason, then payment of all such preceding unpaid Earn-Out Payments will be
due at such time as well. For example, if Earn-Out Payment (ii) were to become
due, and Milestone Event (i) has not yet been achieved and accordingly Earn-
Out Payment (i) had not been paid, then Earn-Out Payment (i) will become due
at the time Earn-Out Payment (ii) becomes due.

(e) With respect to the achievement of any Milestone Event, Buyer shall
provide written notice to the Stockholders' Representative of such occurrence
no later than fifteen (15) Business Days after Buyer becomes aware of the
occurrence thereof. Thereafter, Buyer shall make (or cause to be made) the
corresponding Earn-Out Payment to Securityholders in accordance with Section
3.4 within forty-five (45) days after the occurrence thereof. The Buyer shall
pay interest on any Earn-Out Payment that is not paid on or before the date
such payments are due under this this Agreement at an annual rate equal to [*]
plus the prime rate as published in The Wall Street Journal in effect on the
date such payment was required to be made, calculated on the total number of
days payment is delinquent.

(f) For a period of [*] following the Closing Date, Buyer shall and shall
cause its Affiliates (including the Company) to use Commercially Reasonable
Efforts to achieve (or cause its Affiliates, licensees or sublicensees with
respect to rights to develop or commercialize the Product to achieve) each of
the Milestone Events; provided however, [*]. The parties hereto acknowledge
and agree that Buyer does not currently intend to pursue the Indication set
forth on Exhibit J (the "Excluded Indication"), and that a decision to not
pursue the Excluded Indication will not be a violation of Buyer's obligation
to use Commercially Reasonable Efforts. Without limiting the foregoing,
neither Buyer nor its Affiliates shall take any action, or omit to take any
action, the primary purpose of which is to avoid the achievement of any
Milestone Event.

(g) The Company understands and acknowledges that Buyer and its Affiliates may
have present or future initiatives or opportunities, including initiatives or
opportunities with its Affiliates or third parties, involving products,
programs, technologies or processes that are similar to, and in some instances
may compete with products, programs, technologies or



35

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





processes covered by this Agreement. The Company acknowledges and agrees that
nothing in this Agreement will be construed as a representation, warranty or
covenant that Buyer, or any of its Affiliates will not itself develop,
manufacture or commercialize or enter into business relationships with one (1)
or more of its Affiliates or any third parties to develop, manufacture or
commercialize, products, programs, technologies or processes that are similar
to or that may compete with any product, program, technology or process
covered by a Milestone Event.

(h) Following the Closing until all Earn-Out Payments have been made (or Buyer
and Stockholders' Representative otherwise mutually agree), Buyer shall
provide Stockholders' Representative, within ninety (90) days following
January 1st of each calendar year, with an annual written report of the
efforts of Buyer and any of its Affiliates, licensees or sublicensees to
achieve the Milestone Events and their progress with respect thereto, which
report shall generally describe the status of the development of the Product.

(i) Buyer shall keep, and shall cause its Affiliates and sublicensees to keep,
adequate books and records of accounting for the purpose of confirming whether
any Milestone Event has occurred for a period of five (5) years following the
end of the calendar year to which such books and records pertain.

(j) Commencing the calendar year following the year in which the first
commercial sale of the Product occurs until payment of the Sales Earn-Out
Payment (or Buyer and Stockholders' Representative otherwise mutually agree),
on or prior to the forty-fifth (45th) day following release by Buyer of its
(or its applicable Affiliate's) audited financial statements for each fiscal
year during such period, Buyer shall prepare and deliver to the Stockholders'
Representative (i) a statement setting forth Buyer's determination of Net
Sales with respect to the Sales Earn-Out Goal for such fiscal year. In order
to allow the Stockholders' Representative to verify the proposed determination
with respect to the Sales Earn-Out Goal, Buyer shall provide copies of any
records or other documentation reasonably requested by the Stockholders'
Representative that were used by Buyer in reaching such determination and
shall afford Stockholders' Representative or its designees reasonable access
during normal business hours to appropriate Buyer (or its Affiliate) personnel
to discuss such records or documentation. If the Stockholders' Representative
has any objections to Buyer's determination, then the Stockholders'
Representative may object by delivering a written objection notice and the
Parties shall proceed to resolve such disagreement in accordance with the
dispute resolution procedures set forth in Section 3.3(c), applied mutatis
mutandis. If it is determined through such dispute resolution procedures that
the Sales Earn-Out Goal was achieved, Buyer shall make (or cause to be made)
the Sales Earn-Out Payment to Securityholders in accordance with Section 3.4,
subject to the late payment interest set forth in Section 3.8(c).
Notwithstanding anything in this Agreement to the contrary, subsequent to the
Closing, Buyer shall have sole discretion with regard to all matters relating
to the operation of the Company, its Subsidiaries and their respective
businesses and shall have no obligation, or liability as a result of the
failure, to achieve any of the events described in Section 3.8(a) that would
give rise to an Earn-Out Payment.

(k) Subject to Section 3.8(l), Buyer shall remain responsible for paying any
and all Earn-Out Payments in accordance with this Section 3.8 upon the
achievement of the



36

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





corresponding Milestone Event, whether achieved by Buyer, any of its
Affiliates or any of their licensees or sublicensees with respect to rights to
develop or commercialize the Product.

(l) Unless and until a Carve-Out Transaction occurs, Buyer shall remain
responsible for paying any and all Earn-Out Payments in accordance with this
Section 3.8 upon the achievement of the corresponding Milestone Event, whether
achieved by Buyer, any of its Affiliates or any of their licensees or
sublicensees with respect to rights to develop or commercialize the Product.
Without limiting the foregoing, so long as any of the Earn-Out Payments remain
outstanding, in the event that Buyer or, after a Change of Control or Carve-
Out Transaction, any of its respective successors, assignees or transferees
undergoes a subsequent Change of Control or Carve-Out Transaction, then, and
in each such case, Buyer shall either (i) ensure that (x) each such successor,
assignee or transferee of Buyer or such assets or Product agrees to assume all
obligations of Buyer, including payment of all Earn-Out Payments, set forth in
this Agreement, and (y) has the capabilities, financial and otherwise to do
so, or (ii) Buyer shall agree to remain subject to its obligations hereunder,
including payment of all Earn-Out Payments. In the event of (i) an assignment
by Buyer of this Agreement or (ii) a Carve-Out Transaction, in each case (i)
and (ii), to any Controlled Affiliate of Buyer, but only for so long as it
remains a Controlled Affiliate of Buyer after which the obligations of the
foregoing sentence shall apply, Buyer shall agree to remain liable for the
performance by each such assignee of all obligations, including payment of all
Earn-Out Payments, of Buyer hereunder.

Section 3.9 Stockholders' Representative Expense Amount. At the Closing, Buyer
shall deposit cash in an amount equal to the Stockholders' Representative
Expense Amount into an account designated by the Stockholders' Representative
in accordance with Section 3.6(e). The Stockholders' Representative Expense
Amount shall be used to fund any expenses incurred by the Stockholders'
Representative in the performance of its duties and obligations hereunder. The
Securityholders will not receive any interest or earnings on the Stockholders'
Representative Expense Amount and irrevocably transfer and assign to the
Stockholders' Representative any ownership right that they may otherwise have
had in any such interest or earnings. The Stockholders' Representative will
not be liable for any loss of principal of the Stockholders' Representative
Expense Amount other than as a result of its Actual Fraud, gross negligence or
willful misconduct. The Stockholders' Representative will hold these funds
separate from its corporate funds, will not use these funds for its operating
expenses or any other corporate purposes and will not voluntarily make these
funds available to its creditors in the event of bankruptcy. The Stockholders'
Representative Expense Amount will be held by the Stockholders' Representative
until such time as the Stockholders' Representative determines, in its sole
discretion, that the Stockholders' Representative does not expect to incur any
additional expenses in connection with performing its obligations in such
capacity under this Agreement. Any portion of the Stockholders' Representative
Expense Amount remaining after such date shall be paid by the Stockholders'
Representative to the Paying Agent and the Surviving Company (as applicable)
for further distribution to the Stockholders and the Option Holders in
proportion to their Pro Rata Shares.

Section 3.10 Tax Documentation. The Surviving Company, the Paying Agent and
Buyer shall be entitled to request and collect any Tax forms legally able to
be given, including



37

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





IRS Form W-9, or the appropriate series of IRS Form W-8, as applicable, or any
similar information reasonably necessary, from any Stockholder, Option Holder
or any other recipient of any payment pursuant to, or in connection with, this
Agreement, and such Stockholder, Option Holder or other recipient hereby
covenants to provide such Tax form or information it is legally able to
deliver upon reasonable request by the Surviving Company, the Paying Agent or
Buyer, as the case may be.

Section 3.11 Withholding. The Surviving Company, the Paying Agent and Buyer
shall be entitled to deduct and withhold from any amount otherwise payable
pursuant to, or in connection with, this Agreement to any Stockholder, Option
Holder or other Person, as the case may be, such amounts as the Surviving
Company, the Paying Agent or Buyer is required to deduct and withhold with
respect to the making of such payment under any provision of applicable Tax
Laws. To the extent that amounts are so withheld by the Surviving Company, the
Paying Agent or Buyer, and remitted to the applicable Governmental Entity,
such withheld and remitted amounts shall be treated for all purposes of this
Agreement as having been paid to such Stockholder, Option Holder or other
Person, as the case may be, in respect of which such deduction and withholding
was made by the Surviving Company, the Paying Agent or Buyer, as the case may
be.

Section 3.12 Dissenting Shares.

(a) Notwithstanding any provision of this Agreement to the contrary, Shares
that are outstanding immediately prior to the Effective Time and which are
held by Stockholders who shall not have voted in favor of the Merger or
consented thereto in writing and who shall have demanded properly in writing
appraisal for such Shares in accordance with Section 262 of the DGCL
(collectively, the "Dissenting Shares") shall not be converted into or
represent the right to receive the consideration set forth in Section 3.1.
Such Stockholders shall be entitled to receive such consideration as is
determined to be due with respect to such Dissenting Shares in accordance with
the provisions of Section 262 of the DGCL, except that all Dissenting Shares
held by holders who shall have failed to perfect or who effectively shall have
withdrawn or lost their rights to appraisal of such Shares under Section 262
of the DGCL shall thereupon be deemed to have been cancelled and extinguished
and converted into, as of the Effective Time, the right to receive the
consideration specified in Section 3.1 (as adjusted, if applicable), without
any interest thereon, upon surrender, in the manner provided in Section 3.5,
of the certificate or certificates that formerly evidenced such Dissenting
Shares.

(b) The Company shall give Buyer (i) prompt notice of any demands for
appraisal received by the Company and withdrawals of such demands, and (ii)
the opportunity to direct and/or consult with the Company with respect to all
negotiations and proceedings with respect to demands for appraisal under the
DGCL. Prior to the Effective Time, neither the Company nor Buyer shall, except
with the prior written consent of the other party, make any payment with
respect to any demands for appraisal, offer to settle, or settle or otherwise
negotiate any such demands.



38

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

Except as set forth in the disclosure schedule delivered by the Company prior
to, or concurrently with, the execution of this Agreement (the "Disclosure
Schedule") the Company hereby represents and warrants to Buyer and Merger Sub
as follows:

Section 4.1 Organization, Standing and Power. Each of the Company and its
Subsidiaries is an entity duly organized, validly existing and in good
standing under the laws of its jurisdiction of organization and has all
requisite power and authority to own, lease and operate its properties and to
carry on its business as now being conducted. Each of the Company and its
Subsidiaries is duly qualified to do business and is in good standing in each
jurisdiction in which such qualification is necessary because of the property
owned, leased or operated by it or because of the nature of its business as
now being conducted, except for any failure to so qualify or be in good
standing that individually or in the aggregate would not reasonably be
expected to have a Company Material Adverse Effect. Section 4.1 of the
Disclosure Schedule lists the jurisdictions of organization and qualifications
to do business (or the foreign equivalents, if any) of the Company and each of
its Subsidiaries. The Company has made available to Buyer complete and correct
copies of the organizational documents of each of the Company and its
Subsidiaries, in each case as amended to the date of this Agreement. Section
4.1 of the Disclosure Schedule contains a true and correct list of the
directors and officers of each of the Company and its Subsidiaries as of the
date of this Agreement.

Section 4.2 Authority; Approvals.

(a) The execution, delivery and performance of this Agreement by the Company
and the consummation of the transactions contemplated hereby are within its
power and have been duly and validly authorized by all necessary corporate
action on the part of the Company (other than the approval of the Merger and
the approval and adoption of this Agreement by the Required Stockholder
Approval, and the filing of a Certificate of Merger pursuant to the DGCL).
This Agreement has been duly executed and delivered by the Company, and
(assuming due authorization, execution and delivery by the other parties
hereto) constitutes the valid and binding obligation of the Company,
enforceable against the Company in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium and other similar laws of general applicability relating to or
affecting creditor's rights generally and by the application of general
principles of equity.

(b) The Board of Directors of the Company has, at a meeting duly called and
held at which all the directors of the Company were present, or by written
consent, prior to the execution of this Agreement, unanimously (i) determined
that this Agreement and the Merger are fair to, and in the best interests of
the Company and its stockholders, (ii) resolved that the Merger is fair to and
in the bests interests of the Company and its stockholders and approved and
declared this Agreement and the Merger to be advisable, and (iii) resolved to
recommend that the Company's stockholders adopt this Agreement, and none of
the aforesaid actions by the Board of Directors of the Company has been
amended, rescinded or modified.



39

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(c) The only vote of the holders of any class or series of the Company's
capital stock necessary to approve the Merger are the affirmative votes to
approve the Merger and to approve and adopt this Agreement by the holders of:
(i) a majority of the outstanding shares of the Company's capital stock voting
together as a single class (and in the case of the Preferred Stock, on an as-
converted basis) and (ii) a majority of the outstanding shares of Preferred
Stock voting together as a single class on an as-converted basis
(collectively, the "Required Stockholder Approval").

Section 4.3 Capitalization; Equity Interests.

(a) The authorized capital stock of the Company consists of (i) 72,300,000
shares of Common Stock and (ii) 57,276,605 shares of Preferred Stock, of which
(A) 28,350,632 shares are designated Series A Preferred Stock, and (B)
28,925,973 shares are designated Series B Preferred Stock. As of the date of
this Agreement, 9,536,647 shares of Common Stock, 28,350,632 shares of Series
A Preferred Stock, and 28,925,973 shares of Series B Preferred Stock are
issued and outstanding. As of the date of this Agreement, the outstanding
capital stock of the Company is owned of record as set forth in Section 4.3(a)
of the Disclosure Schedule. Section 4.3(a) of the Disclosure Schedule contains
a complete and correct list as of the date hereof of each outstanding Option,
including the number of Shares subject to each such Option, the grant date,
exercise price and vesting schedule for such Option, the extent to which such
Option is vested and exercisable and the date on which such Option expires.
Except as set forth on Section 4.3(a) of the Disclosure Schedule, no Shares
are held by the Company in treasury.

(b) Section 4.3(b) of the Disclosure Schedule sets forth each of the Company's
Subsidiaries' authorized capital stock and the number of shares of capital
stock issued and outstanding (or, if such Subsidiary is not a corporation, the
number of issued and outstanding voting securities of such Subsidiary or other
ownership interests therein). Except as set forth in Section 4.3(b) of the
Disclosure Schedule, the Company and its Subsidiaries do not have any
Subsidiaries or own or hold any equity or other security interest in any other
Person. Except as set forth in Section 4.3(b) of the Disclosure Schedule, all
issued and outstanding shares of capital stock or other voting securities of,
or ownership interests in, the Company's Subsidiaries are directly or
indirectly owned beneficially and of record by the Company, free and clear of
all Liens, and free of any other limitation or restriction (including any
restriction on the right to vote, sell or otherwise dispose of such capital
stock, other voting securities or ownership interests).

(c) Each Option and share of Restricted Stock was granted in compliance with
the terms of the Equity Plan and applicable Law in all material respects. Each
Option was granted or issued at an exercise price equal to or greater than the
fair market value of the underlying Common Stock on the date of grant, as
determined in accordance with Section 409A of the Code, and none of the
Options, Restricted Stock or any other securities or agreements constitute
"deferred compensation" under Section 409A of the Code. True, correct and
complete copies of (i) the Equity Plan and (ii) the form award agreements
thereunder (and any award agreement that materially deviates from any such
form award agreements) have been made available to Buyer, and such plans and
agreements have not been amended, modified or



40

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





supplemented since being made available or provided to Buyer, and there are no
Contracts or understandings to amend, modify or supplement such plans, forms
or agreements in any case from those furnished to Buyer. The Company does not
have in effect any employee stock purchase plans other than the Equity Plan.
Each Option that is vested is exercisable for an exercise price less than the
Per Common Share Merger Consideration.

(d) Except as set forth in Section 4.3(d) of the Disclosure Schedule, as of
the date of this Agreement, no shares of capital stock or other voting
securities of, or ownership interests in, the Company or any of its
Subsidiaries are reserved for issuance. All outstanding shares of capital
stock or other voting securities of, or ownership interests in, the Company
and its Subsidiaries were duly authorized and validly issued and, with respect
to shares of capital stock, fully paid and nonassessable, and none of such
shares, other voting securities or ownership interests are subject to, and
were not issued in violation of, any purchase option, trust, call option,
right of first refusal or offer, preemptive right, subscription right or any
similar right. Except as set forth in Section 4.3(d) of the Disclosure
Schedule, there are no bonds, debentures, notes or other indebtedness or
securities of the Company or any of its Subsidiaries having the right to vote
(or convertible into, or exchangeable for, securities having the right to
vote) on any matters on which the holders of the Company's or such
Subsidiary's voting securities or interests may vote. Except as set forth in
Section 4.3(d) of the Disclosure Schedule, there are no securities, options,
warrants, calls, rights, commitments, agreements, arrangements or undertakings
of any kind to which the Company or any of its Subsidiaries is a party or by
which any such Person is bound obligating such Person to issue, deliver or
sell, or cause to be issued, delivered or sold, additional shares of capital
stock or other voting securities of, or ownership interests in, such Person or
obligating such Person to issue, grant, extend or enter into any such
security, option, warrant, call right, commitment, agreement, arrangement or
undertaking. Except as set forth in Section 4.3(d) of the Disclosure Schedule,
there are no outstanding rights, commitments, agreements, arrangements or
undertakings of any kind obligating the Company or any of its Subsidiaries to
repurchase, redeem or otherwise acquire any shares of capital stock or other
voting securities of, or ownership interests in, the Company or any of its
Subsidiaries or any securities of the type described in the two immediately
preceding sentences. Except as set forth in Section 4.3(d) of the Disclosure
Schedule, there are no outstanding or authorized stock appreciation, phantom
stock, profit participation or similar rights with respect to the capital
stock of, or other equity or voting interest in, the Company or any of its
Subsidiaries. Except as set forth in Section 4.3(d) of the Disclosure
Schedule, there are no irrevocable proxies and no voting trusts or voting
agreements with respect to any ownership interests of, or other equity or
voting interest in, the Company or any of its Subsidiaries to which the
Company or any of its Subsidiaries is a party, or to the Company's knowledge,
to which a Securityholder is a party. Neither the Company nor any of its
Subsidiaries are committed to declare, pay or set aside for payment any
dividend or other distribution (whether in cash, stock, property or otherwise)
in respect of any Shares or any other securities of the Company or any of its
Subsidiaries. Neither the Company nor any of its Subsidiaries are obligated or
required to make any investment (including in the form of a loan or capital
contribution) in any Person.

(e) Section 4.3(e) of the Disclosure Schedule identifies: (i) each Person with
an offer letter or other Contract that contemplates a grant of an Option, or
who has otherwise



41

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





been contingently promised Options, except for Options that have been granted,
or rights terminated or forfeited, prior to the date of this Agreement (each,
a "Specified Person"); (ii) the number of Shares underlying such contingently
promised Options and the vesting schedule for such contingently promised
Options; (iii) the number of Shares underlying such contingently promised
Options eligible to receive Merger consideration pursuant to and in accordance
with Section 3.1(b) hereof (each, an "Ungranted Option"); and (iv) the
exercise price applicable to each Ungranted Option, assuming such award had
been timely granted as an Option in the Company's ordinary course of business
(the "Deemed Exercise Price").

Section 4.4 Conflicts; Consents. The execution, delivery and performance by
the Company of this Agreement and the consummation of the transactions
contemplated hereby does not and will not (with or without the giving of
notice or the passage of time, or both) (i) conflict with or result in a
breach of the certificates of incorporation, by-laws or other organizational
documents of the Company or any of its Subsidiaries, (ii) except as set forth
in Section 4.4 of the Disclosure Schedule, conflict with, breach or result in
a default (or give rise to any right of termination, modification,
cancellation or acceleration) under any of the provisions of any Material
Contract to which any of the Company or its Subsidiaries is a party, (iii)
violate any Laws applicable to the Company or any of its Subsidiaries or any
such Person's properties or assets, or (iv) result in the creation or
imposition of any Lien (except for a Permitted Lien) upon any property or
assets used or held by the Company or any of its Subsidiaries, except where
the occurrence of any of the foregoing described in clauses (ii), (iii) and
(iv) above would not reasonably be expected to be material to the Company and
its Subsidiary taken as a whole. Except as set forth in Section 4.4 of the
Disclosure Schedule and except for (1) the filing of a premerger notification
and report form under the Hart-Scott-Rodino Act of 1976, as amended, and the
rules and regulations promulgated thereunder (the "HSR Act") and the
expiration or early termination of the applicable waiting period thereunder
and (2) any filings as may be required under the DGCL in connection with the
Merger, no consent or approval by, or notification of or registration or
filing with, any Governmental Entity by the Company or any of its Subsidiaries
is required in connection with the execution, delivery and performance by the
Company of this Agreement or the consummation of the transactions contemplated
hereby.

Section 4.5 Financial Information; Undisclosed Liabilities.

(a) The Company has previously made available to Buyer (i) the unaudited
balance sheet of the Company as of December 31, 2017 and the related
statements of operation, convertible preferred stock and stockholders' equity
and cash flows for the fiscal year ended December 31, 2017 and (ii) the
unaudited balance sheet of the Company as of July 31, 2018 (the "Most Recent
Balance Sheet," and such date, the "Most Recent Balance Sheet Date") and the
related statements of operation, convertible preferred stock and stockholders'
equity and cash flows for the eight-month period then ended (the items in
clauses (i) and (ii), collectively, the "Company Financial Statements"). The
Company Financial Statements are based on the books and records of the Company
and present fairly, in all material respects, the consolidated financial
position of the Company (consolidated with its Subsidiaries, as applicable) as
of the respective dates thereof, and the results of operations, convertible
preferred stock and stockholders' equity and cash flows of the Company
(consolidated with its Subsidiaries, as applicable) for the



42

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





respective periods or as of the respective dates set forth therein, and are
prepared in accordance with GAAP consistently applied during the periods
involved, except as otherwise noted therein and subject to year-end
adjustments and the absence of notes.

(b) Except as set forth in Section 4.5(b) of the Disclosure Schedule or as
reflected in the Most Recent Balance Sheet, the Company and its Subsidiaries
do not have any material liabilities or obligations (whether absolute,
accrued, contingent, matured, or otherwise, and whether due or to become due),
except for liabilities and obligations (i) incurred in the ordinary course of
business consistent with past practice since the Most Recent Balance Sheet
Date, (ii) which would not be required to be recorded in an audited
consolidated balance sheet of the Company and its Subsidiaries (or disclosed
in the notes thereto) that is prepared in accordance with GAAP, (iii) that
constitute Transaction Expenses or (iv) which are disclosed in any section of
the Disclosure Schedule.

Section 4.6 Books and Records; Internal Controls; Off-Balance Sheet
Arrangements.

(a) The books, records and accounts of the Company and its Subsidiaries are
true, complete and correct in all material respects and, with respect to
accounting matters, represent actual, bona fide transactions. The Company and
its Subsidiaries have established and maintained a system of internal
accounting controls designed to provide reasonable assurances that (i)
transactions are executed in accordance with management's authorization, (ii)
transactions are recorded as necessary to permit preparation of the
consolidated financial statements of the Company and its Subsidiaries in
conformity with GAAP and to maintain accountability for assets, (iii) access
to the Company's and its Subsidiaries' assets are permitted only in accordance
with management's authorization, and (iv) the recorded accountability for
assets is compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences, in all such
foregoing cases, as is customary and suitable for the size and stage of
development of the Company.

(b) Neither the Company nor any of its Subsidiaries has received any written
complaint, allegation or claim asserting that the accounting practices,
procedures, methodologies or methods of the Company or any of its Subsidiaries
or their internal accounting controls do not comply with GAAP or applicable
Law in any material respect. To the knowledge of the Company, there is no
significant deficiency or material weakness in the design or operation of the
internal control over financial reporting of the Company or any of its
Subsidiaries.

(c) Neither the Company nor any of its Subsidiaries is a party to, or have any
legally binding commitment to become a party to, any off-balance sheet
partnership or any similar Contract, including any Contract relating to any
transaction or relationship between or among the Company and its Subsidiaries
or among any of its Subsidiaries, on the one hand, and any unconsolidated
affiliate, including any structured finance, special purpose or limited
purpose entity or person, on the other hand or any other "off-balance sheet
arrangement" (as defined in the Securities Exchange Act of 1934, as amended).

Section 4.7 Absence of Changes. Except as set forth in Section 4.7 of the
Disclosure Schedule, between the Most Recent Balance Sheet Date and the date
hereof, the Company and



43

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





its Subsidiaries have been operated in the ordinary course consistent with
past practice in all material respects and there has not been:

(a) any event, occurrence or development that has had, or would reasonably be
expected to have, individually or in the aggregate, a Company Material Adverse
Effect;

(b) any payment, discharge, satisfaction or settlement of any material action,
suit or claim against the Company or any of its Subsidiaries;

(c) any split, combination, reclassification or recapitalization of any of the
Company's or any of its Subsidiaries' capital stock or any issuance or
authorization of any issuance of any securities respect of, in lieu of or in
substitution for shares of capital stock or other securities of the Company or
any of its Subsidiaries;

(d) any declaration, setting aside or payment of any dividend or other
distribution with respect to any shares of capital stock or other voting
securities of, or ownership or voting interests in, the Company or any of its
Subsidiaries or any direct or indirect redemption, purchase or other
acquisition of any such shares, securities or interests (other than
repurchases pursuant to the Equity Plan or any grant agreement entered into
pursuant thereto);

(e) any sale, assignment, pledge, Lien, transfer or other disposition of any
material asset of the Company or any of its Subsidiaries, or any sale,
assignment, transfer or other disposition of any material Intellectual
Property or any other intangible, material assets of the Company or any of its
Subsidiaries;

(f) any creation of any Lien on any material property of the Company or any of
its Subsidiaries, except for Permitted Liens;

(g) any write-down of the value of any material asset of the Company or any of
its Subsidiaries or any write-off as uncollectible of any accounts or notes
receivable of the Company or any of its Subsidiaries or any portion thereof,
other than write-downs or write-offs that are reserved for on the consolidated
balance sheet contained in the Company Financial Statements;

(h) any cancellation of any material debts or claims or any amendment,
termination or waiver of any rights of material value to the Company and its
Subsidiaries, taken as a whole;

(i) any material capital expenditures or commitments or additions to property,
plant or equipment of the Company or any of its Subsidiaries;

(j) any grant of a loan (other than advances for business expenses in the
ordinary course of business) or, except in each case for regular annual
increases, any general increase in the compensation of employees of the
Company or any of its Subsidiaries (including any increase pursuant to any
written bonus, pension, profit-sharing or other benefit or compensation plan,
policy or arrangement or commitment), or any increase in any such



44

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





compensation or bonus payable to any executive officer, manager or director of
the Company or any of its Subsidiaries having an annual salary or remuneration
in excess of $100,000;

(k) any damage, destruction or loss not covered by insurance affecting any
asset or property of the Company or any of its Subsidiaries resulting in
liability or loss in excess of $100,000;

(l) any change in the accounting methods, keeping of books of account, cash
management or accounting practices followed by the Company or any change in
depreciation or amortization policies or rates;

(m) any adoption of, or revocation or change to, any material Tax election,
the adoption or change of any material Tax accounting method or period, the
filing of any amended Tax Return, the entry into any closing agreement or
settlement, the settlement of any Tax claim or assessment, the surrender of
any right to claim a refund of Taxes, or the consent to any extension or
waiver of the statute of limitations period applicable to any Tax claim or
assessment;

(n) any amendment to or modification of or agreement to amend or modify (or
announcement of an intention to amend or modify) the Equity Plan or any Option
or Ungranted Option or equity interest, or any action to accelerate, or which
would reasonably be expected to result in the acceleration of, the timing of
vesting or payment of any rights, compensation, benefits or funding
obligations (other than discretionary acceleration of vesting of Options by
the Company's Board of Directors to the extent accounted for in the Capital
Structure Certificate), or any material determinations, under any collective
bargaining agreement, Plan, employment agreement or otherwise (including in
connection with this Agreement and the transactions contemplated hereby);

(o) any grant of bonuses, whether monetary or otherwise, or increase in any
wages, salary, severance, pension or other compensation or benefits in respect
of its current or former employees, other than as provided for in any written
Contracts that have been made available to Buyer or otherwise as required by
applicable Law;

(p) except to the extent accounted for in the Capital Structure Certificate,
any grant of any awards or rights under any Plan or employment agreement
(including the grant of Options, stock appreciation rights, performance units
or other stock-based awards, or the removal of existing restrictions in any
Contract, Plan or employment agreement or awards made thereunder);

(q) incurrence, assumption or guarantee of any indebtedness for borrowed money
except current liabilities incurred in the ordinary course of business and not
constituting (i) Closing Indebtedness or (ii) an amount in the aggregate in
excess of $250,000;

(r) acquisition by merger or consolidation with, or by purchase of a
substantial portion of the assets or stock of, or by any other manner, any
business or any Person or any division thereof;



45

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(s) abandonment or lapse of or failure to maintain in full force and effect
any Company Registered IP registration;

(t) any amendment to the Company's organizational documents or the
organizational documents of any of the Company's Subsidiaries;

(u) the entry into any Contract between the Company or any of its
Subsidiaries, on the one hand, and a Stockholder or Option Holder or any
current or former director, officer employee, contractor, consultant or agent
of the Company or any of its Subsidiaries, on the other hand, the benefits of
which are contingent, or the terms of which are altered, upon the occurrence
of a transaction involving the Company of the nature contemplated by this
Agreement;

(v) the entry into any Contract that would constitute a Material Contract, or
the acceleration, termination, material modification to or cancellation of any
Material Contract (other than (i) as result of the transactions contemplated
by this Agreement and (ii) the discretionary acceleration of vesting of
Options by the Company's Board of Directors to the extent accounted for in the
Capital Structure Certificate); or

(w) any agreement, whether in writing or otherwise, to take any of the actions
specified in the foregoing items (a) through (v).

Section 4.8 Real Property and Assets.

(a) None of the Company or any of its Subsidiaries owns any real property.
Section 4.8 of the Disclosure Schedule lists all interests in real property
leased, licensed, subleased, occupied or used by the Company or its
Subsidiaries as of the date hereof (the "Leased Real Property"), including as
applicable, the name and address of the landlord of such Leased Real Property,
and each material Contract relating to the use and/or occupancy of such Leased
Real Property, including all leases, subleases, agreements to lease, lease
guarantees, tenant estoppels, subordinations, non-disturbance and attorney
agreements, including all amendments thereto (the "Leases"). The Company or
one of its Subsidiaries has a good and valid leasehold interest in the Leased
Real Property listed in Section 4.8 of the Disclosure Schedule, free and clear
of all Liens except for Permitted Liens. Each Lease is in full force and
effect, and, to the knowledge of the Company, is enforceable against the
landlord that is party thereto in accordance with its terms. There exists no
material default or event of default on the part of the Company or any of its
Subsidiaries under any Leases or, to the knowledge of the Company, any other
party thereto. The Company has made available to Buyer true and complete
copies of all Leases.

(b) Section 4.8(b) of the Disclosure Schedule contains a true, complete and
correct list of all Contracts pursuant to which the Company and each of its
Subsidiaries leases any personal property as lessee or lessor requiring
aggregate payments by or to the Company or any of its Subsidiaries under any
individual such Contract in excess of $100,000 (the "Personal Property
Leases"). Each of the Company and its Subsidiaries has good, valid and
marketable title to, or a valid leasehold interest in, as applicable, all
personal property used in their



46

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





respective businesses, free and clear of all Liens, except for Permitted Liens
or defects in title or failures to be in full force and effect that are not
material to the Company and its Subsidiaries, taken as a whole. Such personal
property (taken as a whole) is in good operating condition and repair,
ordinary wear and tear and deferred maintenance excepted, and constitutes all
personal property materially necessary for the operation of the business of
the Company and its Subsidiaries as presently conducted. The Company has made
available to Buyer true, correct and complete copies of all Personal Property
Leases. None of the personal property owned or leased by the Company or its
Subsidiaries is in the possession, custody or control of any Person other than
the Company or its Subsidiaries.

Section 4.9 Material Contracts.

(a) Section 4.9 of the Disclosure Schedule lists as of the date of this
Agreement each of the following Contracts to which the Company or any of its
Subsidiaries is a party (collectively, along with the Leases and the Personal
Property Leases, the "Material Contracts"):

(i) all Contracts with officers, employees, consultants, advisors, sales
representatives, distributors, sales agents or dealers of the Company or any
of its Subsidiaries, requiring aggregate annual payments by the Company or any
of its Subsidiaries in excess of $100,000;

(ii) all Contracts, including employment Contracts, with any current or former
director, officer, employee, contractor or consultant that require aggregate
annual payments by the Company or any of its Subsidiaries in excess of
$100,000;

(iii) all plans, programs and Contracts that provide for the payment of bonus,
severance, change in control, termination or similar types of compensation or
benefits related to a transaction of the type contemplated hereunder involving
the Company or one of its Subsidiaries or upon the termination or resignation
of any current or former director, officer, employee, contractor or
consultant;

(iv) all collective bargaining agreements or other agreements with a labor or
trade union, employee association, works council, or other employee
representative;

(v) all mortgages, indentures, security agreements, pledges, notes, loan
agreements or guarantees;

(vi) all Contracts establishing any joint venture, joint product development,
consortium, partnership, co-marketing arrangement or unincorporated
association with a third-party;

(vii) all Contracts providing for future capital expenditures in excess of
$100,000;



47

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(viii) all Contracts (including non-competition, non-solicitation and
exclusivity agreements) that impose any material restriction on the activities
or operations of the business of the Company and its Subsidiaries, taken as a
whole, or the use, ownership or operation of any of the material assets of the
Company and its Subsidiaries;

(ix) all Contracts involving a loan (other than accounts receivable from trade
debtors in the ordinary course of business consistent with past practice) or
advance to (other than travel and entertainment allowances to the employees of
the Company or any of its Subsidiaries extended in the ordinary course of
business consistent with past practice), or investment in, any Person;

(x) all management service, financial consulting or financial advisory
Contracts, and any Contracts with any investment or commercial bank, broker,
dealer or finder;

(xi) all Contracts involving the future disposition or acquisition of a
material line of business, significant assets or properties, or any merger,
consolidation or similar business combination transaction;

(xii) all Contracts involving any resolution or settlement of any actual or
threatened material litigation, arbitration or similar proceeding;

(xiii) all Contracts pursuant to which the Company or any of its Subsidiaries
(A) has been granted license rights for any Intellectual Property by any third
party (other than (1) licenses of off-the-shelf commercial software programs,
and (2) non-disclosure agreements and other agreements entered into by the
Company or any of its Subsidiaries in the ordinary course of business); or (B)
has granted to any third party any license of any Company Owned Intellectual
Property or Intellectual Property licensed to the Company or any of its
Subsidiaries (other than licenses pursuant to sponsored research agreements,
material transfer agreements, consulting or service agreements or other
similar agreements entered into by the Company or any of its Subsidiaries in
the ordinary course of business that do not provide an exclusive license or a
license to commercialize);

(xiv) all Contracts granting "most favored nation" or "most favored customer"
or similar rights to any Person other than the Company or any of its
Subsidiaries;

(xv) any agreement with any Governmental Entity; and

(xvi) all other Contracts that require annual payments by or to the Company
and its Subsidiaries after the date hereof in excess of $100,000.

(b) All of the Material Contracts are legal, valid, binding and enforceable
obligations of the Company or its applicable Subsidiary that is a party
thereto and, to the knowledge of the Company, each of the other parties
thereto, in accordance with their terms, except as such enforceability may be
limited by bankruptcy, insolvency, reorganization, moratorium and other
similar laws of general applicability relating to or affecting creditor's
rights generally and by application of general principles of equity. Except as
set forth in



48

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Section 4.9(b) of the Disclosure Schedule, neither the Company nor any of its
Subsidiaries nor, to the knowledge of the Company, any other party to the
Material Contracts is in breach of or default under any obligation thereunder
or has given notice of default to any other party thereunder and, to the
knowledge of the Company, no condition exists that with notice or lapse of
time would constitute a default thereunder. Copies of all such Material
Contracts (including all modifications, amendments and supplements thereto and
waivers thereunder) have been made available to Buyer or its Representatives.

Section 4.10 Environmental Matters. Except as set forth in Section 4.10 of the
Disclosure Schedule:

(a) the Company and its Subsidiaries are, and have at all times been, in
compliance in all material respects with all Environmental Laws;

(b) neither the Company nor any of its Subsidiaries has generated,
transported, treated, stored, or disposed of any Hazardous Substances at or on
the Leased Real Property, except in material compliance with applicable
Environmental Laws, and there has been no Release of any Hazardous Substances
by any Person at or on the Leased Real Property that requires reporting or
remediation by such Person pursuant to any applicable Environmental Law;

(c) except for those matters that are no longer pending on the date of this
Agreement, neither the Company nor any of its Subsidiaries has (i) received
written notice under the citizen suit provisions of any Environmental Law;
(ii) received any written request for information, notice, demand letter,
administrative inquiry or written complaint or claim from any Governmental
Entity under any Environmental Law; (iii) been subject to or, to the Company's
knowledge, threatened with any governmental or citizen enforcement action with
respect to any Environmental Law; or (iv) received written notice of any
unsatisfied liability under any Environmental Law;

(d) each of the Company and its Subsidiaries holds all material licenses,
permits and other governmental authorizations required under all Environmental
Laws applicable to the conduct of the Company's and its Subsidiaries' business
as currently conducted at the Leased Real Property, and neither the Company
nor any of its Subsidiaries have been advised in writing by any Governmental
Entity of any pending or threatened termination, revocation or material and
adverse change in any such permit, license or other governmental
authorization, nor will any such permit or license be terminated or impaired
or become terminable, in whole or in part, as a result of the transactions
contemplated by this Agreement; and

(e) the Company has provided to Buyer true and correct copies of all material
environmental studies, audits, reviews, reports and assessments, if any,
conducted by or on behalf of or in possession, custody or control of the
Company or any of its Subsidiaries bearing on liabilities under Environmental
Laws relating to the past or current operations or facilities of the Company
or any of its Subsidiaries.

Section 4.11 Litigation. Except as set forth in Section 4.11 of the Disclosure
Schedule, (i) there are no actions, suits, investigations, proceedings, claims
or disputes ("Legal



49

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Proceedings") pending or threatened in writing by or before any court or other
Governmental Entity against the Company or any of its Subsidiaries, or to the
knowledge of the Company, the Securityholders, directors, officers, agents or
employees of the Company or any of its Subsidiaries (in their capacities as
such, as opposed to their individual capacities) and (ii) no injunction, writ,
temporary restraining order, decree or any order of any nature has been issued
by any court or other Governmental Entity against the Company or any of its
Subsidiaries, or seeking or purporting to enjoin or restrain the execution,
delivery and performance by the Company of this Agreement or the consummation
by the Company of the transactions contemplated hereby.

Section 4.12 Compliance with Laws; Licenses and Permits. Except as set forth
in Section 4.12 of the Disclosure Schedule, each of the Company and its
Subsidiaries is, and at all times has been, in compliance in all material
respects with all Laws applicable to the Company, any of its Subsidiaries or
their respective businesses. Each of the Company and its Subsidiaries holds
all material federal, state, local and foreign governmental licenses,
approvals, authorizations, licenses, registrations and permits that are
necessary to own, lease and operate their assets and conduct their respective
businesses as presently being conducted (collectively, the "Governmental
Permits"). Except as set forth in Section 4.12 of the Disclosure Schedule and
except for breaches, violations, revocations, non-renewals and failures to be
in full force and effect that would not be material, (i) such licenses and
permits are in full force and effect, (ii) the Company and its Subsidiaries
have complied with all terms of each Governmental Permit held by them, (iii)
no proceeding is pending or, to the knowledge of the Company, threatened, to
revoke or limit any thereof, and (iv) the consummation of the Merger and the
transactions contemplated by this Agreement will not result in the non-
renewal, revocation or termination of any such license or permit.

Section 4.13 Regulatory.

(a) The Company's product candidates for human use or anticipated to be for
human use (the "Product Candidates") are being, and at all times have been,
developed, tested, labelled, manufactured, stored, imported, exported and
distributed, as applicable, in compliance in all material respects with the
FDCA and applicable implementing regulations issued by the FDA, the EMA and
any other applicable Governmental Entities, including, as applicable, those
requirements relating to the FDA's current good manufacturing practices, good
laboratory practices, good clinical practices, investigational use, pre-market
approval and applications to market a new pharmaceutical product, except as
disclosed on Section 4.13(a) of the Disclosure Schedule. The Company has not
received written notice of and, to the Company's knowledge, the Company has
not received notice of, any pending or, to the Company's knowledge, threatened
claim, suit, proceeding, hearing, enforcement, audit, investigation,
arbitration or other action from the FDA alleging that any operation or
activity of the Company is in violation of the FDCA or the respective
counterparts thereof promulgated by applicable Governmental Entities outside
the United States.

(b) The Company has made available to Buyer as of the date of this Agreement a
complete and correct copy of all material documents and applications submitted
by



50

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





or on behalf of the Company to the FDA or EMA and all material correspondence
to or from the FDA or EMA by or on behalf of the Company with respect to the
Product Candidates (any such document, application, supplement or amendment, a
"Regulatory Submission"), all material contact reports or similar reports
documenting meetings, phone calls or other communications by or on behalf of
the Company with the FDA or EMA, studies, communications, memorandum and any
other material written information (internal or external) required to be
prepared in support of or any such material submitted in connection with each
such Regulatory Submission. All Regulatory Submissions (and any supporting
documentation thereto) and any other written information required to be
prepared in support of or any such material submitted in connection with each
such Regulatory Submission, any and all requests for authorizations,
approvals, certificates, waivers, certifications, clearances, notifications,
licenses or permits of the FDA, EMA or any other comparable non-U.S.
Governmental Entity relating to the Company, the business currently conducted
by the Company and the Company's products, when submitted to the FDA or any
other comparable non-U.S. Governmental Entity, including institutional review
boards, independent ethics committees, or similar bodies, were true and
correct in all material respects as of the date of submission or were later
amended to be true and correct in all material respects.

(c) To the Company's knowledge and except as disclosed on Section 4.13(c) of
the Disclosure Schedule, all preclinical studies and tests conducted by or on
behalf of the Company related to the Product for Indications the Company is
currently evaluating have been, and if still pending are being, conducted, to
the extent applicable, in material compliance with research protocols and good
laboratory practices (except as noted in the relevant study or test reports),
and all applicable Law. Except as disclosed on Section 4.13(c) to the
Disclosure Schedule, no preclinical study or test conducted by or on behalf of
the Company of the Product used to support or filed with the IND has been
terminated or suspended prior to completion, and none of the FDA, EMA or any
other applicable Governmental Entity that has or has had jurisdiction over a
preclinical study or test conducted by or on behalf of the Company has
commenced, or, to the Company's knowledge, threatened to initiate, any action
to terminate or suspend or refuse to commence, any proposed or ongoing
preclinical study or test conducted or proposed to be conducted by or on
behalf of the Company.

(d) The Company has not received any notice that the FDA, EMA or any other
Governmental Entity, any relevant institutional review board, independent
ethics committee or any other similar body has initiated, or threatened in
writing to initiate, any action to suspend any Clinical Trial conducted by or
on behalf of the Company, suspend or terminate any "Investigational New Drug"
application sponsored by the Company or otherwise restrict or delay the
preclinical or nonclinical research on or clinical study, in each case of any
of the Product Candidates, or to recall, suspend or otherwise restrict the
manufacture of any of the Product Candidates, or that any relevant
institutional review board or independent ethics committee has refused to
approve any Clinical Trial conducted or proposed to be conducted by or on
behalf of the Company or any substantial amendment to a protocol, any Clinical
Trial conducted or proposed to be conducted by or on behalf of the Company, in
each case with respect to any of the Product Candidates.



51

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(e) The Company is not subject to any investigation that is pending and of
which the Company has been notified in writing or, to the Company's knowledge,
which has been threatened, in each case by (i) the FDA or (ii) the Department
of Health and Human Services Office of Inspector General or Department of
Justice pursuant to the Federal Anti-Kickback Statute (42 U.S.C. ยง1320a-7b(b))
or the Federal False Claims Act (31 U.S.C. ยง3729). The Company has not
submitted any claim for payment to any government healthcare program in
connection with any referrals related to any of the Product Candidates that
violated in any material respect any applicable self-referral Law. The Company
has not submitted any claim for payment to any government healthcare program
related to any of the Product Candidates in material violation of any laws
relating to false claims or fraud, including the Federal False Claim Act (31
U.S.C.ยง 3729), or any applicable state false claim or fraud Law.

(f) To the knowledge of the Company, all manufacturing operations conducted by
or for the benefit of the Company with respect to the Product Candidates have
been and are being conducted in material compliance with all applicable Laws,
including, to the extent applicable, the provisions of the FDA's current good
manufacturing practice regulations, and the respective counterparts thereof
promulgated by the EMA and other Governmental Entities in countries outside
the United States.

(g) Except as disclosed on Section 4.13(g) to the Disclosure Schedule, the
Company has not marketed, advertised, distributed for sale, sold, or
commercialized any product and is not currently marketing, distributing for
sale, selling, or otherwise commercializing any product.

Section 4.14 Intellectual Property.

(a) Each of the Company and its Subsidiaries owns all Company Owned
Intellectual Property, or, to the knowledge of the Company, has validly
licensed, or has the right to use, in the manner currently used by the
Company, all Company Intellectual Property free and clear of all Liens (other
than Permitted Liens). The foregoing is not, and shall not be construed as, a
representation or warranty regarding non-infringement, misappropriation or
other violation by the Company or any of its Subsidiaries of the Intellectual
Property of other Persons.

(b) Section 4.14(b) of the Disclosure Schedule contains a correct, current,
and complete list of all domestic and foreign Patents, Patent Applications,
registered Trademarks and registered Copyrights and applications and
registrations thereof, domain names and any other registrations of or
applications to register Intellectual Property owned by or registered in the
name of the Company or any of its Subsidiaries ("Company Registered IP").

(c) All the Company Registered IP, as registered, filed, issued or applied
for, have been registered in, filed in or (except with respect to
applications) issued by, the official governmental registrars and/or issuers
(or officially recognized issuers) of such items of Intellectual Property, in
the various jurisdictions (national, state, provincial, prefectural, local and
other) indicated on Section 4.14(b) of the Disclosure Schedule, and except as
set forth in such schedule, each such registration, filing and/or issuance (i)
has not been abandoned or canceled, (ii) remains in full force and effect, and
(iii) is not currently subject to any re-examination,



52

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





reissue, interference, opposition or cancellation proceeding (nor, to the
knowledge of the Company, have any been threatened). The Company or one or
more of its Subsidiaries have the exclusive right to file, prosecute and
maintain all Patent Applications and registrations with respect to the Company
Registered IP as owned by the Company or any of its Subsidiaries. Each item of
the Company Registered IP is subsisting, and each item of the Company
Registered IP other than any application is, to the knowledge of the Company,
valid and enforceable. None of the Company Owned Intellectual Property has
ever been found invalid or unenforceable in any administrative, arbitration,
judicial or other proceeding. Neither the Company nor any of its Subsidiaries
has received any written notice claiming or asserting that any Company Owned
Intellectual Property may be invalid or unenforceable.

(d) To the knowledge of the Company, the conduct of the Company's and each of
its Subsidiaries' business as formerly conducted has not infringed,
misappropriated or otherwise violated, and as currently conducted does not and
would not, if the Product (as it exists as of the date of this Agreement) were
sold as of the date of this Agreement, infringe, misappropriate or otherwise
violate the valid Intellectual Property of any Person. For purposes of the
preceding sentence, (a) the Company's and its Subsidiaries' "business" shall
be limited to the research and development of the Product for the treatment of
the Indications set forth in Section 4.14(d) of the Disclosure Schedule and
for no other Indication or use and (b) any "sale" of the Product shall be
limited to a sale of the Product for the treatment of the Indications set
forth in Section 4.14(d) of the Disclosure Schedule and for no other
Indication or use. To the knowledge of the Company, none of the Company Owned
Intellectual Property is being infringed upon by any third party. There are no
Legal Proceedings settled, pending or, to the knowledge of the Company,
threatened (including in the form of offers to obtain a license) (i) alleging
any infringement, misappropriation, or other violation by the Company of the
Intellectual Property of any Person; (ii) challenging the validity,
enforceability, registrability, patentability, or ownership of any Company
Owned Intellectual Property (other than rejections, objections or other
similar challenges in any office actions made in the ordinary course of
prosecution of Company Registered IP); or (iii) by the Company or any other
Person alleging any infringement, misappropriation or violation by any Person
of the Company Owned Intellectual Property. The Company is not subject to any
outstanding or prospective order, decree or ruling issued by a court or other
Governmental Entity that does or could reasonably be expected to restrict or
impair the use of any Company Owned Intellectual Property.

(e) All Intellectual Property that was created by employees or officers of the
Company or any of its Subsidiaries within the scope of their employment is
owned by the Company or its applicable Subsidiary, either by operation of law
or pursuant to a written assignment agreement. All current and former
consultants of the Company or its Subsidiaries who have, in connection with
their performance of consultancy services for the Company or its Subsidiaries,
conceived of or reduced to practice any patentable invention that is related
to the development, manufacture, use or sale of the Product (as it exists as
of the date of this Agreement), has assigned ownership of any of their
interest in such invention to the Company or its applicable Subsidiary
pursuant to a written agreement, subject to applicable institutional policies
with respect to individuals employed by academic or research institutions.
With respect to Company Owned Intellectual Property, other than as set forth
in Section 4.14(e) of the



53

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Disclosure Schedule, to the knowledge of the Company, no employee, officer,
consultant or other Person (other than clinical sites or other Persons
providing services with respect to or participating in the conduct of a
clinical trial in accordance with the applicable protocol) has used any
facilities or received any remuneration from any academic or research
institution or Governmental Entity in connection with such Person's services
to the Company or any of its Subsidiaries.

(f) The Company and each of its Subsidiaries have taken commercially
reasonable steps to maintain the Company Registered IP and to protect the
secrecy and confidentiality of trade secrets (as such term is defined in the
Uniform Trade Secrets Act, "Trade Secrets") owned by the Company or any of its
Subsidiaries. To the knowledge of the Company, no material Trade Secret owned
by the Company or any of its Subsidiaries has been divulged by the Company or
its Subsidiaries or authorized by the Company or its Subsidiaries to be
divulged to any Person other than (i) to the Company or one of its
Subsidiaries or any person to whom the Company or its Subsidiaries has granted
the right to use such information under a non-disclosure agreement,
confidentiality agreement or other agreement that imposes a confidentiality
obligation on the recipient, or (ii) to support any new Patent Application.

(g) The computer hardware, servers, networks, platforms, peripherals, data
communication lines, and other information technology equipment and related
systems that are owned or used by the Company or any of its Subsidiaries
("Company Systems") are reasonably sufficient for the current needs of the
Company's and its Subsidiaries' respective businesses. To the knowledge of the
Company, there has been no unauthorized access, use, intrusion, or breach of
security, or failure, breakdown, performance reduction, or other adverse event
affecting any Company Systems, that has caused or could reasonably be expected
to cause any material liability to the Company or its Subsidiaries. The
Company has taken reasonable actions, consistent with reasonable practices of
clinical-stage biopharmaceutical companies of similar size and scope, to
protect the integrity and security of the Company Systems and the data and
other information stored or processed thereon. The Company maintains
commercially reasonable backup procedures and processes.

(h) In reviewing the representations and warranties in this Section 4.14 and
assisting in preparation of Section 4.14 to the Disclosure Schedule, Jean-Paul
Kress, Laurence Blumberg and Richard Blumberg consulted with the Company's
outside intellectual property counsel.

Section 4.15 Tax Matters. Except as set forth in Section 4.15 of the
Disclosure Schedule:

(a) The Company and each of its Subsidiaries has timely filed (taking into
account applicable and valid extensions of time within which to file) all Tax
Returns required to be filed by it, and paid all Taxes due and payable by it,
whether or not shown or required to be shown on any such Tax Return. All such
Tax Returns are true, correct and complete in all material respects. The
Company and each of its Subsidiaries has made adequate provision on the
Company Financial Statements for all accrued Taxes not due as of the date of
the Most Recent Balance Sheet Date (excluding accruals and reserves for
deferred Taxes established to reflect



54

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





timing differences between book and Tax income). Since the Most Recent Balance
Sheet Date, the Company and each of its Subsidiaries has incurred Taxes only
in the ordinary course of Business other than with respect to any employer
payroll Taxes arising as a result of the transactions pursuant to this
Agreement (which employer payroll Taxes shall constitute Transaction
Expenses). Since the Most Recent Balance Sheet Date, none of the Company or
any of its Subsidiaries has made, revoked or changed any material election in
respect of Taxes, adopted or changed any material accounting method or period
in respect of Taxes, settled or compromised any audit, suit, proceeding,
investigation, claim or other administrative proceeding or court proceeding
relating to Taxes or Tax Returns (each, a "Tax Proceeding"), entered into any
closing agreement or settlement with respect to Taxes, surrendered any right
to claim a refund of Taxes, or filed any amended Tax Return.

(b) Buyer has received, or the Company has made available to Buyer, complete
copies of (i) all income and other material Tax Returns of, or including, the
Company or any of its Subsidiaries for Tax periods ending after December 31,
2013 and (ii) any Tax audit report or other similar correspondence relating to
any Tax Proceedings issued to the Company or any of its Subsidiaries by a
Governmental Entity.

(c) The Company and each of its Subsidiaries has withheld and timely paid over
to the appropriate Governmental Entities all Taxes required to have been
withheld and paid over by it, and has complied in all respects with the rules
and regulations relating to the withholding or remittance of Taxes. The
Company and each of its Subsidiaries has timely collected all sales, use,
goods and services, harmonized sales, value added and similar Taxes required
to be collected by it, and the Company and each of its Subsidiaries has timely
remitted all such Taxes to the appropriate Governmental Entities.

(d) None of the Company or any of its Subsidiaries has requested any extension
of time within which to file any Tax Return, which Tax Return has not since
been filed, other than extensions for income Tax Returns in the ordinary
course of business. There are no waivers, extensions or comparable consents
that have been given by the Company or any of its Subsidiaries regarding the
application of any statute of limitations with respect to the assessment or
collection of, or any other claim related to, any Taxes or Tax Returns of the
Company or any such Subsidiary, including with respect to any claim for a Tax
refund or abatement, which waivers, extensions or comparable consents are
still in effect. There are no Tax Proceedings involving the Company or any of
its Subsidiaries that are currently pending or, to the knowledge of the
Company, threatened, and none of the Company or any of its Subsidiaries has
received a written notice of any Tax Proceedings. There are no Liens on any
assets of the Company or any of its Subsidiaries with respect to Taxes, other
than Permitted Liens. No claim, which has not been resolved, has been made by
any Governmental Entity in a jurisdiction where the Company or any of its
Subsidiaries has not filed a Tax Return, that the Company or applicable
Subsidiary is or may be subject to Tax by such jurisdiction.

(e) None of the Company or any of its Subsidiaries (i) is or has ever been a
member of any consolidated, combined, affiliated or unitary group of
corporations for any Tax purposes (other than a group the common parent of
which was the Company) or (ii) has any



55

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





current or potential liability for Taxes of any Person arising from the
application of Treasury Regulation Section 1.1502-6 or any analogous provision
of state, local or foreign law or as a transferee or successor by Contract or
otherwise. Neither the Company nor any of its Subsidiaries is a party to any
Tax sharing, Tax allocation, Tax indemnity or any similar agreements,
arrangements, or practices (including any advance pricing agreement, closing
agreement or other similar written agreement relating to Taxes with any
Governmental Entity but excluding customary commercial contracts the primary
purpose of which is unrelated to Taxes) that remains in effect.

(f) None of the Company or any of its Subsidiaries has been either a
"distributing corporation" or a "controlled corporation" in a distribution (i)
in which the parties to such distribution purported or intended the
distribution as one to which Section 355 or Section 361 of the Code is
applicable occurring during the last five years, or (ii) which could otherwise
constitute part of a "plan" or "series of related transactions" (within the
meaning of Section 355(e) of the Code) in conjunction with the transactions
contemplated by this Agreement.

(g) No closing agreement pursuant to Section 7121 of the Code (or any similar
provision of state, local or foreign law) has been entered into by or with
respect to the Company or any of its Subsidiaries.

(h) None of the Company or any of its Subsidiaries has been a United States
real property holding corporation within the meaning of Section 897(c)(2) of
the Code during the five-year period ending on the Closing Date.

(i) None of the Company or any of its Subsidiaries has granted to any Person
any power of attorney that is currently in force with respect to any Tax
matter.

(j) None of the Company or any of its Subsidiaries has been a party to a
"listed transaction," as such term is defined in Treasury Regulations Section
1.6011-4(b)(2).

(k) None of the Company or any of its Subsidiaries has engaged or participated
in any transaction that has resulted in a disclosure obligation of a
"reportable transaction" under Section 6011 of the Code and the Treasury
Regulations thereunder or any similar obligation under any predecessor or
successor Tax Law or comparable state, local or foreign Tax Law.

(l) None of the Company or any of its Subsidiaries, as a result of the
execution and delivery of this Agreement or the consummation of the
transactions contemplated by this Agreement, has made any payment, is
obligated to make any payment, or is a party to any agreement that could
obligate Buyer, the Surviving Company, the Company or any of its Subsidiaries
to make a payment that could be treated as an "excess parachute payment" under
Section 280G of the Code (without regard to Sections 280G(b)(4) and 280G(b)(5)
of the Code).



56

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(m) None of the Company or any of its Subsidiaries owns any interest in an
entity, or is a party to any contractual arrangement or joint venture or other
arrangement, that is a partnership for federal income Tax purposes.

(n) None of the Company nor any of its Subsidiaries is, nor ever has been, a
party to a transaction or Contract that is in conflict with the Tax rules on
transfer pricing in any relevant jurisdiction.

(o) The Company and each of its Subsidiaries has maintained, and made
available to Buyer, any material documentation (including any applicable
transfer pricing studies) required in connection with any related party
transactions in accordance with Sections 482 and 6662 of the Code and the
Treasury Regulations promulgated thereunder and any comparable provision of
any other Tax Law.

(p) None of the Company or any of its Subsidiaries has participated in an
international boycott, as defined in Section 999 of the Code.

(q) None of the Company or any of its Subsidiaries owns any interest in any
Person that is treated as a "passive foreign investment company" within the
meaning of Section 1297(a) of the Code.

(r) None of the Company or any of its Subsidiaries (i) is classified for
federal income Tax purposes as a partnership or disregarded entity, (ii) has
ever made an election under Treasury Regulation Section 301.7701-3(c) to be
classified as a partnership or disregarded entity for federal income tax
purposes, or (iii) has ever made a similar election under any comparable
provision of any Tax Law. None of the Company or any of its Subsidiaries has
ever (i) made an election under Section 1362 of the Code to be treated as an S
corporation for federal income tax purposes or (ii) made a similar election
under any comparable provision of any Tax Law. None of the Company or any of
its Subsidiaries has ever been a "personal holding company" within the meaning
of Section 542 of the Code.

(s) None of the Company or any of its Subsidiaries is a party to any gain
recognition agreement under Section 367 of the Code. None of the Company nor
any of its Subsidiaries has incurred (or been allocated) an "overall foreign
loss" as defined in Section 904(f)(2) of the Code that has not been previously
recaptured in full as provided in Sections 904(f)(1) and/or 904(f)(3) of the
Code.

(t) Neither the Company or any of its Subsidiaries will be required to include
any item of income in, or exclude any Tax credit or item of deduction from,
the calculation of its Taxable income or Tax liabilities for any Taxable
period (or any portion thereof) ending after the Closing Date, including as a
result of: (i) any change in, or improper use of, any method of accounting of
the Company or any of its Subsidiaries for a Pre-Closing Tax Period; (ii) any
deferred intercompany gain or any excess loss account described in Treasury
Regulations under Section 1502 of the Code (or any corresponding or similar
provision of state, local or foreign Tax Law) with respect to either the
Company or any of its Subsidiaries; (iii) any "closing agreement" as described
in Section 7121 of the Code (or any corresponding or similar provision of
state,



57

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





local or foreign Tax Law) executed with respect to the Company or any of its
Subsidiaries on or prior to the Closing; (iv) any installment sale or other
open transaction disposition made by the Company or any of its Subsidiaries on
or prior to the Closing Date; (v) any prepaid amount received by the Company
or any of its Subsidiaries on or prior to the Closing Date; or (vi) an
election made pursuant to Section 108(i) of the Code prior to the Closing.

(u) A timely election under Section 83(b) of the Code was made for each share
of Restricted Stock granted in connection with the performance of services
provided to the Company and no payroll Tax withholding shall be required with
respect to any amount paid pursuant to this Agreement with respect to any
share of Restricted Stock.

(v) With respect to Tax matters, there are no outstanding rulings of, or
requests for rulings by, any Governmental Entity addressed to the Company or
any of its Subsidiaries that are, or if issued would be, binding on the
Company or any of its Subsidiaries, nor to the knowledge of the Company has
any shareholder of the Company or any of its Subsidiaries or anyone acting on
the Company or any of its Subsidiaries' behalf requested or received a ruling
from any Governmental Entity relating to the Company or any of its
Subsidiaries.

(w) None of the Company or any of its Subsidiaries has been, and or will be,
be required to pay Tax on any untaxed foreign earnings pursuant to Section 965
of the Code.

(x) Section 4.15(x) of the Disclosure Schedule correctly sets forth the U.S.
federal income Tax entity classification (partnership, corporation, or
disregarded entity) of the Company and each of its Subsidiaries.

(y) There are no audits, examinations, investigations or other proceedings
pending or, to the Company's knowledge, threatened in respect of any Taxes or
Tax matters of the Company or any of its Subsidiaries.

The Company and its Subsidiaries make no representation or warranty regarding
the ability of Buyer or any of its Affiliates (including the Surviving
Company) to utilize any net operating losses, capital losses, Tax credits or
other similar Tax asset or attribute (each a "Tax Attribute") of the Company
and its Subsidiaries for any Tax Period beginning after the Closing Date,
including with respect to any limitation thereon or the amount or value of any
such Tax Attribute in any Tax Period beginning after the Closing Date.

Section 4.16 Labor Relations; Employees.

(a) Except as set forth in Section 4.16(a) of the Disclosure Schedule: (i) the
Company and each Subsidiary is in compliance in all material respects with all
applicable Laws respecting employment and employment practices, including all
Laws relating to labor relations, equal employment opportunities, fair
employment practices, employment discrimination, harassment, retaliation,
reasonable accommodation, disability rights or benefits, immigration, wages,
hours, overtime compensation, child labor, hiring, promotion and termination
of employees, working conditions, meal and break periods, privacy, health and
safety, workers'



58

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





compensation, leaves of absence, paid sick leave and unemployment insurance,
(ii) there are no Legal Proceedings against the Company or any of its
Subsidiary pending, or to the knowledge of the Company, threatened to be
brought or filed, by or with any Governmental Entity or arbitrator in
connection with the employment of any current or former applicant, employee,
consultant or independent contractor of the Company or one of its
Subsidiaries, (iii) there is no labor strike, dispute, slowdown, stoppage or
lockout pending, affecting or, to the knowledge of the Company, threatened
against the Company or any Subsidiary, and (iv) neither the Company nor any
Subsidiary is a party to or bound by any collective bargaining or similar
agreement.

(b) Section 4.16(b) of the Disclosure Schedule contains a true and complete
list of each Plan. For purposes of this Agreement, a "Plan" shall mean any
pension, benefit, retirement, compensation, employment, consulting, profit-
sharing, deferred compensation, incentive, bonus, performance award, phantom
equity, stock or stock-based, change in control, retention, severance,
vacation, paid time off (PTO), medical, vision, dental, disability, welfare,
Code Section 125 cafeteria, fringe-benefit and other similar agreement, plan,
policy, program or arrangement (and any amendments thereto), in each case
whether or not reduced to writing and whether funded or unfunded, including
each "employee benefit plan" within the meaning of Section 3(3) of ERISA,
whether or not tax-qualified and whether or not subject to ERISA, which is or
has been maintained, sponsored, contributed to, or required to be contributed
to by the Company or a Subsidiary for the benefit of any current or former
employee, officer, director, retiree, independent contractor or consultant of
the Company or a Subsidiary or any spouse or dependent of such individual, and
under which the Company or any of its Subsidiaries has or may have any
liability, or with respect to which Buyer or any of its Affiliates would
reasonably be expected to have any liability, contingent or otherwise.

(c) The Company has made available to Buyer a list of all persons who are
employees, independent contractors or consultants of the Company as of the
date hereof, including any employee who is on a leave of absence of any
nature, paid or unpaid, authorized or unauthorized, and sets forth for each
such individual the following: (i) name; (ii) title or position (including
whether full-time or part-time); (iii) hire or retention date; (iv) current
annual base compensation rate or contract fee; (v) summary of commission,
bonus or other incentive-based compensation opportunity, including target
bonus for 2018; and (vi) an identification of the types of fringe benefits
provided to each such individual as of the date hereof.

(d) The Company has made available to Buyer a true and complete copy of each
Plan, all amendments thereto, the most recent IRS determination or opinion
letter (if any), and the most recent annual report (if any) filed in
connection with such Plan.

(e) Each Plan that is intended to be "qualified" within the meaning of Section
401(a) of the Code has received a favorable determination or opinion letter
from the IRS that remains in effect on the date hereof. To the knowledge of
the Company, no event has occurred since such favorable determination letter
was issued that could reasonably be expected to jeopardize the tax-qualified
status of such Plan.

(f) All contributions due with respect to any Plan that is subject to Title I
of ERISA have been made as required under ERISA and have been accrued on the
Company



59

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Financial Statements, in accordance with GAAP (except as indicated in the
notes thereto). The reserves reflected in the Company Financial Statements for
the obligations of the Company under all Plans are adequate in all materials
respects and were determined in accordance with GAAP.

(g) No Plan is subject to the provisions of Section 412 of the Code, Part 3 of
Subtitle B of Title I of ERISA, or Title IV of ERISA.

(h) No Plan constitutes a "multiemployer plan" (within the meaning of Section
3(37) of ERISA), and, with respect to the Company, neither the Company nor any
of its ERISA Affiliates has, in the past five years, contributed to or
otherwise had any obligation or liability in connection with any multiemployer
plan (within the meaning of Section 3(37) of ERISA).

(i) Except as set forth in Section 4.16(i) of the Disclosure Schedule, the
Company has not engaged in a non-exempt "prohibited transaction" with respect
to any Plan (within the meaning of Section 4975 of the Code or Section 406 of
ERISA).

(j) Each Plan has been operated in accordance with its terms in all material
respects, and complies in form and operation in all material respects with
applicable Laws.

(k) Other than routine claims for benefits, there are no actions, claims,
lawsuits or arbitrations pending or, to the knowledge of the Company,
threatened with respect to any Plan.

(l) The requirements of the Consolidated Omnibus Budget Reconciliation Act of
1985, as amended, and the rules and regulations promulgated thereunder
("COBRA") have been met in all material respects with respect to each Plan
subject to COBRA.

(m) Except as set forth in Section 4.16(m) of the Disclosure Schedule, the
Company does not maintain, contribute to, or have an obligation to contribute
to any plan or other arrangement (whether or not a Plan) providing health or
life insurance or other welfare-type benefits for current or future retired or
terminated directors, officers or employees (or their beneficiaries) other
than in accordance with COBRA.

(n) Each Plan can be amended, terminated or otherwise discontinued after the
Closing in accordance with its terms, without material liabilities to Buyer,
the Company or any of their Affiliates other than ordinary administrative
expenses typically incurred in a termination event.

(o) Except as set forth in Section 4.16(o) of the Disclosure Schedule, each
individual who is classified by the Company or a Subsidiary as an independent
contractor has been properly classified for purposes of participation and
benefit accrual under each Plan.

(p) Except as set forth in Section 4.16(p)of the Disclosure Schedule, neither
the execution of this Agreement nor any of the transactions contemplated by
this Agreement will



60

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(either alone or upon the occurrence of any additional or subsequent events):
(i) entitle any current or former director, officer, employee, independent
contractor or consultant of the Company or any Subsidiary to severance pay or
any other payment; (ii) accelerate the time of payment, funding or vesting, or
increase the amount of compensation (including stock-based compensation) due
to any such individual; (iii) limit or restrict the right of the Company to
merge, amend or terminate any Plan; or (iv) increase the amount payable under
or result in any other material obligation pursuant to any Plan.

Section 4.17 Interested Party Transactions. Except as set forth on Section
4.17 of the Disclosure Schedule, no Interested Party has or has had, directly
or indirectly, a five percent (5%) or greater ownership interest in, or is a
director, officer of employee of, any entity which is a party to a Material
Contract, excluding Material Contracts that are (a) employment agreements, (b)
agreements between the Company and its stockholders, or (c) on arm's length
terms and entered into in the ordinary course of business. Except as set forth
on Section 4.17 of the Disclosure Schedule, there is no indebtedness owed to
the Company or any of its Subsidiaries by any Securityholder, director or
officer of the Company or any of its Subsidiaries, other than advances of
travel or other business expenses in the ordinary course of business
consistent with past practice.

Section 4.18 Brokers. No agent, broker, investment banker, person or firm
acting on behalf of the Company or any of its Subsidiaries or under the
authority of the Company or any of its Subsidiaries is or will be entitled to
any broker's or finder's fee or any other commission or similar fee directly
or indirectly from any of the parties hereto in connection with any of the
transactions contemplated hereby.

Section 4.19 Insurance. Section 4.19 of the Disclosure Schedule contains a
list of all insurance policies maintained with respect to the business of the
Company and its Subsidiaries, all of which are in full force and effect in
accordance with their terms and shall remain in full force and effect
following the Closing. Except as set forth on Section 4.19 of the Disclosure
Schedule, neither the Company nor any of its Subsidiaries is in material
default with respect to its obligations under any insurance policy maintained
by them. Neither the Company nor any of its Subsidiaries has received written
notice of termination, cancellation or non-renewal of any such insurance
policies from any of its insurance brokers or carriers. The Company has
complied in all material respects with each such insurance policy and all
premiums due on such insurance policies have either been paid or, if due and
payable prior to the Closing, will be paid prior to the Closing in accordance
with the payment terms of each such insurance policy. Neither the Company nor
any of its Subsidiaries has been denied insurance or suffered the cancellation
of any insurance in the three years preceding the date of this Agreement.
There is no material claim pending by the Company or any of its Subsidiaries
under any insurance policy listed on Section 4.19 of the Disclosure Schedule
as to which coverage has been denied or disputed by the underwriters of such
policy. The insurance policies listed on Section 4.19 of the Disclosure
Schedule are sufficient for compliance in all material respects with all
applicable Laws and Contracts to which the Company or any of its Subsidiaries
is a party or by which it is bound.



61

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Section 4.20 Powers of Attorney. There are no powers of attorney executed by
or on behalf of the Company or any of its Subsidiaries and there is no other
authority (express or implied) outstanding by which any Person, other than by
virtue of such Person's current position as an officer or employee of the
Company, may enter into any Contract or commitment on behalf of the Company or
any of its Subsidiaries.

Section 4.21 Government Restrictions on Business Activities. There is no
order, writ, judgment, injunction, decree or stipulation of any Governmental
Entity binding upon the Company or any of its Subsidiaries that would
reasonably be expected to have the effect of prohibiting or materially
impairing any business practice of the Company or any of its Subsidiaries
(including the ability of the Company and its Subsidiaries to develop,
manufacture, market, license, use, distribute, sell and exploit the Products
and Services), acquisition of property by the Company or its Subsidiaries, or
the conduct of business by the Company and its Subsidiaries as presently
conducted.

Section 4.22 Privacy and Security.

(a) Section 4.22(a) of the Disclosure Schedule sets forth a complete list of
each of the Company's and each of its Subsidiaries' written policies and
procedures relating to Privacy Matters currently in effect (collectively, the
"Company Privacy Policies"). The Company has delivered or made available to
the Buyer true, correct and complete copies of all Company Privacy Policies.

(b) The Company and each of its Subsidiaries has complied in all material
respects with (i) all Laws relating to Privacy Matters, including HIPAA, the
U.S. Health Information Technology for Economic and Clinical Health Act (Pub.
L. No. 111-5) (the HITECH Act), the FTC Red Flags Rule (16 CFR Part 681), and
state privacy and security laws and regulations, in each case, to the extent
applicable to the business of the Company and each of its Subsidiaries as
currently conducted, (ii) any order, writ, judgment, injunction, decree,
stipulation, determination or award of any Governmental Entity relating to
Privacy Matters, to which the Company or any of its Subsidiaries is subject,
and (iii) all in-effect, material requirements of all Business Associate
Agreements (as defined under HIPAA) entered into by the Company or any of its
Subsidiaries (collectively, the "Privacy Commitments"). The Company and each
of its Subsidiaries has required and does require all third parties to which
it provides Personally Identifiable Information or access thereto to use
commercially reasonable efforts to maintain the privacy and security of such
Personally Identifiable Information, including by contractually obligating
such third parties to use commercially reasonable efforts to protect such
Personally Identifiable Information from unauthorized use, access by or
disclosure to any unauthorized Persons.

(c) Neither the Company nor any of its Subsidiaries has received any written
notices from any Person regarding the Company's or any of its Subsidiaries'
failure to comply with any Privacy Commitments, including any notice from any
Covered Entity (as defined under HIPAA) for which the Company or any of its
Subsidiaries is a Business Associate (as defined under HIPAA), or from the
Department of Health and Human Services or any other Governmental Entity,
regarding its failure to comply in any material respect with HIPAA, in each



62

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





case except as would not be material to the Company and its Subsidiaries,
taken as a whole. Neither the Company nor any of its Subsidiaries has
experienced, to the Company's knowledge, any material security breach in which
Personally Identifiable Information has been or may have been stolen or
intentionally and improperly accessed, and neither the Company nor any of its
Subsidiaries has received any written notices or complaints from any Person
regarding any such incident.

(d) The Company and each of its Subsidiaries have used commercially reasonable
efforts to maintain systems and procedures reasonably intended to respond to
complaints received alleging violation of any material Privacy Commitments,
including as to any Person's rights in Personally Identifiable Information in
the possession or under the control of the Company and any of its
Subsidiaries, and the Company and each of its Subsidiaries have complied in
all material respects with such systems and procedures.

(e) No Legal Proceeding is pending or settled or, to the knowledge of the
Company, threatened against the Company or any of its Subsidiaries by any
Person alleging a material violation of any Privacy Commitment, nor, to the
knowledge of the Company, is any investigation of any such violation being
conducted by any Governmental Entity.

(f) The Company is not, and has never been, a Covered Entity (as defined under
HIPAA).

Section 4.23 Disclaimer of Other Representations and Warranties. Except as
otherwise expressly set forth in this Article IV, the Company expressly
disclaims any representations or warranties of any kind or nature, express or
implied, including any representations or warranties as to the accuracy and
completeness of any information regarding the Company or its Subsidiaries,
their respective businesses and affairs or the transactions contemplated
hereby. Without limiting the generality of the foregoing, neither the Company
nor its Subsidiaries nor any representative of the Company or its
Subsidiaries, nor any of the Company's or its Subsidiaries' employees,
officers, directors, securityholders, consultants or advisors, has made, and
shall not be deemed to have made, any representations or warranties in the
materials relating to the business and affairs of the Company or its
Subsidiary that have been made available to Buyer or Merger Sub, including due
diligence materials, or in any presentation of the business and affairs of the
Company or its Subsidiary by the management of the Company or others in
connection with the transactions contemplated hereby, and no statement
contained in any of such materials or made in any such presentation shall be
deemed a representation or warranty hereunder or otherwise or deemed to be
relied upon by Buyer or Merger Sub in executing, delivering and performing
this Agreement and/or the transactions contemplated hereby. It is understood
that any cost estimates, projections or other predictions, any data, any
financial information or any memoranda or similar materials made available by
the Company, its Subsidiary and their representatives, are not and shall not
be deemed to be or be included as representations or warranties of the Company
or its Subsidiary, and are not and shall not be deemed to be relied upon by
Buyer or Merger Sub in executing, delivering and performing this Agreement
and/or the transactions contemplated hereby.



63

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





ARTICLE V 

REPRESENTATIONS AND WARRANTIES OF BUYER AND MERGER SUB

Buyer and Merger Sub jointly and severally represent and warrant to the
Company as follows:

Section 5.1 Organization; Power and Authority. Each of Buyer and Merger Sub is
a corporation duly organized, validly existing and in good standing under the
laws of Delaware. Each of Buyer and Merger Sub is duly qualified to do
business and is in good standing in each jurisdiction in which such
qualification is necessary because of the property owned, leased or operated
by it or because of the nature of its business as now being conducted, except
for any failure to so qualify or be in good standing that, individually or in
the aggregate, would not reasonably be expected to have a Buyer Material
Adverse Effect. Merger Sub is a wholly-owned subsidiary of Buyer.

Section 5.2 Authority; Approvals. The execution, delivery and performance of
this Agreement by each of Buyer and Merger Sub and the consummation of the
transactions contemplated hereby are within their respective corporate powers
and have been duly and validly authorized by all necessary corporate action on
the part of each of Buyer and Merger Sub (other than the filing of a
Certificate of Merger pursuant to the DGCL). This Agreement has been duly
executed and delivered by each of Buyer and Merger Sub, and (assuming due
authorization, execution and delivery by the other parties hereto) constitutes
the valid and binding obligation of each of Buyer and Merger Sub, enforceable
against each of them in accordance with its terms, except as such
enforceability may be limited by bankruptcy, insolvency, reorganization,
moratorium and other similar laws of general applicability relating to or
affecting creditor's rights generally and by the application of general
principles of equity.

Section 5.3 Conflicts; Consents. The execution, delivery and performance by
each of Buyer and Merger Sub of this Agreement and the consummation of the
transactions contemplated hereby does not (i) conflict with or result in a
breach of the certificates of incorporation, by-laws or other organizational
documents of Buyer or Merger Sub, (ii) conflict with, breach or result in a
default (or give rise to any right of termination, cancellation or
acceleration) under any agreement or other instrument or obligation to which
Buyer or Merger Sub is a party, or by which any such Person or its properties
or assets are bound, or (iii) violate any Laws applicable to Buyer or Merger
Sub or any such Person's properties or assets, except where the occurrence of
any of the foregoing described in clauses (ii) or (iii) above, individually or
in the aggregate, would not reasonably be expected to have a Buyer Material
Adverse Effect or prevent or materially delay the consummation of the Merger.
Except for (A) the filing of a premerger notification and report form under
the HSR Act and the expiration or early termination of the applicable waiting
period thereunder, (B) any filings as may be required under the DGCL in
connection with the Merger, and (C) such consents, approvals, notifications,
registrations or filings the failure to obtain which, individually or in the
aggregate, would not reasonably be expected to have a Buyer Material Adverse
Effect or prevent or materially delay the consummation of the Merger, no
consent or approval by, or notification of or registration or filing with, any
Governmental Entity is required in connection with the execution, delivery and



64

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





performance by Buyer or Merger Sub of this Agreement or the consummation of
the transactions contemplated hereby.

Section 5.4 Brokers. No agent, broker, investment banker, Person or firm
acting on behalf of Buyer or Merger Sub or under the authority of Buyer or
Merger Sub is or will be entitled to any broker's or finder's fee or any other
commission or similar fee directly or indirectly from any of the parties
hereto in connection with the Merger or any of the transactions contemplated
hereby.

Section 5.5 Litigation. There are no actions, suits, proceedings, claims or
disputes pending or, to the knowledge of Buyer or Merger Sub, threatened by or
before any court or other Governmental Entity against Buyer or Merger Sub that
bring into question the validity of this Agreement or would reasonably be
expected to have a Buyer Material Adverse Effect. No injunction, writ,
temporary restraining order, decree or any order of any nature has been issued
by any court or other Governmental Entity seeking or purporting to enjoin or
restrain the execution, delivery and performance by Buyer or Merger Sub of
this Agreement or the consummation by Buyer or Merger Sub of the transactions
contemplated hereby.

Section 5.6 Financing. At the Effective Time Buyer will have sufficient cash
and currently-available funds on hand to enable it to make the payments
required by Section 3.6 of this Agreement.

Section 5.7 Disclaimer of Other Representations and Warranties. Except as
otherwise expressly set forth in this Article V, each of Buyer and Merger Sub
expressly disclaims any representations or warranties of any kind or nature,
express or implied, including any representations or warranties as to the
accuracy and completeness of any information regarding Buyer and Merger Sub,
their respective businesses and affairs or the transactions contemplated
hereby. Without limiting the generality of the foregoing, none of Buyer or
Merger Sub or any representative of Buyer or Merger Sub, nor any of Buyer's or
Merger Sub's employees, officers, directors, securityholders, consultants or
advisors, has made, and shall not be deemed to have made, any representations
or warranties in the materials relating to the business and affairs of Buyer
or Merger Sub that have been made available to the Company or its
Subsidiaries, and no statement contained in any of such materials or made in
any such presentation shall be deemed a representation or warranty hereunder
or otherwise or deemed to be relied upon by the Company or any of its
Subsidiaries in executing, delivering and performing this Agreement and/or the
transactions contemplated hereby.

ARTICLE VI 

CERTAIN COVENANTS

Section 6.1 Conduct of Business. (a) From the date of this Agreement until the
earlier to occur of the Closing or the termination of this Agreement pursuant
to and in accordance with the terms of Article X hereof, except as set forth
in Section 6.1 of the Disclosure Schedule, as required by applicable Law, as
permitted or required by this Agreement or otherwise consented to by Buyer in
writing (which consent shall not be unreasonably withheld, conditioned or



65

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





delayed), the Company shall operate its business only in the ordinary course
of business consistent with past practice. During such period, the Company
shall use its commercially reasonable efforts to:

(i) preserve intact the present organization of the Company and its
Subsidiaries;

(ii) pay its debts and other obligations when due and payable;

(iii) keep available the services of the present officers and employees of the
Company;

(iv) preserve the Company's goodwill and relationships with material
customers, suppliers, licensors, licensees, contractors, distributors, lenders
and other Persons having significant business dealings with the Company and
its Subsidiaries;

(v) maintain the material assets and properties of the Company and its
Subsidiaries in good repair, order and condition;

(vi) defend and protect its properties and assets from infringement or
usurpation;

(vii) maintain the Company's insurance policies and risk management programs,
and in the event of casualty, loss or damage to any material assets of the
Company or any of its Subsidiaries, repair or replace such assets in the
reasonable determination of the Company with assets of comparable quality, as
the case may be;

(viii) not pay or grant any bonuses, whether monetary or otherwise, in respect
of its or any of its Subsidiaries' current employees; and

(ix) comply in all material respects with all applicable Laws.

(b) Without limiting the generality of the foregoing, except as set forth in
Section 6.1 of the Disclosure Schedule, the Company shall not, without the
prior written consent of Buyer (which consent shall not be unreasonably
withheld, conditioned or delayed), directly or indirectly take any action (i)
that, if taken prior to the date of this Agreement, would be required to be
disclosed pursuant to Section 4.7 or (ii) that would reasonably be expected to
prevent the satisfaction of any condition to closing set forth in Article VII.

Section 6.2 Access and Information; Confidentiality. From the date of this
Agreement until the earlier of (i) the Closing, and (ii) the termination of
this Agreement in accordance with Article X, the Company shall allow Buyer and
its Representatives to make such reasonable investigation, upon reasonable
notice and during normal business hours, under the supervision of the
Company's personnel and in such a manner as not to materially interfere with
the normal operations of the Company, of the business, operations and
properties of the Company or any



66

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Subsidiary of the Company as is reasonably necessary in connection with the
transactions contemplated by this Agreement. Such investigation shall include
reasonable access to the respective Representatives of the Company and its
Subsidiaries and the properties, books, records and commitments of the Company
and its Subsidiaries. The Company shall furnish Buyer and its Representatives
with such financial, operating and other data and information maintained by
the Company in the ordinary course of business with respect to the Company or
any of the transactions contemplated by this Agreement as Buyer shall from
time to time reasonably request (for the avoidance of doubt, the Company shall
not be required to prepare any additional materials that are not otherwise
prepared by the Company absent entering into this Agreement, except as
explicitly set forth herein). Notwithstanding the foregoing, no access or
information shall be required pursuant to this Section 6.2 to the extent that
in the reasonable good faith judgment of the Company, (i) applicable Law
requires the Company or its Subsidiaries to restrict or prohibit access to any
such properties or information, (ii) the information is subject to
confidentiality obligations to a third party or (iii) disclosure of any such
information or document would jeopardize attorney-client privilege or the
attorney-client work product doctrine; provided, however, that the Company
shall, and shall cause each of its Subsidiaries to, use commercially
reasonable efforts to negotiate in good faith agreements or arrangements that
permit the provision of such information to Buyer without having any such
effects. As soon as reasonably practicable following the date hereof, and in
any event no later than October 15, 2018, the Company shall provide to Buyer
its financial statements for the month ended August 31, 2018. In addition,
following September 30, 2018, the Company shall use commercially reasonable
efforts to perform a quarter-end closing of its financial results and provide
to Buyer its financial statements for the nine months ended September 30, 2018
as soon as reasonably practicable thereafter.

Section 6.3 Required Stockholder Approval; Disclosure Statement.

(a) The Company shall deliver the Written Consent (executed by the Principal
Stockholders) to Buyer promptly following the execution and delivery of this
Agreement by the parties hereto.

(b) As soon as practicable after the delivery of the Written Consent, but in
no event more than ten (10) Business Days after the date hereof, the Company
shall prepare and mail a written disclosure statement (the "Disclosure
Statement"), in a form reasonably acceptable to Buyer, to each of the
Stockholders in accordance with Section 228(e) of the DGCL. Buyer and Merger
Sub shall provide the Company with such information regarding any of them and
any of their Subsidiaries as may be reasonably requested by the Company to be
included in the Disclosure Statement.

(c) The Company shall also use commercially reasonable efforts to cause the
Joinder Agreement to be executed on or prior to the Closing Date by all
Stockholders and Option Holders.

Section 6.4 Best Efforts; Further Assurances.



67

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(a) Upon the terms and subject to the conditions set forth in this Agreement,
each of the parties hereto (other than the Stockholders' Representative) will
use its reasonable best efforts to take, or cause to be taken, all actions,
and to do, or cause to be done, all things necessary, proper or advisable
(including making any requisite filings or giving any requisite notices) under
applicable Laws to consummate and make effective the transactions contemplated
by this Agreement as expeditiously as practicable and to ensure that the
conditions set forth in Article VII are satisfied, insofar as such matters are
within the control of any of them, including, without limitation, using
reasonable best efforts to obtain, prior to the Closing, all consents of third
parties as are necessary for the consummation of the transactions contemplated
hereby; provided, however, that, in connection with obtaining such third party
consents, no Contract shall be amended to increase the amount payable by the
Company or any of its Subsidiaries thereunder or otherwise to be more
burdensome in any material respect to the Company or any of its Subsidiaries,
unless, in each case, mutually agreed in writing by the Company and Buyer.
Without limiting the generality of the foregoing and subject to Section 6.2,
the Company, on the one hand, and Buyer and Merger Sub, on the other hand,
shall each furnish to the other such necessary information and reasonable
assistance as the other party may reasonably request in connection with the
foregoing.

(b) Each Party (other than the Stockholders' Representative) shall use its
reasonable best efforts to (i) promptly obtain all authorizations, consents,
orders and approvals of all Governmental Entities that may be or become
necessary or advisable for its execution and delivery of, and the performance
of its obligations pursuant to, this Agreement and the consummation of the
transaction contemplated hereby, (ii) cooperate fully with the other Party in
promptly seeking to obtain all such authorizations, consents, orders and
approvals, and (iii) provide all such other information to any Governmental
Entity as such Governmental Entity may request in connection herewith. Each
Party (other than the Stockholders' Representative) agrees to file promptly
(but in no event later than five Business Days after the date of this
Agreement) any premerger notification and report form under the HSR Act and
related material required to be filed with the Federal Trade Commission and
the Antitrust Division of the United States Department of Justice with respect
to the Merger and the other transactions contemplated by this Agreement and to
use its reasonable best efforts to obtain an early termination of the
applicable waiting period. Each Party (other than the Stockholders'
Representative) shall supply as promptly as practicable to the appropriate
Governmental Entities any additional information and documentary material that
may be requested by them pursuant to the HSR Act. Each Party (other than the
Stockholders' Representative) agrees to make as promptly as practicable its
respective filings and notifications, if any, under any other merger
notification or control Laws of any other applicable jurisdiction, and to
supply as promptly as practicable to the appropriate Governmental Entities any
additional information and documentary material that may be requested by them
pursuant to such merger notification or control Law. Except as required by
applicable Law, neither the Company, on the one hand, nor Buyer or Merger Sub,
on the other hand, may, without the consent of the other party or parties
(which consent shall not be unreasonably withheld), as applicable, (1) cause
any such filing or submission applicable to it to be withdrawn or refiled for
any reason, including to provide the applicable Governmental Entity with
additional time to review any of the transactions contemplated by this
Agreement, or (2) consent to any voluntary extension of any statutory deadline
or waiting period or to any



68

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





voluntary delay of the consummation of the Merger or the other transactions
contemplated by this Agreement at the behest of any Governmental Entity. Buyer
shall pay 100% of any amounts due with respect to all fees and all other
payments required to be paid to any Governmental Entity in order to obtain any
such authorizations, consents, orders or approvals, and 50% of the amount of
such fees and payments shall be deemed Transaction Expenses for purposes of
this Agreement, so that each of Buyer and the Securityholders bears 50% of
such fees and payments in the event of the Closing.

(c) Without limiting the generality of the foregoing, each Party (other than
the Stockholders' Representative) shall use reasonable best efforts to take
any and all steps necessary or advisable to avoid or eliminate each and every
impediment under any antitrust, competition or trade regulation Law that may
be asserted by any antitrust or competition Governmental Entity or any other
party so as to enable the parties hereto to consummate the Merger and the
other transactions contemplated hereby as promptly as practicable, and in any
event prior to the Termination Date. Notwithstanding any provision of this
Agreement to the contrary, in no event shall Buyer or any of its Affiliates be
required to agree to divest, abandon, license, hold separate or take similar
action with respect to any assets of the Company, any of the Company's
Subsidiaries, Buyer or any Affiliate of Buyer.

(d) Each of Buyer and Merger Sub, on the one hand, and the Company, on the
other hand, shall promptly notify the other of any communication it or any of
its Affiliates or Representatives receives from any Governmental Entity
relating to the matters that are the subject of this Agreement and permit the
other to review reasonably in advance any proposed communication by it to any
Governmental Entity relating to such matters. Except as required by applicable
Law, neither Buyer nor Merger Sub, on the one hand, nor the Company, on the
other hand, shall agree to participate in any meeting with any Governmental
Entity in respect of any filings, investigation (including any settlement of
the investigation), litigation or other inquiry relating to the matters that
are the subject of this Agreement unless it consults with the other in advance
and, to the extent permitted by such Governmental Entity, gives the other the
opportunity to attend and participate at such meeting. Buyer and Merger Sub,
on the one hand, and the Company, on the other hand, shall reasonably
coordinate and cooperate with each other in exchanging such information and
providing such assistance as the other may reasonably request in connection
with the foregoing and in seeking early termination of any applicable waiting
periods, including under the HSR Act. Buyer and Merger Sub, on the one hand,
and the Company, on the other hand, will provide each other with copies of all
correspondence, filings or communications between them or any of their
respective Affiliates and Representatives, on the one hand, and any
Governmental Entity or members of its staff, on the other hand, with respect
to this Agreement and the transactions contemplated by this Agreement;
provided, however, that such materials may be redacted (i) to remove
references concerning the valuation of the business of the Company and its
Subsidiaries, (ii) as necessary to comply with contractual arrangements as of
the date hereof, and (iii) as necessary to address reasonable attorney-client
or other privilege or confidentiality concerns, to the extent that that such
attorney-client or other privilege or confidentiality concerns are not
governed by a common interest privilege or doctrine.



69

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(e) In case at any time after the Effective Time any further action is
necessary to carry out the purposes of this Agreement, each of the parties to
this Agreement shall take or cause to be taken all such necessary action,
including the execution and delivery of such further instruments and
documents, as may be reasonably requested by any Party for such purposes or
otherwise to consummate the transactions contemplated by this Agreement.

Section 6.5 Public Announcements. Buyer and the Company shall issue an initial
joint press release, which shall be mutually agreed upon, with respect to the
transactions contemplated by this Agreement (the "Joint Release"). Thereafter,
the Company and the Buyer will not, and will cause each of their Affiliates
and Representatives not to, issue or cause the publication of any press
release or other public announcement with respect to this Agreement or the
transactions contemplated hereby, without the prior written consent of the
other party, which consent shall not be unreasonably withheld or delayed;
provided, however, that a Party may, without the prior consent of the other
parties hereto, issue or cause the publication of any such press release or
other public announcement to the extent that such party reasonably determines,
after consultation with legal counsel, that such action is required by
applicable Law or by the rules of any applicable self-regulatory organization
or any stock exchange on which any stock of Buyer (or Affiliate thereof) is
listed or traded, in which event (unless prohibited by applicable Laws) such
party will use its commercially reasonable efforts to allow the other parties
hereto reasonable time to comment on such press release or other public
announcement in advance of its issuance or publication, and provided, further,
however, that following the Closing the Buyer will not need any consent with
respect to a press release or other public announcement. Notwithstanding the
foregoing, no Securityholder, and no broker or financial advisor to a
Securityholder or the Company, will issue or cause the publication of any
press release or other public announcement with respect to this Agreement or
the transactions contemplated hereby, without the prior written consent of
Buyer in its sole discretion, except that, each of Apple Tree Partners IV,
L.P. and Partners Innovation Fund LLC may, with the prior written consent of
Buyer, which consent shall not be unreasonably withheld or delayed, issue one
press release which (i) contains substantially the same information with
respect to the transactions contemplated by this Agreement included in the
Joint Release, and (ii) is issued no sooner than the later of (x) eight hours
after the issuance of the Joint Release, or (y) 4:00 p.m. (Eastern time) on
the date of the Joint Release.

Section 6.6 Section 280G. With respect to each employee of the Company or any
Subsidiary of the Company who is, or would reasonably be expected to be as of
the Closing Date, a "disqualified individual" (as defined in Section 280G(c)
of the Code), the Company shall use commercially reasonable efforts to (i) (A)
ensure that any payments that would otherwise constitute a "parachute payment"
(as defined in Section 280G(b)(2) of the Code) shall be exempt from the
definition of "parachute payment" by reason of the exemption provided under
Section 280G(b)(5)(A)(ii) of the Code, and (B) take all actions reasonably
necessary to so exempt such payments (including obtaining any necessary
waivers or consents from such "disqualified individuals") prior to the Closing
Date; or (ii) not make any payments that would constitute a "parachute
payment" (as defined in Section 280G(b)(2) of the Code). At least five (5)
Business Days prior to the delivery to the Stockholders of documents in
connection with the stockholder approval contemplated under subsection (i)
above, the Company will provide Buyer and its



70

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





counsel with a reasonable opportunity to review and comment on all documents
to be delivered to the Stockholders and disqualified individuals in connection
with the waivers and vote.

Section 6.7 Expenses. Each Party shall bear its own fees, costs and expenses
incurred in the pursuit of the transactions contemplated by this Agreement,
including the fees and expenses of its respective counsel, financial advisors
and accountants, except as otherwise expressly contemplated herein. All fees,
costs and expenses of the Paying Agent incurred in connection with the
performance of its duties in respect of this Agreement and the Paying Agent
Agreement and all fees, costs and expenses of the Escrow Agent incurred in the
performance of its duties in respect of this Agreement and the Escrow
Agreement shall be paid by Buyer.

Section 6.8 Tax Matters.

(a) Transfer Taxes. Transfer Taxes arising from the transactions contemplated
by this Agreement shall be borne by the Securityholders. "Transfer Taxes"
means all sales, use, real property transfer, real property gains, transfer,
stamp, registration, documentary, recording or similar Taxes, in each case,
arising from the transactions contemplated by this Agreement, together with
any interest thereon, penalties, fines, costs, fees or additions to Tax. If
Buyer or the Surviving Company is required to file any Tax Return related to
Transfer Taxes, Buyer or the Surviving Company, as the case may be, shall file
such Tax Return and pay any Transfer Taxes and the applicable Securityholders
shall reimburse the paying party for its share of Transfer Taxes within ten
(10) days of written request.

(b) Tax Returns.

(i) The Company and each of its Subsidiaries shall prepare and timely file, or
cause to be prepared and timely filed, all Tax Returns of the Company and its
Subsidiaries with respect to any Pre-Closing Tax Period that are required to
be filed prior to or on the Closing Date. Such Tax Returns shall be complete
and correct in all material respects and shall be prepared in a manner
consistent with past practices of the Company and that does not distort
taxable income; provided that no such Tax Returns that are income Tax Returns
or material Tax Returns shall be filed with any Governmental Entity without
providing such Tax Return to Buyer for its review and written approval, which
approval shall not be unreasonably withheld, conditioned or delayed. The
Company and each of its the Subsidiaries shall timely pay all Taxes due and
payable in respect of such Tax Returns by each such entity, except for Taxes
that are being contested in good faith through appropriate proceedings and for
which appropriate reserves have been established on the books of the Company
or the applicable Subsidiary, as the case may be. The Company shall promptly
notify Buyer of written or, to the knowledge of the Company, unwritten notice
of any Tax Proceeding pending against or with respect to the Company or any of
its Subsidiaries and will not settle or compromise any such Tax Proceeding
without Buyer's prior written consent, which consent shall not be unreasonably
withheld, conditioned or delayed.



71

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(ii) Buyer shall prepare and timely file, or cause to be prepared and timely
filed, all Tax Returns of the Company and its Subsidiaries that are filed
after the Closing Date. If any such Tax Returns relates to a Pre-Closing Tax
Period or a Straddle Period (as defined below), Buyer shall prepare, or caused
to be prepared, such Tax Return consistent with the past practices of the
Company or any Subsidiary, as applicable, unless otherwise required by
applicable Law. If any such Tax Returns relate to a Pre-Closing Tax Period or
a Straddle Period, Buyer shall provide the Stockholders' Representative with a
draft of such Tax Returns for the Company and its Subsidiaries at least ten
(10) Business Days prior to the due date for filing such Tax Returns for the
Stockholders' Representative review and approval, such approval not to be
unreasonably withheld, conditioned or delayed. Any reasonable out-of-pocket
expenses incurred by Buyer or any of its Affiliates in the preparation of any
Tax Return described in this Section 6.8(b)(ii) relating to a Pre-Closing Tax
Period to the extent that such Tax Return is being filed in the ordinary
course after the Closing and does not relate to any breach of a covenant or
representation for which Buyer already would be entitled to indemnification
under this Agreement shall also be treated as an indemnifiable Loss pursuant
to Section 8.1(c). For the avoidance of doubt, any preparation costs for any
Tax Return for a Straddle Period being filed in the ordinary course after the
Closing shall be borne by Buyer.

(c) Straddle Periods. All Taxes of the Company and its Subsidiaries relating
to any Tax period that begins on or before and ends after the Closing Date
(such Tax period, a "Straddle Period") shall be apportioned to, and be the
responsibility of, the Securityholders as follows: (i) real, personal and
intangible property taxes ("Property Taxes") for the portion of the Straddle
Period ending on (and including) the Closing Date shall be equal to the amount
of such Property Taxes for the entire Straddle Period multiplied by a
fraction, the numerator of which is the number of days during the Straddle
Period that are in the portion of the Straddle Period ending on (and
including) the Closing Date and the denominator of which is the total number
of days in the Straddle Period; and (ii) Taxes (other than Property Taxes) for
the portion of the Straddle Period shall be computed as if such taxable period
ended as of the close of business on the Closing Date, provided that
exemptions, allowances, deductions that are calculated on an annual or other
periodic basis (including, but not limited to, depreciation and amortization
deductions) shall be allocated between the period ending as of the close of
business on the Closing Date and the period after the Closing Date in
proportion to the number of days in each such period. For purposes of
allocating income or loss to a Tax period (or portion thereof, if a Straddle
Period) ending on or before the Closing Date, in the case of any Taxes
attributable to the ownership of any equity interest in any partnership or
other "flowthrough" entity, the "flowthrough" income or loss attributable to
an equity interest in such "flowthrough" entity shall be determined as if a
taxable period of such partnership or other "flowthrough" entity ended as of
the close of business on the Closing Date.

(d) Tax Sharing Agreements. Any and all Tax sharing, Tax allocation, Tax
indemnity or similar agreements, arrangements, or practices (including any
advance pricing agreement, closing agreement or other similar written
agreement relating to Taxes with any



72

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Governmental Entity, but excluding customary commercial contracts the primary
purpose of which is unrelated to Taxes) to which the Company or any of its
Subsidiaries is a party or otherwise subject shall be terminated as of the
Closing Date and after the Closing Date none of the Surviving Company, Buyer
or any Affiliate of Buyer shall be bound thereby, have any liability
thereunder, or be obligated to make any payment thereunder.

(e) Covered Securities. On or before the Closing Date, the Company shall
provide Buyer, or at Buyer's request, the Paying Agent or Escrow Agent, the
information described under Treasury Regulations Section 1.6045A-1 with
respect to the Company securities being acquired pursuant to the Agreement,
including (i) whether or not a particular security is a "covered security"
under the applicable Treasury Regulations and (ii) if a security is a "covered
security", each security holder's date of acquisition of, and cost basis in,
the applicable security, and any other information that is required, or
reasonably requested, by Buyer or its designee to comply with Buyer or its
designee's tax reporting obligations under the Code and Treasury Regulations,
including IRS Form 1099-B reporting requirements.

(f) Tax Cooperation. Buyer, the Company, the Surviving Company, the
Stockholders, the Option Holders and the Stockholders' Representative, as the
case may be, shall reasonably cooperate, and shall cause their respective
Affiliates, directors, officers, employees, agents, auditors and other
representatives to reasonably cooperate, in preparing and filing all Tax
Returns and in resolving all disputes and audits with respect to all taxable
periods relating to Taxes, including by maintaining and making available to
each other all records reasonably necessary in connection with Taxes and
making employees available on a mutually convenient basis to provide
additional information or explanation of any material provided hereunder or to
testify at proceedings relating to such matters.

(g) Additional Pre-Closing Tax Covenants. On or prior to the Closing Date,
neither the Company nor any of its Subsidiaries shall, without the prior
written consent of Buyer, which shall not be unreasonably withheld,
conditioned or delayed, make, revoke or change any material Tax election,
adopt or change any material Tax accounting method or period, file any amended
Tax Return, enter into any closing agreement or settlement relating to Taxes,
settle any Tax claim or assessment, surrender any right to claim a refund of
Taxes, or consent to any extension or waiver of the statute of limitations
period applicable to any Tax claim or assessment.

(h) Post-Closing Tax Actions. Buyer and its Affiliates shall not (i) amend any
previously filed Tax Return of the Company or any of its Subsidiaries for a
Pre-Closing Tax Period, (ii) file Tax Returns for a Pre-Closing Tax Period in
a jurisdiction where the Company or any of its Subsidiaries has not
historically filed Tax Returns, (iii) initiate discussions or examinations
with any Governmental Entity regarding Taxes with respect to any Pre-Closing
Tax Period, or (iv) make any voluntary disclosures with respect to Taxes for
Pre-Closing Tax Periods, in each case, without the prior written consent of
the Stockholders' Representative, which shall not be unreasonably withheld,
conditioned or delayed. In addition, neither Buyer nor any of its Affiliates
shall make any election under Sections 338 or 336(e) of the Code or any state,
local or foreign law equivalent in respect of the transactions contemplated by
this Agreement.



73

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(i) Tax Refunds. Any refunds (or credits for overpayment) of Taxes, including
any interest received from a Governmental Entity thereon, attributable to any
Pre-Closing Tax Period of the Company or any of its Subsidiaries shall be for
the account of the Securityholders to the extent such Taxes were paid by the
Company or any of its Subsidiaries, as applicable, prior to the Closing or
actually reduced the Merger Consideration payable to the Securityholders under
this Agreement or were paid by the Securityholders after the Closing pursuant
to the indemnification provisions of this Agreement. Promptly upon any receipt
by the Company or any of its Subsidiaries of any such refund (or credit for
overpayment), Buyer shall pay over, by wire transfer of immediately available
funds, an amount equal to any such refund received (or the amount of any such
credit), including any interest received thereon, to the Paying Agent (for
further distribution to the Securityholders) pursuant to the terms of this
Agreement, with each such Securityholder being entitled to receive its Pro
Rata Share of such amounts. Notwithstanding the foregoing, any Tax refunds (or
credits for overpayment) payable to the Securityholders that are in the nature
of compensation (including, for example, amounts paid to holders of Cancelled
Options in respect of their Options or Ungranted Options) shall be processed
through the payroll system of the Company, the Surviving Company or any of
their Subsidiaries or Affiliates, as applicable, and paid directly to such
recipient (less any applicable withholding Taxes). Any amounts payable to the
Securityholders pursuant to this Section 6.8(i) shall be reduced by the
reasonable incremental third-party costs incurred by Buyer or any of its
Affiliates in connection with obtaining such refund or credit.

(j) Transaction Tax Deductions.

(i) With respect to the preparation of income Tax Returns of the Company or
its Subsidiaries, Buyer, the Company and its Subsidiaries agree that all
Transaction Tax Deductions will be treated as properly allocable to the Pre-
Closing Tax Period that ends on the Closing Date to the extent permitted by
applicable Tax Law. In connection with the foregoing, the Parties agree that
seventy percent (70%) of any success-based fees may be deducted for U.S.
federal income tax purposes pursuant to the safe harbor election in Revenue
Procedure 2011-29, unless such Revenue Procedure is revoked or otherwise
supplanted by any change in applicable Law. The Parties intend that the
transactions contemplated by this Agreement shall cause the income Tax year of
the Company to end as of the Closing Date for U.S. federal income Tax purposes
(and, consistent with this, Buyer shall include the Company in its affiliated
group filing a consolidated U.S. federal income Tax Return beginning on the
date after the Closing Date).

(ii) For purposes of this Agreement, "Transaction Tax Deductions" means (A)
all Tax deductible fees, expenses and interest (including amounts treated as
interest for income Tax purposes and any breakage fees or accelerated deferred
financing fees) incurred by the Company or any of its Subsidiaries with
respect to the payment of Closing Indebtedness in connection with the Closing,
(B) all Tax deductible fees, costs and expenses incurred by the Company or any
of its Subsidiaries that are Transaction Expenses under clause (i) of that
definition, and (C) all Tax deductible compensatory payments made with respect
to the Closing pursuant to Section 3.6, and, without



74

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





duplication, any Tax deductible amounts that are Transaction Expenses under
clauses (ii) and (iii) of that definition and that are paid with respect to
the Closing, in the case of each of (A) through (C), to the extent such fees,
costs or expenses result in a reduction in the Merger consideration received
by the Securityholders or constitute amounts for which Buyer is entitled to,
and able to obtain, indemnification under Article VIII.

Section 6.9 No Solicitations. From the date hereof until the earlier to occur
of (a) the termination of this Agreement or (b) the Closing (such earlier
date, the "End Date"), the Company will not, and will instruct its
Subsidiaries, Affiliates and any Representative of the Company or any of its
Subsidiaries or Affiliates not to, directly or indirectly, (i) discuss,
negotiate, undertake, authorize, recommend, propose or enter into, either as
the proposed surviving, merged, acquiring or acquired entity, any transaction
involving a merger, consolidation, liquidation, recapitalization, business
combination, purchase or disposition of any material amount of the assets of
the Company (other than the sale of assets in the ordinary course of business)
or any of its Subsidiaries or any voting securities or other ownership
interests in the Company or any of its Subsidiaries other than the
transactions contemplated by this Agreement (such other transaction, an
"Acquisition Transaction"), (ii) facilitate, encourage, solicit or initiate
discussions, negotiations or submissions of proposals or offers in respect of
an Acquisition Transaction, (iii) furnish or cause to be furnished, to any
Person or entity, any information concerning the business, operations,
properties or assets of the Company or its Subsidiaries in connection with an
Acquisition Transaction, or (iv) otherwise cooperate in any way with, or
assist or participate in, facilitate or encourage, any effort or attempt by
any other Person to do or seek any of the foregoing. From the date hereof
until the End Date, the Company shall, and shall instruct its Subsidiaries,
Affiliates and their Representatives to, immediately cease and cause to be
terminated any existing discussions or negotiations with any Persons (other
than Buyer and Merger Sub) conducted heretofore with respect to any
Acquisition Transaction. The Company agrees not to (and to cause its
Subsidiaries not to) release any third party from the confidentiality
provisions of any agreement to which the Company or any of its Subsidiaries is
a party prior to the End Date. Furthermore, prior to the End Date, the Company
shall promptly (and in any event within two (2) Business Days after receipt
thereof by the Company or, to the Company's knowledge, its Representatives)
advise Buyer orally and in writing of any Acquisition Transaction proposal,
any request for information with respect to any Acquisition Transaction, or
any inquiry with respect to a proposal for an Acquisition Transaction, the
material terms and conditions of such request or inquiry and the identity of
the Person making the same. The Company agrees that the rights and remedies
for noncompliance with this Section 6.9 shall include having such provision
specifically enforced by any court having equity jurisdiction, it being
acknowledged and agreed that any such breach or threatened breach shall cause
irreparable injury to Buyer and that money damages would not provide an
adequate remedy to Buyer.

Section 6.10 Payoff Letters. Except as set forth in Section 6.10 of the
Disclosure Schedule, the Company shall obtain, no later than two (2) Business
Days prior to the Closing Date, payoff letters (the "Payoff Letters") in
customary form reasonably satisfactory to Buyer from the holders (or the
agents for such holders) of the Closing Indebtedness, if any, and all
documents related thereto, including any credit agreements, pledge agreements,
security agreements, notes and guarantees, and all Liens securing the Closing
Indebtedness shall be



75

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





released or terminated upon the repayment of the Closing Indebtedness in
accordance with the terms of such Payoff Letters. Each Payoff Letter shall set
forth the principal amount of the obligation, any prepayment premiums or fees
or termination fees with respect thereto, any accrued interest thereon and any
expense reimbursement or other amounts due in respect thereof, shall provide
wire instructions and shall provide for the release of, or authorize the
Company to release, all Liens associated with such Closing Indebtedness and
the termination of all other obligations associated therewith upon the payment
of such outstanding amounts.

Section 6.11 Confidential Information.

(a) Except as required by Law, each Party shall keep confidential and not
directly or indirectly reveal, report, publish, disclose or transfer any
information regarding any other Party or the negotiations preceding this
Agreement other than to its Representatives, and each will use such
information solely in connection with the transactions contemplated by this
Agreement, and if the transactions contemplated hereby are not consummated for
any reason, the Company, on the one hand, and Buyer and Merger Sub, on the
other hand, shall return to the Party that provided such information, without
retaining any copies thereof, any schedules, documents or other written
information obtained from such Party in connection with this Agreement and the
transactions contemplated hereby and shall cause all of its Representatives to
whom it may have disclosed such information to do the same.

(b) Following the Closing, the Stockholders' Representative shall keep
confidential and not directly or indirectly reveal, report, publish, disclose
or transfer any information concerning the business and affairs of the Company
or any of its Subsidiaries that is not generally available to the public,
including know-how, trade secrets, customer lists, details of customer or
consultant contracts, pricing policies, financial performance, operational
methods and marketing plans or strategies (collectively, "Confidential
Information"), and will not use such information for the Stockholders'
Representative's own benefit or for the benefit of any other Person (other
than the Securityholders) and shall direct any of the Representatives of the
Stockholders' Representative to whom Confidential Information is disclosed to
do the same. Notwithstanding the foregoing limitations, no Party shall be
required to keep confidential any information that (i) is known or available
through other lawful sources not bound by a confidentiality agreement or other
binding legal obligation, (ii) is or becomes publicly known or generally known
in the industry through no fault of the receiving Party or its agents, (iii)
is requested or required to be disclosed pursuant to Law, provided the other
Parties are given reasonable prior notice thereof to the extent legally
permissible, or (iv) relates solely to the Tax aspects and consequences of the
transactions contemplated by this Agreement.

(c) If the Stockholders' Representative is requested or required (by oral
question or request for information or documents in any Legal Proceeding,
interrogatory, subpoena, civil investigative demand, or similar process) to
disclose any Confidential Information, the Stockholders' Representative shall
notify Buyer promptly of the request or requirement (unless prohibited by
applicable Law) so that Buyer may seek an appropriate protective order or
waive compliance with the provisions of this Section 6.11. If, in the absence
of a protective order or the receipt of a waiver hereunder, the Stockholders'
Representative is, on



76

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





the advice of counsel, compelled to disclose any Confidential Information to
any Governmental Entity, the Stockholders' Representative may disclose the
Confidential Information to the Governmental Entity; provided, however, that
the Stockholders' Representative shall use its commercially reasonable efforts
to obtain, at the request of and expense of Buyer, an order or other assurance
that confidential treatment will be accorded to such portion of the
Confidential Information required to be disclosed as Buyer shall designate.

(d) Notwithstanding the foregoing or anything in this Agreement to the
contrary, following Closing, the Stockholders' Representative shall be
permitted to: (i) after the public announcement of the Merger, publicly
announce that it has been engaged to serve as the Stockholders' Representative
in connection herewith as long as such announcement does not disclose any of
the other terms hereof; and (ii) disclose information on a need-to-know basis
(A) in connection with legal proceedings to enforce or defend the rights of
the Securityholders in connection herewith, (B) to employees, advisors, agents
or consultants of the Stockholders' Representative and (C) to the
Securityholders, in each case in the foregoing clauses (B) and (C) provided
that such recipients are subject to confidentiality obligations with respect
thereto.

Section 6.12 Capital Structure Certificate

(a) At least two (2) Business Days before the Closing Date, the Company shall
deliver to Buyer the Capital Structure Certificate, in a form reasonably
acceptable to Buyer and the Paying Agent, dated and setting forth the
following information with respect to each Stockholder and holder of Cancelled
Options (each, a "Securityholder"): (i) the name and the mailing address of
such Securityholder; (ii) with respect to each Certificate held by such
Securityholder, the certificate number of such Certificate, and the number and
class or series of Common Stock, Series A Preferred Stock or Series B
Preferred Stock represented by such Certificate (and, with respect to each
Option and Ungranted Option held by such Securityholder, the number of shares
of Common Stock underlying such Option or Ungranted Option, as applicable, and
the per share exercise price or Deemed Exercise Price, as applicable,
thereof); (iii) the aggregate exercise price for all Cancelled Options; (iv)
the Series A Per Share Liquidation Preference Amount, the Series B Per Share
Liquidation Preference Amount, and/or the Estimated Per Common Share Closing
Merger Consideration payable with respect to the Shares represented by such
Certificate (and, with respect to each Option and Ungranted Option, the
portion of the Estimated Aggregate Closing Merger Consideration payable with
respect to such Option and Ungranted Option) and whether any Taxes are
required to be withheld by the Company or Buyer from such amounts (including
withholding Taxes to be taken into account in calculating the Grossed-Up
Expense Amount Contribution and the corresponding reduction in other amounts
paid to a Stockholder or Option Holder as described in Section 3.6(e)); (v)
the portion of each of the Earn-Out Payments, the Escrow Fund Release Amount
and the Representative Expense Fund Release Amount distributable with respect
to the Shares represented by such Certificate (or with respect to the Options
and Ungranted Options) held by such Securityholder, if ever; and (vi) such
other information which the Buyer may reasonably request at least four (4)
Business Days before the Closing Date.



77

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(b) Other than as provided in this Agreement and the agreements referenced
herein, upon consummation of the transactions contemplated by this Agreement,
and the payment of the consideration payable hereunder in respect of the
Shares and Cancelled Options as provided for in the Capital Structure
Certificate, Buyer, Merger Sub, the Company and the Surviving Company will
have no further obligations in respect of the Shares and Cancelled Options
(including any obligation to make any cash or non-cash payment in respect of
any such Shares or Cancelled Options).

Section 6.13 Termination of Benefit Plans

(a) Effective as of no later than the day immediately preceding the Closing
Date, the Company shall withdraw from the Plan intended to include a Code
Section 401(k) arrangement (the "401(k) Plan") and shall spin out the assets
and liabilities therefrom that are attributable to participants in such 401(k)
Plan who are the Company's current and former employees into a new plan
intended to qualify under Section 401(k) of the Code and immediately terminate
such new plan, unless Buyer provides written notice at least ten (10) Business
Days prior to the Closing Date that the Company shall not withdraw from such
401(k) Plan and such 401(k) Plan shall not be terminated. Unless Buyer
provides such written notice to the Company at least ten (10) Business Days
prior to the Closing Date, the Company shall provide Buyer with evidence that
such 401(k) Plan has been terminated effective as of the day immediately
preceding the Closing Date pursuant to resolutions of the board of directors
of the Company. The form and substance of such resolutions shall be subject to
review and reasonable approval of Buyer. The Company also shall take such
other actions in furtherance of terminating such 401(k) Plan as Buyer may
reasonably require. In the event that termination of a 401(k) Plan would
reasonably be anticipated to trigger liquidation charges, surrender charges or
other fees other than ordinary administrative expenses incurred in connection
with the plan freeze and termination then the Company shall take such actions
as are necessary to reasonably estimate the amount of such charges and/or fees
and provide such estimate in writing to Buyer no later than fifteen (15) days
prior to the Closing Date.

(b) Effective as of no later than the day immediately preceding the Closing
Date, the Company and its Subsidiaries shall terminate any and all group
severance, separation, deferred compensation or salary continuation plans,
programs or arrangements maintained by the Company and any of its Subsidiaries
and all Plans set forth in Section 6.13(b) of the Disclosure Schedule. For the
avoidance of any doubt, the termination of the Plans pursuant to the preceding
sentence shall be effected without any payment or benefit (or giving rights to
any payment or benefit, contingent or otherwise) thereunder. The Company shall
provide Buyer evidence that such Plans have been terminated pursuant to
resolutions of the boards of directors of the Company and of its Subsidiaries,
as applicable (the form and substance of which resolutions shall be subject to
review and reasonable approval of Buyer).

Section 6.14 Employee Matters.

(a) For a period of [*] following the Closing Date (the "Continuation
Period"), Buyer shall, or shall cause its Affiliates or the Surviving Company
to, provide to each employee of the Company who continues employment with
Buyer, any of its Affiliates or the



78

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Surviving Company at the Effective Time (each, a "Continuing Employee") with
(i) a base salary or hourly wage rate (as applicable) that is at least equal
to that provided to the Continuing Employee immediately prior to the Effective
Time, (ii) an annual cash incentive opportunity for calendar year 2018 that is
at least equal to that provided to the Continuing Employee immediately prior
to the Effective Time and (iii) employee health, welfare and severance
benefits (excluding retirement and equity incentives) that are substantially
similar in the aggregate to those provided to the Continuing Employee
immediately prior to the Effective Time. For the avoidance of doubt, nothing
contained in this Section 6.14 shall affect Buyer's (or its applicable
Affiliate's) right to terminate any Continuing Employee after the Closing.

(b) Buyer shall use, or shall cause its Affiliates or the Surviving Company to
use, commercially reasonable efforts to ensure that, each Continuing Employee
who continues employment with Buyer, any of its Affiliates or the Surviving
Company immediately following the Continuation Period receives full credit for
purposes of eligibility to participate, vesting, benefit accrual, vacation
entitlement and severance benefits for service with the Company (or
predecessor employers to the extent the Company provides such past service
credit) under the comparable employee benefit plans, programs and policies of
Buyer, its Affiliates or the Surviving Company, as applicable, in which such
employees are eligible to participate; provided, however, that the foregoing
shall not apply (i) with respect to any defined benefit pension plan or
retiree medical benefits, or (ii) to the extent that its application would
result in a duplication of benefits.

(c) Except as provided for in this Section 6.14, nothing in this Agreement is
intended nor shall be construed to (i) be treated as an amendment to any
particular Plan, (ii) prevent Buyer from amending or terminating any of its
benefit plans in accordance their terms, (iii) create a right in any employee
to employment with the Company, Buyer, any of its Affiliates or the Surviving
Company for any period of time (under Section 6.14(a) or otherwise), or (iv)
create any third-party beneficiary rights in any employee of the Company with
respect to the compensation, terms and conditions of employment and/or
benefits that may be provided to any Continuing Employee by Buyer, any of its
Affiliates or the Surviving Company or under any benefit plan which Buyer any
of its Affiliates or the Surviving Company may maintain.

Section 6.15 Indemnification of Directors and Officers of the Company.

(a) If the Merger is consummated, then until the sixth anniversary of the
Effective Time, Buyer will cause the Surviving Company to fulfill and honor in
all respects the obligations of the Company to its present and former
directors, officers, consultants and employees (the "Company Indemnified
Parties") pursuant to indemnification agreements with the Company in effect on
the date of this Agreement identified on Section 6.15(a) of the Disclosure
Schedule and pursuant to the Company Charter and bylaws, in each case, in
effect on the date of this Agreement (the "Company Indemnification
Provisions"), with respect to claims arising out of acts or omissions
occurring at or prior to the Effective Time which are asserted after the
Effective Time. Any claims for indemnification made under this Section 6.15(a)
on or prior to the sixth anniversary of the Effective Time shall survive such
anniversary until the final resolution thereof.



79

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(b) Prior to the Effective Time, the Company shall purchase tail insurance
coverage for the Company's directors and officers in a form reasonably
acceptable to the Company and Buyer which shall provide such directors and
officers with coverage for no more than six (6) years following the Effective
Time with respect to claims arising out of acts or omissions occurring at or
prior to the Effective Time (the "Insurance Coverage"), which Insurance
Coverage shall be reasonably comparable to the Company's insurance coverage
immediately prior to the date of this Agreement. Buyer shall maintain (or
cause the Surviving Company to maintain) such Insurance Coverage in full force
and effect, and continue to honor the obligations thereunder during the term
thereof. The Insurance Coverage shall be accompanied by an endorsement that
names Buyer as a successor-in-interest thereto. To the extent that the premium
for such insurance coverage does not exceed a one-time payment of $125,000,
depending on the necessary timing of the payment, either (i) if the Company
pays such premium prior to the Closing, the Company shall be credited with the
amount of such premium paid as a current asset in the calculation of Net
Closing Working Capital, or (ii) if the premium is paid simultaneously with
the Closing or immediately following the Closing, the Buyer shall pay such
premium directly on the Company's behalf.

(c) This Section 6.15 shall survive the consummation of the Merger, is
intended to benefit each Company Indemnified Party, shall be binding on all
successors and assigns of the Surviving Company and Buyer, and shall be
enforceable by the Company Indemnified Parties, who are express third party
beneficiaries of this Section 6.15; provided, however, that recourse shall
first be against the Insurance Coverage until it is exhausted before recovery
against Buyer shall take place. Notwithstanding anything to the contrary
herein, the obligations under this Section 6.15 shall not be terminated or
modified in a manner as to adversely affect any Company Indemnified Party
without the consent of such affected Company Indemnified Party.

(d) In the event that following the Effective Time, Buyer, the Surviving
Company or any of their respective heirs, successors or assigns (i)
consolidates with or merges into any other Person and shall not be the
continuing or surviving corporation or entity of such consolidation or merger,
(ii) transfers or conveys all or substantially all of its properties and
assets to any Person or (iii) commences a dissolution, liquidation, assignment
for the benefit of creditors or similar action, then, and in each such case,
to the extent necessary, proper provision shall be made so that the heirs,
successors and assigns of Buyer or the Surviving Company, as the case may be,
shall assume the obligations set forth in this Section 6.15.

Section 6.16 Financing. Buyer will have, on the date on which any Earn-Out
Payment is due under Section 3.8 of this Agreement, sufficient cash and
currently-available funds on hand to enable it to make such Earn-Out Payment.

ARTICLE VII 

CONDITIONS PRECEDENT



80

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Section 7.1 Conditions Precedent to Obligations of Each Party. The respective
obligations of each Party to effect the Merger shall be subject to the
fulfillment or satisfaction, prior to or on the Closing Date, of each of the
following conditions precedent:

(a) Approvals. Any waiting period under the HSR Act applicable to the Merger
shall have expired or been terminated.

(b) No Injunctions, Orders or Restraints; Illegality. No preliminary or
permanent injunction or other order, decree or ruling issued by a court or
other Governmental Entity of competent jurisdiction nor any statute, rule,
regulation or executive order promulgated or enacted by any Governmental
Entity of competent jurisdiction shall be in effect which would have the
effect of (i) making the consummation of the Merger illegal or (ii) otherwise
prohibiting the consummation of the Merger.

(c) Stockholder Approval. The Required Stockholder Approval shall have been
obtained in accordance with the Company Charter and the DGCL, and shall not
have been rescinded or revoked and shall remain in full force and effect.

Section 7.2 Conditions Precedent to Obligations of Buyer and Merger Sub. The
obligations of Buyer and Merger Sub to effect the Merger shall be subject to
the fulfillment or satisfaction, prior to or on the Closing Date, of each of
the following conditions precedent:

(a) Representations and Warranties. (i) The Fundamental Representations shall
be true and correct in all material respects (without giving effect to any
limitation as to "materiality" or "Company Material Adverse Effect" set forth
in any such representation or warranty) as of the date of this Agreement and
as of the Closing Date, as if made as of such time (except to the extent
expressly made as of an earlier date, in which case as of such date), and (ii)
the other representations and warranties contained in Article IV shall be true
and correct in all respects (without giving effect to any limitation as to
"materiality" or "Company Material Adverse Effect" set forth in any such
representation or warranty) as of the date of this Agreement and as of the
Closing Date, as if made as of such time (except to the extent expressly made
as of an earlier date, in which case as of such date), except for inaccuracies
of representations or warranties the circumstances giving rise to which,
individually or in the aggregate, have not resulted in and would not
reasonably be expected to result in a Company Material Adverse Effect;

(b) Performance of Obligations. The Company shall have performed in all
material respects and complied in all material respects with all agreements
and conditions contained in this Agreement that are required to be performed
or complied with by it prior to or at the Closing Date;

(c) Company Material Adverse Effect. Since the date hereof, no Company
Material Adverse Effect shall have occurred that is continuing;



81

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(d) Closing Certificate. Buyer shall have received a certificate dated the
Closing Date and signed by an authorized officer of the Company, in his or her
capacity thereof, certifying that the conditions specified in Sections
7.2(a)-(c) have been satisfied;

(e) Corporate Authority. Buyer shall have received copies of the resolutions
duly adopted by the Board of Directors and Stockholders of the Company
authorizing the execution and delivery of this Agreement and the consummation
of the Merger and the other transactions contemplated hereby, certified as
true, correct and unmodified as of the Closing Date by the Secretary of the
Company;

(f) Closing Estimates and Capital Structure Certificate. The Company shall
have delivered to Buyer a statement setting forth the Estimated Net Closing
Working Capital Adjustment, the Estimated Transaction Expenses, the Estimated
Closing Indebtedness and the Estimated Closing Cash in accordance with Section
3.2 and the Capital Structure Certificate;

(g) Escrow Agreement. The Escrow Agreement shall have been executed and
delivered by each of the Stockholders' Representative and the Escrow Agent;

(h) Paying Agent Agreement. The Paying Agent Agreement shall have been
executed and delivered by each of the Stockholders' Representative and the
Paying Agent;

(i) Joinder Agreements. Joinder Agreements have been obtained from
Stockholders accounting for no less than ninety-five percent (95%) of the
Shares outstanding immediately prior to the Effective Time.

Section 7.3 Conditions Precedent to Obligations of the Company. The
obligations of the Company to effect the Merger shall be subject to the
fulfillment or satisfaction, prior to or on the Closing Date, of each of the
following conditions precedent:

(a) Representations and Warranties. The representations and warranties of
Buyer and Merger Sub contained in Article V shall be true and correct in all
material respects (without giving effect to any limitation as to "materiality"
or "Buyer Material Adverse Effect" set forth in any such representation or
warranty) as of the date of this Agreement and as of the Closing Date, as if
made as of such time (except to the extent expressly made as of an earlier
date, in which case as of such date);

(b) Performance of Obligations. Buyer and Merger Sub shall have performed in
all material respects and complied in all material respects with all
agreements and conditions contained in this Agreement that are required to be
performed or complied with by them prior to or at the Closing;

(c) Closing Certificate. The Company shall have received a certificate dated
the Closing Date and signed by an authorized officer of Buyer, certifying that
the conditions specified in Sections 7.3(a)-(b) have been satisfied; and



82

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(d) Escrow Agreement. The Escrow Agreement shall have been executed and
delivered by Buyer and the Escrow Agent.

(e) Paying Agent Agreement. The Paying Agent Agreement shall have been
executed and delivered by Buyer and the Paying Agent.

ARTICLE VIII 

INDEMNIFICATION

Section 8.1 Indemnification of Buyer Indemnified Parties. From and following
the Closing and subject to the limitations contained in this Article VIII,
each of Buyer, the Surviving Company and their respective officers, directors,
employees, agents, Affiliates, successors and assigns (each a "Buyer
Indemnified Party" and, together, the "Buyer Indemnified Parties") shall be
indemnified and held harmless by the Securityholders, severally and not
jointly, from and against all claims, losses, liabilities, damages,
deficiencies, costs and expenses, including reasonable attorneys' fees and
expenses (individually a "Loss" and, collectively, "Losses") incurred by the
Buyer Indemnified Parties arising out of or resulting from:

(a) any breach of any representation or warranty of the Company contained in
Article IV or any certificate, agreement or other document delivered pursuant
hereto or made by any Securityholder in any Joinder Agreement (provided that
such indemnification in respect of such Joinder Agreement may only be
recovered against the Securityholder that is a party thereto, including the
portion of the Escrow Fund attributable to such Securityholder);

(b) any breach of any covenant of the Company contained in this Agreement or
contained in any Joinder Agreement (provided that such indemnification in
respect of such Joinder Agreement may only be recovered against the
Securityholder that is a party thereto, including the portion of the Escrow
Fund attributable to such Securityholder);

(c) any (i) Taxes of the Company or any of its Subsidiaries for all Pre-
Closing Tax Periods and for the portion of any Straddle Period ending on the
Closing Date as determined pursuant to Section 6.8(c), except solely to the
extent the amount of such Taxes was included in the calculation of the Net
Closing Working Capital or Transaction Expenses; (ii) any Transfer Taxes,
(iii) Taxes of another Person (other than the Company or any of its
Subsidiaries) imposed on the Company or any of its Subsidiaries (or any
successor thereto), (A) as a transferee or successor, or (B) pursuant to any
Contract existing at any time prior to the Closing; (iv) Taxes of any member
of an affiliated, consolidated, combined or unitary group of which the Company
or any Subsidiary is or was a member on or prior to the Closing Date as a
result of the provisions of Treasury Regulation Section 1.1502-6 or the
analogous provisions of any state, local or foreign Laws; (v) Taxes related to
any untaxed foreign earnings pursuant to Section 965 of the Code; (vi) Taxes
attributable to the failure by the Company, any of the Company's Subsidiaries,
or any Securityholder to perform any covenant or agreement in this Agreement
relating to Taxes or any inaccuracy in any certificate, instrument or
agreement delivered by or on behalf of the Company, any of the Subsidiaries,
or any Securityholder pursuant to this Agreement relating to Taxes (provided
that such indemnification in respect of a failure by any Securityholder to
perform any such covenant or agreement, or any



83

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





inaccuracy in any such certificate, instrument or agreement delivered by or on
behalf of any Securityholder, may only be recovered against such
Securityholder, including the portion of the Escrow Fund attributable to such
Securityholder); and (vii) withholding Taxes attributable to payments made to
Securityholders under this Agreement (for which the applicable Securityholder
shall indemnify the Buyer Indemnified Parties);

(d) any Transaction Expenses or Closing Indebtedness to the extent not taken
into account in determining the Adjustment Amount pursuant to Section 3.3,
provided that in any case the amount of the employer's share of any employment
or payroll (including, for avoidance of doubt, Medicare and social security)
Taxes with respect to any Earn-Out Payments, payment of the Final Aggregate
Merger Consideration or any payments from the Escrow Fund shall be considered
a Loss hereunder and shall be offset against such Earn-Out Payment, payment of
the Final Aggregate Merger Consideration or payment from the Escrow Fund;

(e) any amount paid by Buyer, the Company or the Surviving Company to any
Stockholder with respect to Dissenting Shares in excess of the Per Common
Share Merger Consideration paid by Buyer pursuant to this Agreement as of the
date such amount is paid multiplied by the number of Dissenting Shares held by
such Stockholder, and all Losses incurred by Buyer, the Company or the
Surviving Company in connection with the exercise (and/or attempted exercise)
of all dissenters' rights;

(f) any claims or threatened claims by or purportedly on behalf of any holder
or former holder of shares of capital stock of the Company or rights to
acquire capital stock of the Company in such holder's or former holder's
capacity as such relating to matters arising at or before the Effective Time,
including claims related to distributions, dividends, stock splits, stock
dividends, conversions or preemptive rights;

(g) any claims by any current or former Securityholders (or any of their
Affiliates, successors or assigns), any holders of Options being canceled
pursuant to Section 3.1(b)(ii) or any Persons contingently promised Options
that the distribution of payments hereunder to such Person as set forth on the
Capital Structure Certificate was less than the amount owed to such Person in
respect of his, her or its Shares, Options, Ungranted Options or other options
or promised options or equity as a result of any inaccuracy in the
calculations and determinations set forth on the Capital Structure Certificate
or with respect to any claims regarding promised options or equity, or vesting
or acceleration of vesting; or

(h) any claim against the Surviving Company, Buyer or any of their Affiliates
by a Securityholder based on any act or failure to act, or any alleged act or
failure to act, of the Stockholders' Representative (including Actual Fraud,
gross negligence, willful misconduct or bad faith) in breach of its
obligations hereunder, including any failure or alleged failure to distribute
properly all or any portion of the consideration payable hereunder.

Section 8.2 Indemnification of Securityholder Indemnified Parties. From and
following the Closing and subject to the limitations contained in this Article
VIII, each of the Securityholders and their respective officers, directors,
employees, agents, Affiliates, successors and assigns (each a "Securityholder
Indemnified Party" and, together, the "Securityholder



84

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Indemnified Parties") shall be indemnified and held harmless by Buyer from and
against all Losses incurred by the Securityholder Indemnified Parties arising
out of or resulting from:

(a) any breach of any representation or warranty of Buyer or Merger Sub
contained in Article V or any certificate, agreement or other document
delivered pursuant hereto; or

(b) any breach of any covenant of Buyer or Merger Sub contained in this
Agreement.

Section 8.3 Indemnification Procedures.

(a) The party making a claim under this Article VIII (whether the Buyer
Indemnified Parties or the Securityholder Indemnified Parties) is referred to
as the "Indemnified Party", and the party against whom such claims are
asserted under this Article VIII (whether the Buyer or, collectively, the
Securityholders) is referred to as the "Indemnifying Party". For purposes of
this Article VIII, (i) if any Buyer Indemnified Party comprises the
Indemnified Party, any references to Indemnifying Party (except provisions
relating to an obligation to make or right to receive payments) shall be
deemed to refer to the Stockholders' Representative (on behalf of the
Securityholders), and (ii) if Buyer comprises the Indemnifying Party, any
references to the Indemnified Party (except provisions relating to an
obligation to make or right to receive payments) shall be deemed to refer to
the Stockholders' Representative (on behalf of the Securityholders). Any
payment to be made to the Securityholders as the Indemnified Party shall be
distributed to the Paying Agent or shall be processed through the payroll
system of the Company, the Surviving Company or any of their Subsidiaries or
Affiliates, as applicable, for further distribution to the Securityholders in
accordance with this Agreement and the Paying Agent Agreement. If any
Indemnified Party receives written notice of the commencement of any action or
proceeding or the assertion of any claim by a third party or the imposition of
any penalty or assessment for which a claim for indemnification may be made
under this Article VIII (a "Third Party Claim") or otherwise discovers the
liability, obligation or facts giving rise to such claim for indemnity, and
such Indemnified Party intends to seek indemnity pursuant to this Article
VIII, such Indemnified Party shall promptly, and in any event within ten (10)
Business Days, provide the Indemnifying Party with written notice of such
Third Party Claim, stating in reasonable detail the nature, basis and the
amount thereof, to the extent known, along with copies of the relevant
documents evidencing such Third Party Claim and the basis for indemnification
sought. Failure of the Indemnified Party to give such notice will not prohibit
such Indemnified Party from seeking indemnification hereunder, except if and
to the extent that the Indemnifying Party is materially prejudiced thereby.
The Indemnifying Party shall be entitled to participate in the defense of a
Third Party Claim and, to the extent that it wishes, to assume the defense of
a Third Party Claim, if, within thirty (30) days from receipt of any such
notice of a Third Party Claim, the Indemnifying Party provides written notice
to the Indemnified Party that the Indemnifying Party intends to undertake such
defense; provided, however, that if the Third Party Claim (w) is brought by a
Governmental Authority or involves potential criminal liability of the
Indemnified Party, (x) primarily seeks specific performance or injunctive or
other equitable relief and not monetary damages, (y) involves a claim for
patent infringement, or (z) seeks monetary



85

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





damages in excess of 200% of the amount available to the Indemnified Party for
indemnification under the Escrow Fund and the Reserve Escrow Account, then the
Indemnified Party shall be entitled to assume and control the defense of such
Third Party Claim by providing written notice to the Indemnifying Party. If
the Indemnified Party has assumed the defense of such Third Party Claim, the
Indemnified Party shall keep the Indemnifying Party reasonably informed of all
material events and developments, including promptly providing copies of any
correspondence and court filings, with respect to such matter. If the
Indemnifying Party has assumed the defense of such Third Party Claim, the
Indemnified Party shall have the right to employ separate counsel in any such
action and to participate in (but not control) the defense thereof. The
reasonable fees and disbursements of such counsel shall be at the expense of
the Indemnified Party, provided, that if in the reasonable opinion of counsel
to the Indemnified Party (provided that such counsel shall discuss with
counsel to the Indemnifying Party prior to providing such opinion), (A) there
are legal defenses available to an Indemnified Party that are different from
or additional to those available to the Indemnifying Party; or (B) there
exists a conflict of interest between the Indemnifying Party and the
Indemnified Party that cannot be waived, the Indemnifying Party shall be
liable for the reasonable fees and expenses of counsel to the Indemnified
Party in each jurisdiction for which the Indemnified Party reasonably
determines separate counsel is required. If the Indemnifying Party elects not
to compromise or defend such Third Party Claim, fails to promptly notify the
Indemnified Party in writing of its election to defend as provided in this
Agreement, or fails to use commercially reasonable efforts to prosecute the
defense of such Third Party Claim, the Indemnified Party may, subject to
Section 8.3(b), pay, compromise, defend such Third Party Claim and seek
indemnification for any and all Losses arising out of or resulting from such
Third Party Claim. The Stockholders' Representative and Buyer shall cooperate
with each other in all reasonable respects in connection with the defense of
any Third Party Claim, including making available records relating to such
Third Party Claim and furnishing, without expense (other than reimbursement of
actual out-of-pocket expenses) to the defending party, management employees of
the non-defending party as may be reasonably necessary for the preparation of
the defense of such Third Party Claim.

(b) Notwithstanding any other provision of this Agreement, the Indemnifying
Party shall not enter into settlement of any Third Party Claim without the
prior written consent of the Indemnified Party, except as provided in this
Section 8.3(b). If a firm offer is made to settle a Third Party Claim without
leading to liability or the creation of a financial or other obligation on the
part of the Indemnified Party and provides, in customary form, for the
unconditional release of each Indemnified Party from all liabilities and
obligations in connection with such Third Party Claim and the Indemnifying
Party desires to accept and agree to such offer, the Indemnifying Party shall
give written notice to that effect to the Indemnified Party. If the
Indemnified Party fails to consent to such firm offer within thirty (30) days
after its receipt of such notice, the Indemnified Party may continue to
contest or defend such Third Party Claim and in such event, the maximum
liability of the Indemnifying Party as to such Third Party Claim shall not
exceed the amount of such settlement offer. If the Indemnified Party fails to
consent to such firm offer and also fails to assume defense of such Third
Party Claim, the Indemnifying Party may settle the Third Party Claim upon the
terms set forth in such firm offer to settle such Third Party Claim. If the
Indemnified Party has assumed the defense pursuant to Section 8.3(a), it shall
not agree to any settlement without the written consent of the Indemnifying
Party, which consent shall not be



86

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





unreasonably withheld or delayed (it being understood and agreed that it shall
be reasonable for the Stockholders' Representative to withhold such consent if
the Stockholders' Representative believes in good faith that there is not any
underlying basis for indemnification with respect to such settlement);
provided, that no settlement of any such Third Party Claim shall be
determinative of the amount of Losses relating to such matter, except with the
consent of the Stockholders' Representative, which consent shall not be
unreasonably withheld or delayed and which shall be deemed to have been given
unless the Stockholders' Representative shall have objected within thirty (30)
days after written request for such consent by the Buyer Indemnified Parties.

(c) This Section 8.3(c) and not Section 8.3(a) or Section 8.3(b) shall apply
with respect to Tax Claims. After the Closing, the Buyer Indemnified Party and
the Stockholders' Representative shall promptly notify the other party in
writing upon receipt of any written notice of any pending or threatened audit
or assessment, suit, proposed adjustment, deficiency, dispute, administrative
or judicial proceeding or similar claim relating to Taxes with respect to
damages for which Buyer may be indemnified under this Agreement (a "Tax
Claim"). Failure of the Buyer Indemnified Party to give such notice will not
prohibit such Buyer Indemnified Party from seeking indemnification hereunder,
except if and to the extent that the Stockholders' Representative, acting on
behalf of the Stockholders and Option Holders, is materially prejudiced
thereby. The Buyer Indemnified Party will control, without affecting its or
any other Indemnified Party's rights to indemnification under this Agreement,
the defense of all Tax Claims; provided, however, that the Stockholders'
Representative and its counsel (at the Securityholders' sole expense) may
participate in (but not control the conduct of) the defense of any such Tax
Claim, and provided, further, that the Buyer Indemnified Party may not settle
or compromise any Tax Claim relating to a Pre-Closing Tax Period or, with
respect to any Straddle Period, the portion of such taxable period ending on
and including the Closing Date, without the Stockholders' Representative's
consent (not to be unreasonably withheld, conditioned or delayed).

(d) Any claim by an Indemnified Party on account of a Loss which does not
result from a Third Party Claim or a Tax Claim (a "Direct Claim") shall be
asserted by the Indemnified Party giving the Indemnifying Party reasonably
prompt written notice thereof, but in any event not later than ten (10)
Business Days after the Indemnified Party becomes aware of such Direct Claim.
The failure to give such prompt written notice shall not, however, relieve the
Indemnifying Party of its indemnification obligations, except and only to the
extent that the Indemnifying Party is materially prejudiced thereby. Such
notice by the Indemnified Party shall state in reasonable detail the nature,
basis and the amount of the Direct Claim, to the extent known, along with
copies of the relevant documents evidencing such Direct Claim and the basis
for indemnification sought. The Indemnifying Party shall have thirty (30) days
after its receipt of such notice to respond in writing to such Direct Claim.
The Indemnified Party shall allow the Indemnifying Party and its professional
advisors to investigate the matter or circumstance alleged to give rise to the
Direct Claim, and whether and to what extent any amount is payable in respect
of the Direct Claim and the Indemnified Party shall assist the Indemnifying
Party's investigation by giving such information and assistance as the
Indemnifying Party or any of its professional advisors may reasonably request.
If the Indemnifying Party does not so respond



87

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





within such 30-day period, the Indemnifying Party shall be deemed to have
agreed to such Direct Claim.

Section 8.4 Limitations on Indemnification.

(a) Notwithstanding anything in this Agreement to the contrary except as
provided in Section 8.4(h), (i) the Buyer Indemnified Parties shall not be
entitled to assert any claim for indemnification under Section 8.1(a), other
than with respect to a breach of a Fundamental Representation, unless and
until the aggregate liability for Losses suffered by the Buyer Indemnified
Parties thereunder exceeds [*] (the "Threshold"); provided, that in the event
that the aggregate liability for Losses exceeds the Threshold, the Buyer
Indemnified Parties shall be entitled to recover for all such Losses; (ii) the
aggregate amount of all Losses for which the Securityholders shall be liable
for indemnification under Sections 8.1(a) (other than with respect to a breach
of a Fundamental Representation or Actual Fraud by the Company) and 8.1(c),
shall not exceed [*]); (iii) [*]and (iv) [*] if any.

(b) Notwithstanding anything in this Agreement to the contrary, (i) the
Securityholder Indemnified Parties shall not be entitled to assert any claim
for indemnification under Section 8.2(a) unless and until the aggregate
liability for Losses suffered by the Securityholder Indemnified Parties
thereunder exceeds [*]; provided, that in the event that the aggregate
liability for Losses exceeds [*], the Securityholder Indemnified Parties shall
be entitled to recover for all such Losses ; and (ii) the aggregate amount of
all Losses for which Buyer shall be liable for indemnification under Section
8.2(a) shall not exceed [*].

(c) [*]. [*]. For the avoidance of doubt, subject to Section 11.9, the Buyer
Indemnified Parties shall have no other remedies with respect to any and all
claims and Losses relating to or arising from this Agreement or the
transactions contemplated hereby (other than claims of, or causes of actions
arising from, Actual Fraud against the alleged perpetrator of such Actual
Fraud or a Securityholder who participated in or had actual knowledge of such
Actual Fraud) other than as set forth in the preceding sentences.

(d) The Buyer Indemnified Party shall use commercially reasonable efforts, to
the extent required by applicable Law, to mitigate Losses for which
indemnification may be claimed by such party pursuant to this Agreement upon
and after becoming aware of any event that could reasonably be expected to
give rise to any such Losses.

(e) The amount of any Losses that any Buyer Indemnified Party is entitled to
receive pursuant to this Article VIII shall be reduced by any related
recoveries which such Buyer Indemnified Party actually receives under
applicable insurance policies or from any other Person alleged to be
responsible for any such Losses. If a Buyer Indemnified Party actually
receives any amounts under applicable insurance policies, or from any other
Person alleged to be responsible for any Losses, subsequent to an
indemnification payment being made by the Securityholders hereunder, then such
Buyer Indemnified Party shall promptly pay to the Paying Agent and Surviving
Company (as applicable) for distribution to the Securityholders, in each case
in an amount equal to such indemnification payment, up to the amount received
by the Buyer Indemnified Party, net of any previously unpaid or unreimbursed
expenses incurred by



88

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





such Buyer Indemnified Party in collecting such amount and the aggregate
increase in insurance premiums that are directly and proximately caused by
such Losses.

(f) Notwithstanding anything to the contrary contained herein, except to the
extent payable pursuant to a Third Party Claim or a Tax Claim, no Party shall
be liable to any other Party (including its respective heirs, legal
representatives, successors or assigns, as the case may be, hereunder) for any
punitive damages, except if and to the extent any such damages are recovered
against an Indemnified Party pursuant to a Third Party Claim or a Tax Claim.
Each Party hereby waives any claims that these exclusions deprive such party
of an adequate remedy.

(g) The Securityholders shall have no indemnification obligation for any Taxes
of the Company or any of its Subsidiaries resulting from any action taken by
the Company or any of its Subsidiaries after the Closing on the Closing Date
outside the ordinary course of business.

(h) Subject to Section 11.9, each of Buyer, the Company (in its capacity as
the Surviving Company and the successor to Merger Sub) and Merger Sub hereby
acknowledges and agrees that, should the Closing occur, its sole and exclusive
remedy with respect to any and all claims and Losses relating to or arising
from this Agreement, any agreement entered into or document delivered in
connection with this Agreement (including the Joinder Agreements) or the
transactions contemplated hereby or thereby (other than claims of, or causes
of action arising from, Actual Fraud in which the alleged perpetrator of such
Actual Fraud participated) shall be governed by, and subject to, the terms and
provisions set forth in this Article VIII. Notwithstanding the foregoing,
nothing in this Article VIII will limit any Indemnified Party's right to seek
and obtain specific performance or injunctive relief to which any Party may be
entitled.

Section 8.5 Survival of Representations, Warranties and Covenants. Subject to
the limitations and other provisions of this Agreement, the representations
and warranties contained herein shall survive the Closing and shall remain in
full force and effect until the date that is [*]. Notwithstanding the
foregoing, any claims asserted in good faith with reasonable specificity (to
the extent known at such time) and in writing by notice from the Indemnified
Party to the Indemnifying Party prior to the expiration date of the applicable
survival period shall not thereafter be barred by the expiration of the
relevant representation or warranty and such claims shall survive until
finally resolved.

Section 8.6 Tax Treatment of Indemnification Payments. All indemnification
payments made under this Agreement shall be treated by the parties as an
adjustment to the Purchase Price for Tax purposes, unless otherwise required
by Law.

Section 8.7 Effect of Investigation. The representations, warranties and
covenants of the Indemnifying Party, and the Indemnified Party's right to
indemnification with respect thereto, shall not be affected or deemed waived
by reason of any investigation made by or on behalf of the Indemnified Party
(including by any of its Representatives) or by reason of the fact that the
Indemnified Party or any of its Representatives knew or should have known that
any such



89

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





representation or warranty is, was or might be inaccurate or by reason of the
Indemnified Party's waiver of any condition set forth in Section 7.2 or
Section 7.3, as the case may be.

Section 8.8 Materiality. Notwithstanding anything to the contrary contained in
this Agreement, for purposes of calculating the amount of Losses incurred in
connection with any breach or inaccuracy of any representation or warranty or
any breach or non-fulfillment of any covenant, agreement or obligation (but
not for purposes of determining the existence thereof), any and all references
to "Company Material Adverse Effect" (other than as set forth in Section
4.7(a))," "material" or other materiality terms shall be disregarded (it being
understood that the word "Material" in the defined term "Material Contract"
shall not be disregarded for any of such purposes).

Section 8.9 Additions to Escrow Account.

(a) In the event that prior to the expiration of the applicable survival
period set forth in Section 8.5, Buyer has made a good faith claim for
indemnification that is not yet satisfied out of the Escrow Account (an
"Unresolved Claim"), and Buyer thereafter becomes obligated to make an Earn-
Out Payment pursuant to Section 3.8 at a time when such Unresolved Claim
remains open (or, in the case of any claim for indemnification under Sections
8.1(d), 8.1(e), 8.1(f), 8.1(g) or 8.1(h) that is related to payments to be
distributed pursuant to such Earn-Out Payment, a claim that occurs at the time
of such Earn-Out Payment), then, subject to the limitations set forth in
Section 8.4(a), Buyer may deposit in an escrow account other than the Escrow
Account (the "Reserve Escrow Account") with the Escrow Agent governed by an
escrow agreement in substantially the same form as the Escrow Agreement (the
"Reserve Escrow Account Agreement") a portion of such Earn-Out Payment equal
to the portion of Buyer's good faith estimate of the Losses associated with
such Unresolved Claim recoverable under this Article VIII in excess of the
difference of (I) the balance of the Escrow Fund and the amount in the Reserve
Escrow Account at such time minus (II) Buyer's good faith estimate of the
Losses associated with any other Unresolved Claims that remain open (the
"Unresolved Claim Amount"). For the avoidance of doubt, subject to the
limitations in Section 8.4(a), any claim for indemnification that has settled
or been finally determined by a court of competent jurisdiction and results in
Losses that have not been satisfied out of the Escrow Account shall be deemed
an "Unresolved Claim" hereunder.

(b) In the event Buyer exercises its right to deposit a portion of an Earn-Out
Payment in the Reserve Escrow Account pursuant to Section 8.9(a), Buyer shall
provide the Stockholders' Representative with written notice in advance
thereof (but in any event not later than fifteen (15) Business Days prior to
depositing a portion of such Earn-Out Payment). Such notice by Buyer shall
state in reasonable detail the nature, basis and the amount of the Unresolved
Claim, along with copies of the relevant documents evidencing such Unresolved
Claim. In the event any Securityholder identifies any issues with or errors in
Buyer's good faith estimation, Buyer shall consider in good faith such
identified issues or errors and shall make downward revisions to such good
faith estimation as appropriate.

(c) In any case where Buyer is entitled to deposit a portion of an Earn-Out
Payment in the Reserve Escrow Account pursuant to Section 8.9(a), Buyer shall,
within fifteen



90

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





(15) Business Days after the date on which such Earn-Out Payment was due, (i)
deposit in the Reserve Escrow Account the amount by which such Earn-Out
Payment was reduced pursuant to Section 8.9(a) (each such payment, an "Escrow
Account Addition") for the purpose of securing the Unresolved Claim giving
rise to such Escrow Account Addition and (ii) deliver a written notice to the
Stockholders' Representative stating that Buyer has exercised its right to
deposit a portion of such Earn-Out Payment in the Reserve Escrow Account
pursuant to this Section 8.9, the amount so deposited and a confirmation that
such amount has been paid into the Reserve Escrow Account. The Escrow Agent
shall disburse any Escrow Account Additions (i) upon receipt of a written
instrument delivered to the Escrow Agent that is executed by both Buyer and
the Stockholders' Representative that instructs the Escrow Agent as to the
disbursement of some or all of the Escrow Account Additions to the
Securityholders or Buyer to be processed through the payroll system of the
Company, the Surviving Company or any of their Subsidiaries or Affiliates, as
the case may be, or (ii) upon receipt of an order of a court of competent
jurisdiction, a copy of which is delivered to the Escrow Agent by either Buyer
or the Stockholders' Representative, that instructs the Escrow Agent that some
or all of the Escrow Account Additions is required to be disbursed to the
Securityholders or Buyer to be processed through the payroll system of the
Company, the Surviving Company or any of their Subsidiaries or Affiliates, as
the case may be. Any interest accrued upon an Escrow Account Addition shall be
paid to the recipient of such Escrow Account Addition; provided, that if such
Escrow Account Addition is divided among Buyer, the Securityholders, and/or is
processed through the payroll system of the Company, the Surviving Company or
any of their Subsidiaries or Affiliates (as the case may be), the interest
accrued upon such Escrow Account Addition shall be divided among Buyer and the
Securityholders and processed through the payroll system of the Company, the
Surviving Company or any of their Subsidiaries or Affiliates (as the case may
be) in the same proportion as the Escrow Account Addition is divided and paid
to Buyer and the Securityholders and processed through the payroll system of
the Company, the Surviving Company or any of their Subsidiaries or Affiliates
(as the case may be).

ARTICLE IX 

STOCKHOLDERS' REPRESENTATIVE

Section 9.1 Stockholders' Representative.

(a) Appointment. By voting in favor of the adoption of this Agreement, the
approval of the principal terms of the Merger, and the consummation of the
Merger or participating in the Merger and receiving the benefits thereof,
including the right to receive the consideration payable in connection with
the Merger, each Stockholder and Option Holder constitutes and appoints the
Stockholders' Representative to act as his, her or its representative, agent
and attorney-in-fact for all purposes in connection with this Agreement and
the agreements ancillary hereto, with full authority to act on behalf of, and
to bind, each such Person for purposes of this Agreement and the agreements
ancillary hereto, and the Stockholders' Representative hereby accepts such
appointment. The Stockholders' Representative shall have full power and
authority to represent all of such holders and their successors with respect
to all matters arising under this Agreement and the agreements ancillary
hereto and all actions taken by



91

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





the Stockholders' Representative hereunder and thereunder shall be binding
upon all such Securityholders and their successors as if expressly confirmed
and ratified in writing by each of them. The Stockholders' Representative
shall be entitled to take any and all actions that it believes are necessary
or appropriate under this Agreement and the agreements ancillary hereto for
and on behalf of such Securityholders, as fully as if such Securityholders
were acting on their own behalf, including dealing with Buyer, the Paying
Agent and the Escrow Agent under this Agreement or the Escrow Agreement with
respect to all matters arising hereunder or thereunder, taking any and all
other actions specified in or contemplated hereby or thereby, and engaging
counsel, accountants or other representatives, in connection with the
foregoing matters. Without limiting the generality of the foregoing, the
Stockholders' Representative shall have full power and authority to effect and
interpret all the terms and provisions of this Agreement (including the
determination of the Adjustment Amount, the prosecution, defense or settlement
of any claims for indemnification under Article VIII and the authorization of
disbursements and payments in accordance with the terms hereof) and the Escrow
Agreement and to consent to any amendment hereof or thereof on behalf of all
such Securityholders and their successors.

(b) Exculpation and Indemnification of the Stockholders' Representative. The
Stockholders' Representative may act upon any instrument or other writing
believed by the Stockholders' Representative in good faith to be genuine and
to be signed or presented by the proper Person. The Stockholders'
Representative will incur no liability of any kind with respect to any action
or omission by the Stockholders' Representative in connection with its
services pursuant to this Agreement and any agreements ancillary hereto,
except in the event of liability directly resulting from the Stockholders'
Representative's Actual Fraud, gross negligence or willful misconduct. The
Stockholders' Representative shall not be liable for any action or omission
pursuant to the advice of nationally recognized outside counsel. The
Securityholders shall, severally (based on each Securityholder's Pro Rata
Share compared to the aggregate of the Pro Rata Shares of all Securityholders)
and not jointly, indemnify the Stockholders' Representative and its members,
managers, directors, officers, contractors, agents and employees
(collectively, the "Stockholders' Representative Group") from and against any
and all losses, liabilities, damages, claims, penalties, fines, forfeitures,
actions, fees, costs and expenses (including the reasonable fees and expenses
of counsel and experts and their staffs and all expense of document location,
duplication and shipment) (collectively, "Representative Losses") arising out
of or in connection with the Stockholders' Representative's execution and
performance of this Agreement and any agreements ancillary hereto, in each
case as such Representative Loss is suffered or incurred; provided, that in
the event that any such Representative Loss is finally adjudicated to have
been directly caused by the Actual Fraud, gross negligence or willful
misconduct of the Stockholders' Representative, the Stockholders'
Representative will reimburse the Securityholders the amount of such
indemnified Representative Loss to the extent attributable to such Actual
Fraud, gross negligence or willful misconduct. If not paid directly to the
Stockholders' Representative Group by the Securityholders, any such
Representative Losses may be recovered by the members of the Stockholders'
Representative Group from (i) the Stockholders' Representative Expense Amount,
(ii) the amounts in the Escrow Fund at such time as remaining amounts would
otherwise be distributable to the Securityholders, and (iii) from any Earn-Out
Payments at such time as any such amounts would otherwise be distributable to
the Securityholders; provided, that while this



92

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





section allows the Stockholders' Representative Group to be paid from the
aforementioned sources of funds, this does not relieve the Securityholders
from their obligation to promptly pay such Representative Losses as they are
suffered or incurred, nor does it prevent the Stockholders' Representative
Group from seeking any remedies available to it at law or otherwise. In no
event will the Stockholders' Representative be required to advance its own
funds on behalf of the Securityholders or otherwise. Notwithstanding anything
in this Agreement to the contrary, any restrictions or limitations on
liability or indemnification obligations of the Securityholders set forth
elsewhere in this Agreement are not intended to be applicable to the
indemnities provided to the Stockholders' Representative under this section.
The foregoing indemnities will survive the Closing, the resignation or removal
of the Stockholders' Representative or the termination of this Agreement.
Furthermore, the Stockholders' Representative shall not be required to take
any action unless the Stockholders' Representative has been provided with
funds, security or indemnities which, in its determination, are sufficient to
protect the Stockholders' Representative against the costs, expenses and
liabilities which would reasonably be expected to be incurred by the
Stockholders' Representative in performing such actions. In no event shall the
Stockholders' Representative be liable hereunder or in connection herewith for
any indirect, punitive damages, special damages or consequential damages.

(c) Access to Information. The Stockholders' Representative shall be given
reasonable access (upon reasonable advance written notice and during normal
business hours) by Buyer to all information of and concerning any claims for
indemnification under Article VIII and which is in the possession, custody or
control of Buyer or the Surviving Company and the reasonable assistance of
Buyer's and the Surviving Company's officers and employees as is reasonably
necessary for purposes of performing the Stockholders' Representative's duties
under this Agreement and exercising its rights under this Agreement, including
for the purpose of evaluating any claims for indemnification under Article
VIII by any Buyer Indemnified Party provided, however, that the Stockholders'
Representative shall treat confidentially and not, except in connection with
enforcing its rights under this Agreement, disclose any nonpublic information
from or concerning any claims for indemnification under Article VIII to anyone
(except to the Stockholders' Representative's attorneys, accountants or other
advisers, to Securityholders and on a need-to-know basis to other individuals
who have agreed to keep such information confidential pursuant to a standard
non-disclosure agreement).

(b) Reasonable Reliance. In the performance of its duties hereunder, the
Stockholders' Representative shall be entitled to rely upon any document or
instrument reasonably believed by it to be genuine, accurate as to content and
signed by any Stockholder or Option Holder, Buyer, the Escrow Agent or the
Paying Agent. The Stockholders' Representative may assume that any Person
purporting to give any notice in accordance with the provisions hereof has
been duly authorized to do so. Buyer may rely and shall be protected in
acting, or refraining from acting, upon any written notice, instruction or
request furnished to it hereunder and reasonably believed by Buyer to be
genuine and to have been signed or presented by the Stockholders'
Representative as if such written notice, instruction or request had been
furnished to it by all the Securityholders. The Stockholders' Representative
may, in all questions arising under this Agreement, rely on the advice of
counsel and for anything done, omitted or suffered in



93

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





good faith by the Stockholders' Representative in accordance with such advice,
and the Stockholders' Representative shall not be liable to the
Securityholders in connection therewith.

(c) Attorney-in-Fact.

(i) The Stockholders' Representative is hereby appointed and constituted the
true and lawful attorney-in-fact of each Stockholder and Option Holder with
full power in their name and on their behalf to act according to the terms of
this Agreement in the good faith discretion of the Stockholders'
Representative; and in general to do all things and to perform all acts
including, without limitation, executing and delivering any other agreements,
certificates, receipts, instructions, notices or instruments contemplated by
or deemed advisable in connection with this Agreement. Such appointment shall
be deemed to be a power coupled with an interest.

(ii) This power of attorney and all authority hereby conferred is granted and
shall be irrevocable, subject to replacement of the Stockholders'
Representative pursuant to Section 9.1(f), and shall not be terminated by any
act of any Stockholder or Option Holder by operation of Law, whether by such
holder's death, disability, protective supervision or any other event.

(iii) Each Stockholder and Option Holder waives any and all defenses that may
be available to contest, negate or disaffirm the action of the Stockholders'
Representative taken in good faith under this Agreement.

(iv) Notwithstanding the power of attorney granted in this Section 9.1, no
agreement, instrument, acknowledgement or other act or document shall be
ineffective by reason only of a Stockholder or Option Holder having signed or
given such act or document directly instead of the Stockholders'
Representative.

(d) Liability. If the Stockholders' Representative is required to determine
the occurrence of any event or contingency, the Stockholders' Representative
may request from any Stockholder or Option Holder or any other Person such
reasonable additional evidence as the Stockholders' Representative in its sole
discretion may deem necessary to determine any fact relating to the occurrence
of such event or contingency, and may at any time inquire of and consult with
others, including any Stockholder or Option Holder, and the Stockholders'
Representative shall not be liable to any such Stockholder or Option Holder,
as the case may be, for any damages resulting from its delay in acting
hereunder pending its receipt and examination of additional evidence requested
by it. Notwithstanding any other provision of this Agreement or any other
agreement entered into or document delivered in connection with the
transactions contemplated by this Agreement, in no event shall the
Stockholders' Representative, in its capacity as such, be liable to Buyer,
Merger Sub, the Company, the Surviving Company or any of their respective
Representatives or Affiliates (other than for Actual Fraud or willful
misconduct or gross negligence).

(e) Successor Representatives. The Securityholders shall designate one or more
Persons reasonably acceptable to the Securityholders collectively having a Pro
Rata Share



94

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





greater than 50% to serve as successor Stockholders' Representative in the
event of the Stockholders' Representative's incapacity, bankruptcy,
dissolution or resignation, which Person or Persons shall in such event
succeed to and become vested with all the rights, powers, privileges and
duties of the Stockholders' Representative under this Agreement. Each
successor Stockholders' Representative shall designate one or more Persons
reasonably acceptable to the Securityholders collectively having a Pro Rata
Share greater than 50% to serve as successor Stockholders' Representative in
the event of such successor Stockholders' Representative's death, incapacity,
bankruptcy, dissolution or resignation.

ARTICLE X 

TERMINATION

Section 10.1 Termination by Mutual Consent. This Agreement may be terminated,
and the Merger may be abandoned, at any time prior to the Effective Time by
mutual written consent of the Company and Buyer.

Section 10.2 Termination by Either Buyer or the Company. This Agreement may be
terminated, and the Merger may be abandoned at any time prior to the Effective
Time, by written notice of Buyer or the Company to the other Parties in the
following circumstances:

(a) any order, decree, ruling or other non-appealable final action has been
issued by a Governmental Entity permanently restraining, enjoining or
otherwise prohibiting consummation of the Merger; provided, however, that the
right to terminate this Agreement pursuant to this Section 10.2(a) shall not
be available to any Party whose failure to comply with the terms of this
Agreement has resulted in such order, decree, ruling or other non-appealable
final action;

(b) the Merger shall not have been consummated on or prior to 11:59 p.m.
(Eastern time) on the date that is six (6) months following the date hereof
(the "Termination Date"); provided, however, that (i) the right to terminate
this Agreement pursuant to this Section 10.2(b) shall not be available to any
Party whose failure to act has been a principal cause of or resulted in the
failure of the Merger to occur on or before such date and such action or
failure to act constitutes a material breach of this Agreement, and (ii) if
the failure of the Merger to occur on or before such date is caused solely as
a result of a delay in securing termination of any waiting period under the
HSR Act or to obtain the approval of the FTC, the Antitrust Division of the
Department of Justice or other Governmental Entity, as applicable, the
Termination Date shall be extended to 11:59 p.m. (Eastern time) on the date
that is nine (9) months following the date hereof; or

(c) the Written Consent shall not have been delivered to the Company, with a
copy to Buyer, within twenty-four (24) hours following the execution and
delivery of this Agreement by the Parties; provided, however, that the right
to terminate this Agreement pursuant to this Section 10.2(c) may not be
exercised at any time following the delivery of the Required Stockholder
Approval.



95

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Section 10.3 Termination by the Company. This Agreement may be terminated, and
the Merger may be abandoned at any time prior to the Effective Time, by action
of the Board of Directors of the Company, if the Company is not in material
breach of its obligations under this Agreement and there is a breach by Buyer
or Merger Sub of any material representation, warranty, covenant or other
agreement of them contained in this Agreement and such breach has not been
cured within thirty (30) days after written notice thereof to Buyer, or such
breach cannot be cured, and would cause a condition set forth in Section 7.3
to be incapable of being satisfied.

Section 10.4 Termination by Buyer. This Agreement may be terminated, and the
Merger may be abandoned at any time prior to the Effective Time, by written
notice given to the Company by Buyer, if Buyer is not in material breach of
its obligations under the Agreement and (a) there is a breach by the Company
of any material representation, warranty, covenant or other agreement of it
contained in this Agreement, and such breach has not been cured within thirty
(30) days after written notice thereof to the Company, or such breach cannot
be cured, and would cause a condition set forth in Section 7.2 to be incapable
of being satisfied, or (b) if the Written Consent shall have been rescinded or
revoked.

Section 10.5 Effect of Termination and Abandonment. In the event of
termination of this Agreement and the abandonment of the Merger pursuant to
this Article X, written notice thereof shall be given to the other Parties,
and this Agreement (other than as set forth in this Section 10.5 and other
than Section 6.5 (Public Announcements), Section 6.7 (Expenses), Article I,
Section 9.1(b) (Stockholders' Representative), Article X and Article XI) shall
become void and of no effect with no liability on the part of any Party (or of
any of its respective Representatives); provided, however, except as otherwise
provided herein, no such termination shall relieve any Party of any liability
or damages resulting from any material and willful breach of this Agreement.
If this Agreement is terminated and the Merger is abandoned pursuant to this
Article X, all confidential information received by Buyer or its
Representatives and Affiliates with respect to the Company, its Subsidiaries
and their respective Affiliates shall be treated in accordance with the
Confidentiality Agreement, which shall remain in full force and effect
notwithstanding the termination of this Agreement.

ARTICLE XI 

MISCELLANEOUS

Section 11.1 Entire Agreement. This Agreement (including the exhibits and
schedules hereto) and the Confidentiality Agreement set forth the entire
understanding of the parties hereto with respect to the transactions
contemplated hereby, and, except as set forth in this Agreement, there are no
representations or warranties, express or implied, made by any Party with
respect to the subject matter of this Agreement and the Confidentiality
Agreement. Except for the matters set forth in the Confidentiality Agreement,
any and all previous agreements and understandings between or among the
parties hereto regarding the subject matter hereof, whether written or oral,
are superseded by this Agreement and the agreements referred to or
contemplated herein.

Section 11.2 Assignment and Binding Effect; No Third Party Beneficiaries. This
Agreement shall not be assigned by any Party without the prior written consent
of the other



96

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Parties; provided, however, that Buyer shall be permitted to assign this
Agreement at any time to any Affiliate of Buyer (provided that Buyer shall
nonetheless remain liable for all of its obligations hereunder following such
assignment, including payment of the Earn-Out Payments in accordance with
Section 3.8(l)). All the terms and provisions of this Agreement shall be
binding upon and inure to the benefit of and be enforceable by the respective
successors and assigns of the parties hereto. Except as provided in Section
6.15 and Article VIII, this Agreement is for the sole benefit of the Parties
and their permitted successors and assigns and nothing herein expressed or
implied shall give or be construed to give any Person, other than the Parties
and such successors and assigns, any legal or equitable rights hereunder. Any
purported assignment in violation of this Section 11.2 shall be void. Nothing
in this Agreement shall constitute an amendment to any Plan, and no Plan shall
be amended absent a separate written amendment that complies with such Plan's
amendment procedures.

Section 11.3 Notices. All notices, requests, consents, claims, demands,
waivers and other communications hereunder shall be in writing and shall be
deemed to have been given (a) when delivered by hand (with written
confirmation of receipt); (b) when received by the addressee if sent by a
nationally recognized overnight courier (receipt requested); (c) on the date
sent by facsimile or e-mail of a PDF document (with confirmation of
transmission) if sent during normal business hours of the recipient, and on
the next Business Day if sent after normal business hours of the recipient or
(d) on the third day after the date mailed, by certified or registered mail,
return receipt requested, postage prepaid. Such communications must be sent to
the respective parties at the following addresses (or at such other address
for a party as shall be specified in a notice given in accordance with this
Section 11.3):

If to Buyer, Merger Sub or the Surviving Company:

Alexion Pharmaceuticals, Inc.

121 Seaport Boulevard

Boston, Massachusetts 02210

Email: ellen.chiniara@alexion.com

| 
---|--- 

Attention:

|

General Counsel 

with a copy (which shall not constitute notice) to:

Foley Hoag LLP

Seaport West

155 Seaport Boulevard

Boston, Massachusetts 02210

Facsimile: (617) 832-7000

Email: mhaddad@foleyhoag.com

Attention: Mark A. Haddad, Esq.



If to the Company:

Syntimmune, Inc.

116 Huntington Avenue



97

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Boston, MA 02116

Email: jeanpaul.kress@syntimmune.com

| 
---|--- 

Attention:

|

Chief Executive Officer 

with a copy (which shall not constitute notice) to:

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

Attention: Richard A. Hoffman; Daniel A. Lang

Email: RHoffman@goodwinlaw.com; DLang@goodwinlaw.com

| 
---|--- 

Facsimile:

|

(617) 977-9449; (646) 558-4131 

If to the Stockholders' Representative:

Shareholder Representative Services LLC

950 17th Street, Suite 1400

Denver, CO 80202

Attention: Managing Director

Email: deals@srsacquiom.com

Facsimile: (303) 623-0294

Telephone: (303) 648-4085



Section 11.4 Amendment and Modification. This Agreement may be amended,
modified or supplemented at any time prior to the Effective Time by mutual
agreement of Buyer, Merger Sub, the Company and the Stockholders'
Representative, except as provided in Section 251(d) of the DGCL. Any
amendment, modification or revision of this Agreement and any waiver of
compliance or consent with respect hereto shall be effective only if in a
written instrument executed by the Parties.

Section 11.5 Governing Law; Jurisdiction; Enforcement. The law, including the
statutes of limitation, of the State of Delaware shall govern this Agreement,
the interpretation and enforcement of its terms and any claim or cause of
action (in law or equity), controversy or dispute arising out of or related to
it or its negotiation, execution or performance, whether based on contract,
tort, statutory or other law, in each case without giving effect to any
conflicts-of-law or other principle requiring the application of the law of
any other jurisdiction.

(a) For purposes of this Agreement, each of the parties hereto hereby (i)
consents to service of process in any legal action, suit or proceeding among
the parties to this Agreement arising in whole or in part under or in
connection with the negotiation, execution and performance of this Agreement
in any manner permitted by the laws of the State of Delaware, (ii) agrees that
service of process made in accordance with this Section 11.5 or made by
registered or certified mail, return receipt requested, at its address
specified pursuant to Section 11.3, will constitute good and valid service of
process in any such legal action, suit or proceeding, and (iii) waives and
agrees not to assert (by way of motion, as a defense, or



98

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





otherwise) in any such legal action, suit or proceeding any claim that service
of process made in accordance with clause (i) or (ii) does not constitute good
and valid service of process. Each of the Parties (a) consents to submit
itself to the exclusive personal jurisdiction of the Delaware Court of
Chancery, New Castle County, or if that court does not have jurisdiction, a
federal court sitting in the State of Delaware in any action or proceeding
arising out of or relating to this Agreement or any of the transactions
contemplated by this Agreement, (b) agrees that all claims in respect of such
action or proceeding may be heard and determined in any such court, (c) agrees
that it will not attempt to deny or defeat such personal jurisdiction by
motion or other request for leave from any such court, and (d) agrees not to
bring any action or proceeding arising out of or relating to this Agreement or
any of the transactions contemplated by this Agreement in any other court.
Each of the Parties waives any defense or inconvenient forum to the
maintenance of any action or proceeding so brought and waives any bond, surety
or other security that might be required of any other Party with respect
thereto.

(b) Without limiting the third party beneficiary rights described in Section
11.2, this Agreement may only be enforced against, and any claim or cause of
action based upon, arising out of, or related to this Agreement or the
transactions contemplated hereby (other than pursuant to the Voting
Agreements, the Joinder Agreements, or a Letter of Transmittal) may only be
brought against, the Persons that are expressly named as parties hereto (and,
with respect to Article IX, against the Securityholders) and then only with
respect to the specific obligations set forth herein with respect to such
party. Except to the extent they are a named party to this Agreement (and then
only to the extent of the specific obligations undertaken by such named party
in this Agreement and not otherwise) or as set forth in a Voting Agreement, a
Joinder Agreement, or a Letter of Transmittal (and except for, with respect to
Article IX, the Securityholders), no past, present or future director,
officer, employee, incorporator, member, partner, stockholder, Affiliate,
agent, attorney, advisor or representative of any party or of any Affiliate of
any of the foregoing shall have any personal liability (whether in contract,
tort, equity or otherwise) for any one or more of the representations,
warranties, covenants, agreements or other obligations or liabilities of any
one or more of the Company, Buyer or Merger Sub under this Agreement (whether
for indemnification or otherwise) or for any claim based on, arising out of,
or related to this Agreement or the transactions contemplated hereby.

Section 11.6 Waiver of Jury Trial. EACH PARTY ACKNOWLEDGES AND AGREES THAT ANY
CONTROVERSY WHICH MAY ARISE UNDER THIS AGREEMENT IS LIKELY TO INVOLVE
COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PARTY HEREBY
IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PARTY MAY HAVE TO A
TRIAL BY JURY IN RESPECT OF ANY PROCEEDINGS DIRECTLY OR INDIRECTLY ARISING OUT
OF OR RELATING TO THIS AGREEMENT OR THE MERGER AND THE OTHER TRANSACTIONS
CONTEMPLATED BY THIS AGREEMENT. EACH PARTY CERTIFIES AND ACKNOWLEDGES THAT (i)
NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED,
EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF
PROCEEDINGS, SEEK TO ENFORCE THE FOREGOING WAIVER, (ii) EACH PARTY UNDERSTANDS
AND HAS CONSIDERED THE IMPLICATIONS OF THIS WAIVER, (iii) EACH PARTY MAKES
THIS WAIVER



99

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





VOLUNTARILY AND (iv) EACH PARTY HAS BEEN INDUCED TO ENTER INTO THIS AGREEMENT
BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION
11.6.

Section 11.7 Severability. If any term or other provision of this Agreement is
determined to be invalid, illegal or incapable of being enforced by any rule
of Law or public policy, all other terms and provisions of the Agreement shall
remain in full force and effect. Upon such determination, the parties hereto
shall negotiate in good faith to modify this Agreement so as to give effect to
the original intent of the Parties to the fullest extent permitted by
applicable Law.

Section 11.8 Counterparts. This Agreement may be executed in one or more
counterparts (including by facsimile or other electronic transmission), each
of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Delivery of an executed counterpart of
a signature page to this Agreement by facsimile or by electronic delivery in
PDF or other electronic format based on common standards will be effective as
delivery of a manually executed counterpart of this Agreement.

Section 11.9 Specific Performance. The Parties agree that irreparable damage
would occur in the event that any of the covenants or agreements set forth
herein were not performed by them in accordance with the terms hereof or were
otherwise breached and that each of the Parties shall be entitled to an
injunction or injunctions to prevent breaches of such covenants and agreements
and to enforce specifically such covenants and agreements (without any
requirement to post any bond or other security in connection with seeking such
relief), in addition to any other remedy at law or equity, exclusively in the
Delaware Court of Chancery and any state appellate court therefrom within the
State of Delaware (or, if the Delaware Court of Chancery declines to accept
jurisdiction over a particular matter, any state or federal court within the
State of Delaware). The Parties agree not to raise any objections to the
availability of the equitable remedy of specific performance to prevent or
restrain breaches of this Agreement by the Company, on the one hand, and to
prevent or restrain breaches of this Agreement by Buyer or Merger Sub, on the
other hand, and to specifically enforce the terms and provisions of this
Agreement to prevent breaches or threatened breaches of, or to enforce
compliance with, the covenants and obligations of the parties under this
Agreement. For purposes of this Section 11.9, each of the Parties hereby
consents to service of process in accordance with the terms of Section
11.5(b).

Section 11.10 Mutual Drafting. The Parties acknowledge that they are
sophisticated parties and have been represented by legal counsel throughout
the negotiation and drafting of this Agreement and the transactions
contemplated hereby, and that the terms of the provisions hereof have been
carefully negotiated by such legal counsel. Accordingly, the Parties hereby
agree that the presumptions of Laws or rules relating to the interpretation of
contracts against the drafter of any particular clause should not be applied
to this Agreement or any agreement or instrument executed in connection
herewith, and each Party hereby waives the application thereof.

Section 11.11 Continuing Counsel. Buyer and Merger Sub each hereby
acknowledges that Goodwin Procter LLP ("Goodwin") has acted as counsel to the
Company with respect to this



100

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Agreement, the Merger and the transactions contemplated hereby. Each of Buyer
and Merger Sub agrees that it will not, and will cause the Surviving Company
not to, seek to disqualify Goodwin from acting or continuing to act as counsel
to the Stockholders' Representative (solely in its capacity as the
Stockholders' Representative) and/or certain or all of the Securityholders in
connection with a dispute hereunder or in any way related to any inquiry,
investigation, claim, litigation, or proceeding relating to the Merger or the
transactions contemplated hereby. Buyer and Merger Sub further agree that, as
to all communications among any counsel for the Company or any Securityholder,
including, but not limited to, Goodwin or any outside or in-house counsel, and
the Company, the Stockholders' Representative and/or any such Securityholder
that relate in any way to the Merger, the transactions contemplated hereby or
any similar actual or potential transaction prior to the Closing (the
"Privileged Information"), the attorney-client privilege and the expectation
of client confidence belongs to the Stockholders' Representative and/or any
such Securityholders and may be controlled by the Stockholders' Representative
and any such Securityholders and shall not pass to or be claimed by Buyer,
Merger Sub, the Surviving Company or any of their Affiliates. Neither Buyer
nor Merger Sub will seek to obtain such communications, whether by seeking a
waiver of the attorney-client privilege or through other means, and neither
Goodwin nor any other counsel for the Company shall have any duty whatsoever
to reveal or disclose to Buyer or Merger Sub any such Privileged Information.
Notwithstanding the foregoing, in the event that a dispute arises between
Buyer, the Surviving Company and its Affiliates, on the one hand, and a third
party other than the Stockholders' Representative or a Securityholder, on the
other hand, Buyer, the Surviving Company and its Affiliates may assert the
attorney-client privilege to prevent disclosure of confidential communications
to such third party; provided, however, that neither Buyer, the Surviving
Company or its Affiliates may waive such privilege without the prior written
consent of the Stockholders' Representative.

[Signature Page Follows]

The parties hereto, intending to be legally bound hereby, have duly executed
this Agreement and Plan of Merger as of the date first above written.



ALEXION PHARMACEUTICALS, INC.



| 
---|--- 

By:

|

/s/ Ludwig Hantson 
Name: Ludwig Hantson, Ph. D. 
Title: Chief Executive Officer 

 

101

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





The parties hereto, intending to be legally bound hereby, have duly executed
this Agreement and Plan of Merger as of the date first above written.



SYRACUSE MERGER SUB, INC.



| 
---|--- 

By:

|

/s/ Paul Clancy 
Name: Paul Clancy 
Title: President 

 

[Signature Page to Agreement and Plan of Merger]

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





The parties hereto, intending to be legally bound hereby, have duly executed
this Agreement and Plan of Merger as of the date first above written.



SYNTIMMUNE, INC.





| 
---|--- 

By:

|

/s/ Jean-Paul Kress 
Name: Jean-Paul Kress, M.D. 
Title: Chief Executive Officer 

 







































[Signature Page to Agreement and Plan of Merger]

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





The parties hereto, intending to be legally bound hereby, have duly executed
this Agreement and Plan of Merger as of the date first above written.



SHAREHOLDER REPRESENTATIVE SERVICES LLC, solely in its capacity as the
Stockholders' Representative





| 
---|--- 

By:

|

/s/ Sam Riffe 
Name: Sam Riffe 
Title: Executive Director 

 



[Signature Page to Agreement and Plan of Merger]

* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *





Exhibit H



Product Criteria



[*].





* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *







Exhibit I



| 
---|--- 

1)

|

[*]. 

 



* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

* * *







Exhibit J



Excluded Indication



[*].





* Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.

\t    '

